gblx20200630

0001437749-20-019228.txt : 20200902 0001437749-20-019228.hdr.sgml : 20200902 20200902163930 ACCESSION NUMBER: 0001437749-20-019228 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200902 DATE AS OF CHANGE: 20200902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GB SCIENCES INC CENTRAL INDEX KEY: 0001165320 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 593733133 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55462 FILM NUMBER: 201157339 BUSINESS ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 BUSINESS PHONE: (844) 843-2569 MAIL ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 FORMER COMPANY: FORMER CONFORMED NAME: Growblox Sciences, Inc. DATE OF NAME CHANGE: 20140603 FORMER COMPANY: FORMER CONFORMED NAME: Signature Exploration & Production Corp. DATE OF NAME CHANGE: 20080602 FORMER COMPANY: FORMER CONFORMED NAME: Diabetic Treatment Centers of America, Inc. DATE OF NAME CHANGE: 20040812 10-Q 1 gblx20200630_10q.htm FORM 10-Q gblx20200630_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 10-Q

__________________________

(Mark One)

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission file number: 000-55462

GB SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other Jurisdiction of Incorporation or organization)

59-3733133

(IRS Employer I.D. No.)

3550 W. Teco Avenue

Las Vegas, Nevada 89118

Phone: (866) 721-0297

(Address and telephone number of

principal executive offices)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☒

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). ☐ Yes ☒ No

There were 280,532,686 shares of common stock, par value $0.0001 per share, outstanding as of September 1, 2020.

Table of Contents

GB SCIENCES, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED June 30, 2020

INDEX

	Page

PART I. FINANCIAL INFORMATION	3
ITEM 1. Financial Statements (Unaudited)	3
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	36
ITEM 4. Controls and Procedures	36
PART II – OTHER INFORMATION	37
ITEM 1. Legal Proceedings	37
ITEM 1A. Risk Factors	37
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	37
ITEM 3. Defaults Upon Senior Securities	38
ITEM 4. Mine Safety Disclosures	38
ITEM 5. Other Information	38
ITEM 6. Exhibits	38

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements (Unaudited)

Table of Contents

GB SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	As of June 30,			As of March 31,
	2020			2020
CURRENT ASSETS:		(unaudited)
Cash and cash equivalents	$	101,230		$	151,766
Accounts receivable, net of allowance for doubtful accounts of $126,650 and $130,378 at June 30, 2020 and March 31, 2020, respectively		192,509			117,967
Inventory, net		1,545,891			1,445,839
Prepaid expenses and other current assets		57,057			60,885
Note receivable		5,224,423			5,224,423
TOTAL CURRENT ASSETS		7,121,110			7,000,880
Property and equipment, net		5,360,299			5,533,833
Intangible assets, net of accumulated amortization of $15,344 and $12,287 at June 30, 2020 and March 31, 2020, respectively		1,776,045			1,699,966
Deposits and other noncurrent assets		91,504			91,504
Operating lease right-of-use assets, net		24,684			26,685
TOTAL ASSETS	$	14,373,642		$	14,352,868
CURRENT LIABILITIES:
Accounts payable	$	2,712,122		$	2,559,914
Accrued interest		654,760			397,652
Accrued liabilities		1,188,938			888,012
Notes and convertible notes payable and line of credit, net of unamortized discount of $247,695 and $608,580 at June 30, 2020 and March 31, 2020, respectively		6,327,113			5,534,728
Indebtedness to related parties		712,176			586,512
Note payable to related party		151,923			151,923
Income tax payable		601,822			592,982
Finance lease obligations, current		146,211			166,769
Operating lease obligations, current		7,579			7,265
TOTAL CURRENT LIABILITIES		12,502,644			10,885,757
Operating lease obligations, long term		20,499			22,515
Finance lease obligations, long term		3,499,612			3,533,090
TOTAL LIABILITIES		16,022,755			14,441,362
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at June 30, 2020 and March 31, 2020, respectively		28,054			27,554
Additional paid-in capital		97,574,001			97,271,157
Accumulated deficit		(99,251,168	)		(97,387,205	)
TOTAL EQUITY/(DEFICIT)		(1,649,113	)		(88,494	)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)	$	14,373,642		$	14,352,868

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

	For the Three Months Ended June 30,

	2020			2019

Sales revenue	$	551,197		$	910,676
Cost of goods sold		(491,795	)		(624,369	)
Gross profit		59,402			286,307
General and administrative expenses		804,708			2,065,549
LOSS FROM OPERATIONS		(745,306	)		(1,779,242	)
OTHER EXPENSE
Interest expense		(795,313	)		(437,815	)
Debt default penalty		(286,059	)		-
Other expense		(11,182	)		-
Total other expense		(1,092,554	)		(437,815	)
LOSS BEFORE INCOME TAXES		(1,837,860	)		(2,217,057	)
Income tax expense		(8,840	)		(57,392	)
LOSS FROM CONTINUING OPERATIONS		(1,846,700	)		(2,274,449	)
Loss from discontinued operations		-			(264,434	)
NET LOSS		(1,846,700	)		(2,538,883	)
Net loss attributable to non-controlling interest		-			(132,216	)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	$	(1,846,700	)	$	(2,406,667	)

Net loss attributable to common stockholders of GB Sciences, Inc.
Continuing operations	$	(1,846,700	)	$	(2,274,449	)
Discontinued operations		-			(132,218	)
Net loss	$	(1,846,700	)	$	(2,406,667	)

Net loss per common share – basic and diluted
Continuing operations	$	(0.01	)	$	(0.01	)
Discontinued operations		-			-
Net loss	$	(0.01	)	$	(0.01	)

Weighted average common shares outstanding - basic and diluted		277,968,516			244,036,524

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

	Three Months Ended June 30,
	2020			2019
OPERATING ACTIVITIES:
Net loss	$	(1,846,700	)	$	(2,538,883	)
Loss from discontinued operations		-			(264,434	)
Net loss from continuing operations		(1,846,700	)		(2,274,449	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		13,028			99,485
Stock-based compensation		-			176,402
Bad debt expense/(recovery)		(3,728	)		51,344
Amortization of debt discount and beneficial conversion feature		510,885			200,382
Interest expense on conversion of notes payable		-			17,225
Default penalty on convertible note payable		286,059			-
Changes in operating assets and liabilities:
Accounts receivable		(70,814	)		126,579
Prepaid expenses and other current assets		3,828			192,733
Decrease in deposits and other noncurrent assets		-			8,762
Inventory		64,602			(311,887	)
Accounts payable		72,280			(222,008	)
Accrued expenses		264,662			100,887
Accrued interest		247,549			86,719
Income tax payable		8,840			-
Indebtedness to related parties		125,664			-
Net cash used in operating activities of continuing operations		(323,845	)		(1,747,826	)
Net cash used in operating activities of discontinued operations		-			(883,295	)
Net cash used in operating activities		(323,845	)		(2,631,121	)
INVESTING ACTIVITIES:
Purchase of property and equipment		-			(170,647	)
Acquisition of intangible assets		-			(39,027	)
Net cash used in investing activities of continuing operations		-			(209,674	)
Net cash used in investing activities of discontinued operations		-			(48,000	)
Net cash used in investing activities		-			(257,674	)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock		-			745,975
Proceeds from warrant exercises		151,202			-
Proceeds from convertible notes payable		150,000			2,500,000
Proceeds from line of credit		5,000			-
Fees for issuance of convertible note		-			(175,000	)
Brokerage fees for issuance of common stock and warrants		(15,121	)		(91,104	)
Principal payments on debt and lease obligations		(17,772	)		(62,641	)
Net cash provided by financing activities of continuing operations		273,309			2,917,230
Net cash used in financing activities of discontinued operations		-			(114,881	)
Net cash provided by financing activities		273,309			2,802,349
Net change in cash and cash equivalents		(50,536	)		(86,446	)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		151,766			227,758
CASH AND CASH EQUIVALENTS AT END OF PERIOD		101,230			141,312
Less: cash and cash equivalents classified as discontinued operations		-			(107,738	)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	$	101,230		$	33,574

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC.

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

For the Three Months Ended June 30, 2020 and 2019

(unaudited)

	Three Months Ended June 30,
	2020		2019
Cash paid for interest	$	-	$	-
Cash paid for income tax	$	-	$	-

Non-cash transactions:
Depreciation capitalized in inventory	$	164,654	$	148,353
Property capitalized under operating leases	$	-	$	213,218
Patent filing and drafting costs capitalized in intangible assets	$	78,226	$	-
Discount on convertible notes payable attributable to warrant modification	$	150,000	$	-
Stock issued upon conversion of long-term note payable	$	-	$	170,000
Induced dividend from warrant exercises	$	17,263	$	74,400
Cumulative effect of the new lease standard	$	-	$	7,551

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY/(DEFICIT)

For the Three Months Ended June 30, 2020 and 2019

(unaudited)

	Shares			Amount			Additional Paid-In Capital		Accumulated Deficit			Non-Controlling Interest			Total
Balance at March 31, 2019		240,627,102		$	24,063		$	93,020,015	$	(84,743,836	)	$	8,855,757		$	17,155,999

Issuance of stock for debt conversion		1,000,000			100			169,900		-			-			170,000
Exercise of warrants for stock		1,957,500			196			175,979		-			-			176,175
Share based compensation expense		-			-			176,402		-			-			176,402
Issuance of stock for cash, net of issuance costs		3,668,167			367			478,329		-			-			478,696
Exchanged shares issued to consultant for options		(400,000	)		(40	)		40		-			-			-
Inducement dividend from warrant exercises		-			-			74,400		(74,400	)		-			-
Cumulative effect of the new lease standard		-			-			-		(7,551	)		-			(7,551	)
Net loss		-			-			-		(2,406,667	)		-			(2,406,667	)
Loss attributable to non-controlling interest		-			-			-		-			(132,216	)		(132,216	)
Balance at June 30, 2019		246,852,769		$	24,686		$	94,095,065	$	(87,232,454	)	$	8,723,541		$	15,610,838

	Shares		Amount		Additional Paid-In Capital		Accumulated Deficit			Non-Controlling Interest		Total
Balance at March 31, 2020		275,541,602	$	27,554	$	97,271,157	$	(97,387,205	)	$	-	$	(88,494	)

Exercise of warrants for stock, net of issuance costs		4,991,084		500		135,581		-			-		136,081
Discount on convertible notes payable attributable to warrant modification		-		-		150,000		-			-		150,000
Inducement dividend from warrant exercises		-		-		17,263		(17,263	)		-		-
Net loss		-		-		-		(1,846,700	)		-		(1,846,700	)
Balance at June 30, 2020		280,532,686	$	28,054	$	97,574,001	$	(99,251,168	)	$	-	$	(1,649,113	)

The accompanying unaudited notes are an integral part of these unaudited condensed consolidated financial statements

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note 1 – Background and Significant Accounting Policies

GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property.

Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes two issued USPTO Patents, five USPTO patent applications, four provisional USPTO patent applications, and one USPTO application that we anticipate filing by the end of calendar year 2020, as well as licenses for three additional patents covering novel cannabinoid delivery systems. In addition to the USPTO patents and patent applications, the company has filed 28 patent applications internationally.

We were incorporated in the State of Delaware on April 4, 2001, under the name “Flagstick Venture, Inc.” On March 28, 2008, stockholders owning a majority of our outstanding common stock approved changing our then name “Signature Exploration and Production Corp.” as our business model had changed.

On March 13, 2014, we entered into a definitive assets purchase agreement for the acquisition of assets, including the Growblox™ cultivation technology which resulted in a change in our corporate name on April 4, 2014, from Signature Exploration and Production Corporation to Growblox Sciences, Inc.

Effective December 12, 2016, the Company amended its Certificate of Corporation pursuant to shareholder approval as reported in the Form 8-K filed on October 14, 2016. Pursuant to the amendment the Company’s name was changed from Growblox Sciences, Inc. to GB Sciences, Inc.

Effective April 8, 2018, Shareholders of the Company approved the change in corporate domicile from the State of Delaware to the State of Nevada and increase in the number of authorized capital shares from 250,000,000 to 400,000,000. Effective August 15, 2019, Shareholders of the Company approved an increase in authorized capital shares from 400,000,000 to 600,000,000.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulations S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending March 31, 2021. The balance sheet at March 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended March 31, 2020.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Principles of Consolidation

We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not wholly owned is included as a separate component of equity. The non-controlling participants’ share of the net loss is included as “Net loss attributable to non-controlling interest” on the unaudited consolidated statements of operations.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not readily apparent from other sources. The actual results the Company experiences may differ materially and adversely from these estimates.

Reclassifications

Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC have been separated from the comparative period amounts to confirm to the current period presentation as discontinued operations as the result of the sale of the Company’s interest in GB Sciences Louisiana, LLC (Note 10). The reclassifications had no effect on the reported financial position, results of operations or cash flows of the Company.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Discontinued Operations

Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes.

There were no assets or liabilities of discontinued operations included in the Company's condensed consolidated balance sheets as of June 30, 2020 and March 31, 2020.

The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three months ended June 30, 2020 and 2019 were as follows:

	For the Three Months Ended June 30,
	2020								2019
	Continuing			Discontinued		Total			Continuing			Discontinued			Total
Sales revenue	$	551,197		$	-	$	551,197		$	910,676		$	-		$	910,676
Cost of goods sold		(491,795	)		-		(491,795	)		(624,369	)		-			(624,369	)
Gross profit		59,402			-		59,402			286,307			-			286,307
General and administrative expenses		804,708			-		804,708			2,065,549			201,840			2,267,389
LOSS FROM OPERATIONS		(745,306	)		-		(745,306	)		(1,779,242	)		(201,840	)		(1,981,082	)
OTHER EXPENSE
Interest expense		(795,313	)		-		(795,313	)		(437,815	)		(62,594	)		(500,409	)
Debt default penalty		(286,059	)		-		(286,059	)		-			-			-
Other expense		(11,182	)		-		(11,182	)		-			-			-
Total other expense		(1,092,554	)		-		(1,092,554	)		(437,815	)		(62,594	)		(500,409	)
LOSS BEFORE INCOME TAXES		(1,837,860	)		-		(1,837,860	)		(2,217,057	)		(264,434	)		(2,481,491	)
Income tax expense		(8,840	)		-		(8,840	)		(57,392	)		-			(57,392	)
NET LOSS	$	(1,846,700	)	$	-	$	(1,846,700	)	$	(2,274,449	)	$	(264,434	)	$	(2,538,883	)

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Long-Lived Assets

Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may exist under authoritative guidance. The annual testing date is March 31. When management believes impairment indicators may exist, projections of the undiscounted future cash flows associated with the use of and eventual disposition of property and equipment are prepared. If the projections indicate that the carrying value of the property and equipment are not recoverable, we reduce the carrying values to fair value. These impairment tests are heavily influenced by assumptions and estimates that are subject to change as additional information becomes available. No indicators of impairment were identified by the Company as of June 30, 2020.

Inventory

We value our inventory at the lower of the actual cost of our inventory, as determined using the first-in, first-out method, or its current estimated net realizable value. We periodically review our physical inventory for excess, obsolete, and potentially impaired items and reserve accordingly. Our reserve estimate for excess and obsolete inventory is based on expected future use.

Beneficial Conversion Feature of Convertible Notes Payable

The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470-20, Debt with Conversion and Other Options and Emerging Issues Task Force (“EITF”) 00-27, “Application of Issue No. 98-5 to Certain Convertible Instruments”. A beneficial conversion feature (“BCF”) exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. In accordance with this guidance, the BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The Company calculates the fair value of warrants issued with the convertible notes using the Black-Scholes valuation model and uses the same assumptions for valuing any employee options in accordance with ASC Topic 718 Compensation – Stock Compensation. The only difference is that the contractual life of the warrants is used.

The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.

Revenue Recognition

The FASB issued Accounting Standards Codification (“ASC”) 606 as guidance on the recognition of revenue from contracts with customers. Revenue recognition depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company adopted the guidance on April 1, 2018 and applied the cumulative catch-up transition method.

The Company’s only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, the Company is required to separately identify each performance obligation resulting from its contracts from customers, which may be a good or a service. A contract may contain one or more performance obligations. All of the Company’s contracts with customers, past and present, contain only a single performance obligation, the delivery of distinct physical goods. Because fulfillment of the company’s performance obligation to the customer under ASC 606 results in the same timing of revenue recognition as under the previous guidance (i.e. revenue is recognized upon delivery of physical goods), the Company did not record any material adjustment to report the cumulative effect of initial application of the guidance.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Earnings/(loss) per Share

The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,412,936 and 158,404,020 potentially dilutive common shares at June 30, 2020 and March 31, 2020, respectively. However, such common stock equivalents were not included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

Recent Accounting Pronouncements

Recently Adopted Standards

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-13, "Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). Financial Instruments—Credit Losses (Topic 326) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. ASU 2016-13 affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this ASU are effective for smaller reporting companies for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its financial statements.

In August 2018, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted the standard on April 1, 2020. The adoption of this guidance did not have a material impact on the Company’s financial statements.

All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note 2 – Going Concern

The Company’s financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $(99,251,168) at June 30, 2020. The Company had a working capital deficit of $(5,381,534) at June 30, 2020, compared to $(3,884,877) at March 31, 2020. In addition, the Company has consumed cash in its operating activities of $(323,845) for the three months ended June 30, 2020, compared to $(2,631,121) including $(883,295) from discontinued operations for the three months ended June 30, 2019. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in achieving its goals.

In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

Note 3 – Inventory

Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms.

	June 30, 2020			March 31, 2020

Raw materials	$	129,133		$	91,465
Work in progress		923,737		$	1,166,511
Finished goods		619,491		$	466,319
Subtotal		1,672,361			1,724,295
Allowance to reduce inventory to net realizable value		(126,470	)		(278,456	)
Total inventory, net	$	1,545,891		$	1,445,839

Note 4 – Leases

The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2024 to 2025.

As a result of the adoption of ASC 842, certain real estate and equipment operating leases have been recorded on the balance sheet with a lease liability and right-of-use asset ("ROU"). Application of this standard resulted in the recognition of ROU assets of $182,624, net of accumulated amortization, and a corresponding lease liability of $190,173 at the April 1, 2019, the date of adoption. Accounting for finance leases is substantially unchanged.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% to 11.5%. Operating leases were discounted at a rate of 17.0%.

Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 months or less are not recorded on the consolidated balance sheet.

During the three months ended June 30, 2020, finance lease costs recorded in the consolidated financial statements were $143,599, of which $104,924 represents interest expense and $38,675 represents amortization of the right-of-use assets. Operating lease costs were $3,243, of which $1,242 represents interest expense and $2,001 represents amortization of the right-of-use assets.

Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of June 30, 2020, from continuing operations are as follows:

Year Ending				Operating
March 31,	Finance Leases			Leases

2021 (9 months)	$	422,801		$	8,836
2022		544,296			11,779
2023		560,625			11,779
2024		577,444			3,926
2025		594,767			-
Thereafter		3,781,101			-
Total minimum lease payments		6,481,034			36,320
Less: Amount representing interest		(2,835,211	)		(8,242	)
Present value of minimum lease payments		3,645,823			28,078
Less: Current maturities of capital lease obligations		(146,211	)		(7,579	)
Long-term capital lease obligations	$	3,499,612		$	20,499

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note 5 – Notes Payable and Line of Credit

0% Note Payable dated October 23, 2017

On October 23, 2017, the Company amended the existing Nevada Medical Marijuana Production License Agreement (“Amended Production License Agreement”). Per the terms of the Amended Production License Agreement, GB Sciences purchased the remaining percentage of the production license resulting in the 100% ownership of the license. GB Sciences also received 100% ownership of the cultivation license included in the original Nevada Medical Marijuana Production License Agreement. In exchange, GB Sciences made one-time payment of $500,000 and issued a 0% Promissory Note in the amount of $700,000 payable in equal monthly payments over a three-year period commencing on January 1, 2018.

The present value of the note was $521,067 on the date of its issuance based on an imputed interest rate of 20.3% and the Company recorded a discount on notes payable of $178,933. During the three months ended June 30, 2020, the Company recorded interest expense of $7,321 related to amortization of the note discount. The remaining unamortized discount as of June 30, 2020 was $(6,607).

The Company has been in default on this note since June of 2019, and as of the date of this report, fifteen monthly payments on the note totaling $291,660 are unpaid. As the result of the default, the Company has accrued penalty interest at the rate of 10% according to the terms of the Promissory Note. Total penalty interest accrued was $9,236 for the three months ended June 30, 2020. If the Company is unable to cure the default within ten days of receiving a written notice, the lender will have the option to accelerate the remaining balance owed of $369,445, but must notify the Company in writing should it choose to do so. The Company is currently in the process of negotiating a settlement and/or forbearance agreement with the lender and anticipates repayment of the note upon receiving proceeds from the sales of the Company's Teco and Nopah facilities (Note 11).

8% Line of Credit dated November 27, 2019

In connection with the Binding Letter of Intent dated November 27, 2019 (Note 11), the Company entered into a promissory note and received a line of credit for up to $470,000 from the purchaser of the Company's membership interest in its Nevada facilities. The purpose of the line of credit is to supply working capital for the Nevada operations. The note matures upon the close of the sale of membership interests. As of June 30, 2020, the Company has received $485,000 in advances under the line of credit, reflecting an informal agreement with the lender to increase the Line of Credit limit by $15,000. The Company accrued interest of $9,641 on the line of credit for the three months ended June 30, 2020, and the balance of the line of credit was $485,000 at June 30, 2020. Upon the close of the sale of the Teco Facility all principal and interest due under the line of credit will be considered satisfied in full.

8% Note Payable dated May 7, 2020

On May 7, 2020, the Company received $135,000 cash from an investor, net of $(15,000) in brokerage fees, and issued a $150,000 promissory note. The note bears interest at a rate of 8.0% per annum. The note is to be repaid upon the first proceeds received from the $8,000,000 promissory note related to the sale of the Company's membership interest in GB Sciences Louisiana, LLC (Note 10), or from the proceeds of the sale of the Teco Facility (Note 11). As inducement to enter into the note transaction, the Company repriced 8,002,500 preexisting warrants held by the investor to an exercise price of $0.04. The repriced warrants were valued at $272,085 on the date of the transaction using the Black-Scholes Model, which exceeded the value of the warrants prior to the price reduction of $49,525 by $222,560. As the result of the increase in the estimated fair value of the warrants, the Company recorded a full discount on notes payable of $(150,000). During the three months ended June 30, 2020, the Company recorded interest expense of $151,742 related to the note consisting of accrued interest of $1,742 and $150,000 related to amortization of the note discount. Unamortized discount remaining at June 30, 2020 was $0.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Summary of Notes Payable

As of June 30, 2020, the following notes payable were recorded in the Company’s consolidated balance sheet:

	As of June 30, 2020
Short-Term Notes Payable	Face Value		Discount			Carrying Value
6% Convertible promissory notes payable (Note 6)	$	1,257,000	$	(58,812	)	$	1,198,188
8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6)		1,271,863		(182,276	)		1,089,587
8% Convertible Promissory Note dated April 23, 2019 (Note 6)		3,041,500		-			3,041,500
0% Note Payable dated October 23, 2017 (Note 5)		369,445		(6,607	)		362,838
8% Line of Credit dated November 27, 2019 (Note 5)		485,000		-			485,000
8% Note Payable dated May 7, 2020 (Note 5)		150,000		-			150,000
Total Short-Term Notes Payable	$	6,574,808	$	(247,695	)	$	6,327,113

Note 6 – Convertible Notes

March 2017 $2M Convertible Note Offering

In March 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.60 per share for the period of three years. Between March 2017 and May 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $2,000,000. The Notes are payable within three years of issuance and are convertible into 8,000,000 shares of the Company’s common stock. The Company also issued 8,000,000 common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years. The Company recorded an aggregate discount on convertible notes of $1,933,693, which included $904,690 related to the relative fair value of beneficial conversion features and $1,029,003 for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model.

July 2017 $7.2M Convertible Note Offering

In July, 2017, the Company entered into a Placement Agent’s Agreement with a third-party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company’s common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company’s’ common stock at an exercise price of $0.65 per share for the period of three years. Between July 2017 and December 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $7,201,000. The Notes are payable within three years of issuance and are convertible into 28,804,000 shares of the Company’s common stock. The Company also issued 28,804,000 common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years.The Company recorded an aggregate discount on convertible notes of $7,092,796, which included $3,142,605 related to the relative fair value of beneficial conversion features and 3,950,191 for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model.

As of June 30, 2020, convertible notes having a carrying value of $ 1,198,188, net of unamortized discount of $ (58,812) remained outstanding from the March 2017 and July 2017 note offerings, and accrued interest on the notes is $228,052. Discount amortization was $96,527 for the three months ended June 30, 2020.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

8% Senior Secured Convertible Promissory Note dated February 28, 2019

On February 28, 2019, the Company issued a $1,500,000 8% Senior Secured Convertible Promissory Note and entered into the Note Purchase Agreement and Security Agreement with CSW Ventures, L.P. (together, “CSW Note”). The note matures on August 28, 2020 and is convertible at any time until maturity into 8,823,529 shares of the Company’s common stock at $0.17 per share. Collateral pledged as security for the note includes all of the Company’s 100% membership interests in GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC, which together represent substantially all of the Company’s cannabis cultivation and production operations and assets located at the Teco facility in Las Vegas, Nevada. The intrinsic value of the beneficial conversion feature resulting from the market price of the Company’s common stock in excess of the conversion price was $176,471 on the date of issuance, and the Company recorded a discount on the CSW Note in that amount.

On May 28, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $170,000 of the principal balance of the 8% Senior Secured Promissory Note dated February 28, 2019. Accordingly, the Company issued 1,000,000 shares of its common stock based on a $0.17 per share conversion price. In connection with the conversions, $ 17,225 in unamortized discount was recorded as interest expense and the Company reduced the carrying amount of convertible notes payable by $152,775. After conversion, the remaining balance outstanding was $1,330,000.

On July 12, 2019, the Company entered into the Amendment to Note Documents and the Amended and Restated 8% Senior Secured Promissory Note (together, “Amended CSW Note”). The Amended CSW Note increased the note balance by $100,000 to reflect an additional $100,000 advanced to the Company on July 12, 2019, by $41,863 to add accrued interest to date to the principal balance, and decreased the conversion price to $0.11 per share, with the remaining terms substantially unchanged from the original CSW Note.

We evaluated the modification under the guidance in ASC 470-50 and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the CSW Note on the amendment date. The carrying value of the amended note on the date of extinguishment was $1,338,057, net of a beneficial conversion feature discount of $133,806, and we recorded a loss on extinguishment of $124,158.

On August 1, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $ 110,000 of the principal balance of the Amended CSW Note at $0.11 per share. Accordingly, the Company issued 1,000,000 shares of its common stock. In connection with the conversions, $9,579 in unamortized discount was recorded as interest expense and the Company has reduced the carrying amount of convertible notes payable by $100,421. After conversion, the remaining balance outstanding was $ 1,361,863.

On October 23, 2019, the Company entered into the Amendment to Promissory Note. The October 23, 2019 amendment decreased the conversion price to $0.08 per share, with the remaining terms substantially unchanged from the Amended CSW Note.

We evaluated the modification under the guidance in ASC 470-50 and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the Amended CSW Note immediately prior to the 2nd Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was $1,269,067, net of a beneficial conversion feature discount of $92,796, and we recorded a loss on extinguishment of $92,796.

On November 27, 2019, the Company entered into the Second Amendment to Note Documents and the Second Amended and Restated 8% Senior Secured Promissory Note (together, “2nd Amended CSW Note”). The 2nd Amended CSW Note decreased the conversion price to $0.04 per share and increased the note balance by $30,000 to reflect an advance received on that date, with the remaining terms substantially unchanged from the Amended CSW Note.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

We evaluated the modification under the guidance in ASC 470-50 and determined that the 2nd Amended CSW Note represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the Amended CSW Note immediately prior to the 2nd Amended CSW Note; however, no loss on extinguishment was recorded because the net consideration paid for the 2nd Amended CSW Note was equal to the extinguished carrying value of the Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was $1,361,863.

On December 16, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $120,000 of the principal balance of the Amended CSW Note at $0.04 per share and we issued 3,000,000 shares of common stock. In connection with the conversions, $57,551 in unamortized discount was recorded as interest expense, and the Company has reduced the carrying amount of convertible notes payable by $62,449. After conversion, the remaining balance outstanding was $1,271,863 and the carrying amount of the note was $687,021, net of $584,842 in unamortized discount from the beneficial conversion feature.

During the three months ended June 30, 2020, we recorded interest expense of $252,573 related to the CSW Note and its amendments consisting of $25,367 in accrued interest and $227,206 related to amortization of the note discount. As of June 30, 2020, the carrying amount of the CSW Note was $1,089,587, net of unamortized discount of $(182,276).

The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on October 1, 2019, January 1, 2020, March 1, 2020, and June 1, 2020, and for nonpayment of an income tax liability related to the March 31, 2018 tax year. The terms of the note provide that the Company has 5 days to cure a default caused by nonpayment of interest and ten days to cure a default caused by noncompliance with affirmative or negative debt covenants. The lender has agreed to provide forbearance of the defaults in connection with the sale of the Teco facilities, and the Company anticipates that the CSW Note will be settled in full upon close of the sale of the Company's interests in its Nevada operations to an entity affiliated with CSW Ventures, L.P. (Note 11).

8% Convertible Promissory Note dated April 23, 2019

On April 23, 2019, the Company entered into the Note Purchase Agreement with Iliad Research and Trading, L.P. ("Iliad") and issued an 8% Convertible Promissory Note with a face value of $2,765,000. The Note was issued with original issue discount of $265,000 and is convertible into shares of the Company’s common stock at a price of $0.17 per share at the option of the note holder at any time until the Note is repaid. The Note matures on April 22, 2020. A total discount of $440,000 was recorded on the note, which includes $265,000 of original issue discount and $175,000 in fees paid to brokers.

During the year ended March 31, 2020, the Company honored the conversion of a total of a total of $125,000 of accrued interest on the Iliad Note at reduced conversion rates. On October 30, 2019, the Company received notice of the conversion of $75,000 at $0.06 per share and issued 1,250,000 shares of its common stock. The fair value of the shares issued exceeded the fair value of the shares issuable under the original terms of the Note by $64,706, and the Company recorded an induced conversion expense. On November 18, 2019, the Company received notice of the conversion of $50,000 of the note balance at $0.0375 per share and issued 1,333,333 shares of its common stock.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

On April 22, 2020, the Company failed to make payment of the principal and accrued interest due under the Iliad Note, resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10%. As the result of the default, Company recorded an expense of $9,559 related to a 10% increase in the accrued interest balance, which is recorded in interest expense, and $276,500 related to the 10% increase in the principal balance, which is recorded in debt default penalty and other expense. As of June 30, 2020, the principal balance due under the note was $3,041,500, including the 10% penalty increase to the principal balance, and accrued interest was $192,649, including an increase of $9,559 attributable to the 10% default penalty.

During the three months ended June 30, 2020, interest expense related to the note was $130,659, of which $29,831 was amortization of the note discount and $100,828 was interest accrued at the pre-default rate of 8.0% through April 22, 2020, and at the default rate of 15.0% for the period from April 23, 2020 through June 30, 2020.

On May 20, 2020, Iliad filed a lawsuit against the Company in the Third Judicial District Court of Salt Lake County in the State of Utah demanding repayment of the note. The lawsuit further seeks to compel the Company to participate in arbitration pursuant to the arbitration provisions contained within the Note Purchase Agreement and to prohibit the Company to raise funds through the issuance of its common stock unless the note is paid in full simultaneously with such issuance. The Company filed a confession of judgment in response to the complaint and does not intend to defend the lawsuit. On July 14, 2020, the Court entered judgment in favor of Iliad in the amount of $3,264,594 and the judgment accrues interest at the default rate of 15% per annum. The Company will also be responsible for reasonable attorney's fees and costs incurred by Iliad for obtaining and collecting on the judgment. The amount of such fees has not been established as of the date of this report. The Company believes it will have sufficient resources to repay the Iliad Note from the proceeds of the sale of the Teco Facility and the note receivable therefrom, along with the proceeds of the note receivable from Wellcana Group from the sale of the Company's membership interest in GB Sciences Louisiana, LLC.

Note 7 – Capital Transactions

Sale of Common Stock and Exercise of Warrants

On April 1, 2020, the Company entered into the Advisory Agreement with its brokers and effected a temporary decrease in the exercise price of the Company's outstanding warrants to $0.03-$.05 per share. As a result of the price reduction, the Company received notice of the exercise of 4,991,084 warrants during the three months ended June 30, 2020 and received proceeds of $136,081, net of brokerage fees of $(15,121).

At June 30, 2020, 79,547,077 warrants at exercise prices ranging from $0.25 to $1.00 per share and 13,366,334 options with a weighted average exercise price of $0.28 were outstanding.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note 8 – Commitments and Contingencies

On September 18, 2017 GB Sciences finalized its agreement with Louisiana State University (“LSU”) AgCenter to be the sole operator of the LSU’s medical marijuana program. The LSU Board of Supervisors entered into a five-year agreement that has an option to renew for two additional five-year terms with GB Sciences.

The contract includes the Company’s commitment to make an annual research investments of $500,000 to the LSU AgCenter. The Company retained its 50% interest in the research relationship with LSU after the sale of its membership interest in GB Sciences Louisiana, LLC (Note 10), and accordingly remains obligated for $250,000 of the $500,000 annual research investment for three years, or a total commitment of $750,000. The research investment is paid annually in September and amortized over a one-year period. On August 4, 2020, the Company received its first payment under the Wellcana Note Receivable, net of the $250,000 research contribution due for the twelve month period ended September 30, 2020, and our commitment for that twelve month period was paid by the purchaser with the funds withheld from the note payment. The monetary contributions will be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, of which AgCenter would retain 50% of those rights with the other 50% retained 25% each by the Company and by GB Sciences Louisiana, LLC.

On August 24, 2020, the Company entered into a letter of intent with the purchaser to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the purchaser will assume the annual $250,000 research contribution commitment to LSU and the Company will retain no rights in the intellectual property developed under the research relationship (Note 10).

Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, alleging that she was subjected to sexual harassment and retaliatory discharge. The Company received the Notice of Charge of Discrimination on or about May 15, 2019. The Company submitted its response to the Notice of Discrimination Charge on July 26, 2019. It is the Company's position that Ms. Russel was not an employee of the Company, but rather was an independent contractor. The Company intends to aggressively respond to the charge. To date, the NERC has not issued a ruling regarding the charge.

On April 22, 2020, the Company failed to repay any of the outstanding balance of the Convertible Promissory Note Payable to Iliad Research and Trading, L.P. (Note 6), resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10% and the Company recorded expense of $286,059 related to the default. As of June 30, 2020, the total balance due under the note was $3,234,149 including accrued interest of $192,649.

On April 22, 2020, the Company was served notice of a lawsuit filed in the Eighth Judicial District Court in Clark County, Nevada, filed by a contractor who had been hired to perform architectural and design services. The lawsuit demands payment of $73,050 for the services provided. The Company intends to negotiate a settlement and the full amount demanded in the lawsuit of $73,050 is accrued in accounts payable as of June 30, 2020.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

From time to time, the Company may become involved in certain legal proceedings and claims which arise in the ordinary course of business. In management’s opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, the Company would record a reserve for the claim in question. If and when the Company records such a reserve, it could be material and could adversely impact its results of operations, financial condition, and cash flows.

Note 9 – Related Party Transactions

As of June 30, 2020 the Company is indebted to its officers and directors for a total of $712,176, consisting of $447,633 in unpaid wages, $109,087 in directors’ compensation, $84,497 in unpaid bonuses, and $70,959 in reimbursements for business expenses.

In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid fees and bonuses. The note matures upon receipt of the first payment from the Wellcana Note Receivable (Note 10). The note and interest accrued was repaid on August 4, 2020, when the related funds were withheld from the first payment to the Company under the Wellcana Note Receivable (Note 12).

Note 10 – Sale of Membership Interests in GB Sciences Louisiana, LLC

On February 12, 2018, the Company’s wholly-owned subsidiary, GB Sciences Louisiana, LLC (“GBSLA"), issued members’ equity interests equal to 15% in GBSLA to Wellcana Group, LLC (“Wellcana”) for $3 million. Under the GBSLA operating agreement, Wellcana had an option to make additional capital contributions for the purchase of up to an additional 35% membership interest in GBSLA, at the rate of 5% membership interest per $1 million contributed. To date, Wellcana has made additional cash contributions of $7.0 million and its non-controlling interest in GBSLA increased to 49.99%. The capital contributions were used to fund the buildout of the Petroleum Drive facility and to pay for the operating costs of GBSLA.

On November 15, 2019, the Company entered into the Membership Interest Purchase Agreement ("MIPA") with Wellcana Plus, LLC ("Purchaser"), an affiliate of Wellcana Group, LLC. In consideration for the sale of its remaining 50.01% membership interest in GBSLA, the Company received the $8,000,000 Promissory Note ("Wellcana Note") and may receive up to an additional $8,000,000 in earn-out payments.

On August 24, 2020, the Company entered into a letter of intent with Wellcana to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the Company will receive payments totaling $5,224,423, including the forgiveness by Wellcana of $324,423 in liabilities and the payment of $4,900,000 in cash, on or before October 15, 2020, less any cash payments made by Wellcana up to the date of the final payment. Upon receipt of the payment, all liabilities owed to the Company by Wellcana, including the $8,000,000 note receivable and any potential earn-out payments will be considered satisfied in full. Wellcana will assume the annual $250,000 research contribution commitment to LSU (Note 8) and the Company will retain no rights in the intellectual property developed under the research relationship. In addition, the Company agreed to reduce the $750,000 note payment due on September 1, 2020 to $500,000. Should Wellcana fail to make the $4,900,000 payment, less any offsets from payments made to date on the note receivable, the term sheet will be void and the original terms of the Membership Interest Purchase Agreement and $8,000,000 note receivable will prevail.

As a result of the August 24, 2020 letter of intent, the Company determined that the amount of the note that was collectible as of March 31, 2020 was $5,224,423 and recorded a loss on modification of note receivable of $1,895,434 for the year ended March 31, 2020. As of June 30, 2020, the balance of the note receivable was $5,224,423.

The Company granted forbearance of the June 1, 2020 payment from Wellcana in light of the circumstances created by the COVID-19 epidemic. The payment was received by the Company on August 4, 2020, net of the Company's $250,000 research contribution commitment to LSU for the twelve months ended September 2020 (Note 8) and the principal and accrued interest payable to John Davis (Note 5) totaling $189,423 as of the date of payment.

For all periods presented in the unaudited financial statements, the assets, liabilities, income, and cash flows of GBSLA have been reclassified to discontinued operations.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note 11 – Sale of Membership Interests in Nevada Subsidiaries

On November 15, 2019, we entered into a Binding Letter of Intent ("Teco LOI") to sell 75% of the Company's membership interest interests in GB Sciences Nevada, LLC, and GB Sciences Las Vegas, LLC, for $3.0 million cash upon close and up to an additional $3.0 million in earn-out payments after close. In connection with the Teco LOI, we entered into a Management Agreement with the purchaser whereby the facilities will be managed by an affiliate of the purchaser until the close of the sale. As part of the transaction, the Company also entered into a Line of Credit of up to $470,000 with the purchaser (Note 5) to fund the operations of Teco. The line of credit accrues interest at a rate of 8% and the Company pledged its interest in the Teco facilities as collateral for the note, subject to the preexisting lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 (Note 6). The Line of Credit will be considered satisfied in full upon close of the sale of the Teco Facility.

On March 24, 2020, we entered into the Membership Interest Purchase Agreement ("Teco MIPA") which formalized the sale of the Teco Subsidiaries and modified the terms of the sale. Pursuant to the Teco MIPA, the Company will sell 100% of its membership interests in GBSN and GBLV for $4,000,000 cash upon close and will receive a $4,000,000 8% promissory note to be paid in monthly installments over 36 months.

On July 24, 2020, the Company entered into the Loan Agreement, 8% Secured Promissory Note, and Security Agreement (together, the "July 24 Note") with AJE Management, LLC, which established a revolving loan of up to $500,000 that the Company may draw on from time to time. The loan is collateralized by the Teco Facility, subject to the preexisting lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 (Note 6). Any advances will be made at the sole discretion of the lender following a written request made by the Company. Contemporaneously with the Loan Agreement, the Company and AJE Management entered into the Amendment to the Membership Interest Purchase Agreement with AJE Management. The amendment provides that any balances outstanding under the July 24 Note at the time of the close of the sale of the Teco Facility will be forgiven in exchange for a reduction to the $4,000,000 note receivable that the Company will receive as consideration for the sale of the Teco Facility. The reduction to the note receivable will be equal to 3 times the balance outstanding under the July 24 Note on the date of the close of the sale of the Teco Facility. As of the date of this report, the Company has not received any advances under the July 24 Note.

The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada has been subject to an indefinite moratorium since October 2019. In a meeting held on July 21, 2020, the Nevada Cannabis Compliance Board lifted the moratorium, however, the board has indicated that there are over 90 requests pending and it will take up to several months to process the entire backlog of pending license transfers. Based on this information, we cannot provide any assurances as to the timing of the close of the sale. The lifting of the moratorium and processing of cannabis license transfers have been delayed by the COVID-19 pandemic and could be further delayed if the pandemic continues.

The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company’s wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not begun under the Nopah License. On November 27, 2019, the Company entered into a Binding Letter of Intent to sell its 100% interest in GB Sciences Nopah, LLC (the “Nopah LOI”), with the transaction closing upon transfer of the Nopah License. As consideration for the transfer of the license, the Company will receive $300,000 and the purchaser will pay all expenses related to the upkeep and maintenence of the Nopah License. The transfer of the Nopah License is subject to the same restrictions on license transfers discussed above.

Note 12 – Subsequent Events

Capital Transactions

On July 24, 2020, the Company entered into the Loan Agreement, 8% Secured Promissory Note, and Security Agreement (together, the "July 24 Note") with AJE Management, LLC, which established a revolving loan of up to $500,000 that the Company may draw on from time to time. The loan is collateralized by the Teco Facility, subject to the pre-existing lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 (Note 6). Any advances will be made at the sole discretion of the lender following a written request made by the Company. Contemporaneously with the Loan Agreement, the Company and AJE Management entered into the Amendment to the Membership Interest Purchase Agreement with AJE Management. The amendment provides that any balances outstanding under the July 24 Note at the time of the close of the sale of the Teco Facility will be forgiven in exchange for a reduction to the $4,000,000 note receivable that the Company will receive as consideration for the sale of the Teco Facility (Note 11). The reduction to the note receivable will be equal to 3 times the balance outstanding under the July 24 Note on the date of the close of the sale of the Teco Facility. As of the date of this report, the Company has not received any advances under the July 24 Note.

Table of Contents

GB SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2020

(unaudited)

Note Receivable

The Company granted forbearance of the June 1, 2020 payment to Wellcana in light of the circumstances created by the COVID-19 epidemic. The payment was received by the Company on August 4, 2020, net of the Company's annual $250,000 research contribution commitment to LSU (Note 10) and the principal and accrued interest payable to John Davis (Note 5) totaling $189,423 as of the date of payment.

On August 24, 2020, the Company entered into a letter of intent with Wellcana to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the Company will receive payments totaling $5,224,423, including the forgiveness by Wellcana of $324,423 in liabilities and the payment of $4,900,000 in cash, on or before October 15, 2020, less any cash payments made by Wellcana up to the date of the final payment. Upon receipt of the payment, all liabilities owed to the Company by Wellcana, including the $8,000,000 note receivable and any potential earn-out payments will be considered satisfied in full. Wellcana will assume the annual $250,000 research contribution commitment to LSU (Note 10) and the Company will retain no rights in the intellectual property developed under the research relationship. In addition, the Company agreed to reduce the $750,000 note payment due on September 1, 2020 to $500,000. Should Wellcana fail to make the $4,900,000 payment, less any offsets from payments made to date on the note receivable, the term sheet will be void and the original terms of the Membership Interest Purchase Agreement and $8,000,000 note receivable will prevail.

On August 31, 2020, the Company granted a 30-day forbearance of the $500,000 payment due on September 1, 2020. Any payments received prior to October 15, 2020 will be applied to the $4,900,000 balance due under the August 24, 2020 letter of intent.

Litigation

Table of Contents

ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts” or “continue” , which list is not meant to be all-inclusive and other such negative terms and comparable technology. These forward-looking statements, include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include among other things: (1)product demand, market and customer acceptance of GB Sciences products, equipment and other goods, (ii) ability to obtain financing to expand its operations, (iii) ability to attract qualified personnel, (iv)competition pricing and development difficulties, (v) general industry and market conditions and growth rates, unexpected natural disasters, and other factors, which we have little or no control: and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”). The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this report.

The following discussion highlights the Company’s results of operations and the principal factors that have affected our financial condition, as well as our liquidity and capital resources for the periods described and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis is based on the Company’s unaudited financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read this discussion and analysis together with such financial statements and the related notes thereto.

Overview

Table of Contents

Plan of Operation

Drug Discovery and Development of Novel Cannabis-Based Therapies

Through its wholly-owned, Canadian subsidiary, GBS Global Biopharma, Inc. ("GBSGB"), the Company has conducted ground-breaking research embracing the complexity of the whole plant led by Dr. Andrea Small-Howard, the Company’s Chief Science Officer and Director, and Dr. Helen Turner, Vice President of Innovation and Dean of the Natural Sciences and Mathematics Department at Chaminade University. Small-Howard and Turner posited that complex mixtures of cannabinoids and terpenes that are derived from native mixtures in the cannabis plant, but with precise optimizations, would provide more targeted and effective treatments for specific disease conditions than either single cannabinoids or whole plant formulations. They developed a rapid screening and assaying system which tested thousands of combinations of cannabinoids and terpenes in vitro against cell-based models of disease. This process identified precise mixtures of cannabinoids and terpenes, many of which contained no THC, to treat categories of disease conditions, including neurological disorders, inflammation, heart disease, metabolic syndrome, chronic and neuropathic pain.

GBSGB’s drug discovery process combines: 1) HTS: high throughput screening of tens of thousands of combinations of compounds derived from specific chemovars of the cannabis plant in well-established cellular models of diseases, and 2) NPP: a proprietary Network Pharmacology Platform algorithm for the prediction of complex therapeutic mixtures that the Company spent two-and-a-half-years training and testing against cell assay data. This combined approach to drug discovery increases research efficiency and accuracy reducing the time from ideation to patenting from 7 years to 1.5 years. Screening of cannabis-based mixtures for drug discovery involves the testing of specific combinations of plant chemicals from many naturally occurring cannabis chemovars and the use of live models for these diseases that have been well established by other researchers. First, the Company finds chemovars that show some therapeutic activity, and then refines these natural mixtures to optimize their effectiveness in cellular assays by removing compounds that do not act synergistically with the others in the mixtures. The Company also use its internally-validated Network Pharmacology Platform to prioritize and eliminate some potential combinations, which reduces the time in the discovery period.

The U.S. Patent and Trademark Office allows complex mixtures to be claimed as Active Pharmaceutical Ingredients. GBSGB has two issued patents and a series of pending patents containing cannabis-derived complex mixtures that act as therapeutic agents for specific disease categories, as described below. GBSGB’s pending patents are protected whether the individual compounds are derived from the cannabis plant, another plant, synthetically produced, or derived from a combination of sources for the individual chemical compounds in these mixtures.

GBS Global Biopharma, Inc. has made significant strides in the past year with respect to both its drug discovery research and product development programs. Our lead pharmaceutical programs in both Parkinson’s disease and chronic neuropathic pain are now in preclinical animal studies with Dr. Lee Ellis of the National Research Council (NRC) Canada in Halifax, Nova Scotia. In addition, the two patents which protect GBSGB’s formulations in our lead development programs have been issued by the US Patent and Trademark Office (USPTO). Achieving these significant milestones is driving interest in these novel therapeutic programs.

For its lead program in PD therapeutics, GBSGB announced that it has obtained the statistically significant reduction of Parkinson’s-disease like symptoms using its proprietary complex mixtures in an animal model of Parkinson’s disease (PD). Several of GBSGB’s PD formulations significantly reduced the symptoms, while the most effective formula reduced the symptoms back to the baseline activity of normal animals. In addition, the toxicity studies for these PD formulas came back without any significant negative findings. These important preclinical results will be included in GBS’ Investigational New Drug (IND) application with the US FDA to enter human clinical trials as soon as possible. New therapies to address Parkinson’s disease symptoms are needed to help those afflicted with this debilitating disease. The combined direct and indirect costs associated with Parkinson’s disease are estimated at $52 billion in the U.S. alone.

For Parkinson’s disease, the initial clinical prototypes of GBSGB’s Cannabinoid-Containing Complex Mixtures (CCCM™) are being formulated by Catalent Pharma using Catalent’s Zydis® Orally Disintegrating Tablet (ODT) technology. This ODT format was selected for the PD formulas because it dissolves on the tongues of patients without the need to swallow for ease of use in patients with PD, who often have difficulties with swallowing. GBSGB selected Catalent as its development partner for the PD therapies due to Catalent’s prior experience in working on US FDA-approved, cannabinoid-containing drugs, their Schedule I drug manufacturing facilities, their familiarity with US FDA and international regulatory and manufacturing requirements, their expertise in tackling formulation challenges, and their ability to achieve the stability and dosing necessary for these novel complex mixtures. In addition to its Zydis® technology, Catalent has early drug development services and additional oral drug delivery solutions available for the efficient delivery of GBSGB's proprietary APIs.

Table of Contents

For its lead chronic neuropathic pain program, GBSGB is testing its Cannabinoid-Containing Complex Mixtures (CCCM) and Myrcene-Containing Complex Mixtures (MCCM) both as encapsulated, time-released nanoparticles, as well as in non-encapsulated forms of these therapeutic mixtures in an animal model at the NRC in Halifax, Nova Scotia. In preparation for human clinical trials, our standard MCCM and the time-released MCCM are currently being compared in an animal model that demonstrates their potential effectiveness at treating chronic pain. The early results from this preclinical research project look very promising.

The two patents which protect formulations in the Company’s lead therapeutic programs have been issued by the USPTO. The issuance of U.S. Patent No. 10,653,640 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Neurodegenerative Diseases" on May 19, 2020 protects methods of using GBSGB’s proprietary cannabinoid-containing complex mixtures (CCCM™) for treating Parkinson’s Disease (PD). This was an important milestone in the development of these vitally-important therapies and validates GBSGB’s drug discovery platform. In the US alone, the combined direct and indirect costs associated with Parkinson’s disease are estimated at $52 billion, and new therapies to address Parkinson’s disease symptoms are greatly needed. This was also the first time that a US patent has been awarded for a cannabis-based complex mixture defined using this type of drug discovery method. The first US patent for PD therapies validated our drug discovery platform and strengthened our intellectual property portfolio of unique CCCM’s™, each targeting one of up to 60 specific clinical applications. The issuance of GBSGB’s second US patent for active pharmaceutical ingredients that are complex mixtures identified by our biotech platform further confirms that GBSGB’s pharmaceutical compositions can be patent-protected for use as biopharmaceutical and nutraceutical products. The US Patent entitled “Myrcene-Containing Complex Mixtures Targeting TRPV1” protects methods of using GBSGB’s proprietary Myrcene-Containing Complex Mixtures (“MCCM”) for the treatment of pain disorders related to arthritis, shingles, irritable bowel syndrome, sickle cell disease, and endometriosis. In the US alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. The Company believes that it is important to create safer, less addictive alternatives to opioids for the treatment of chronic pain disorders, like GBSGB’s myrcene-containing complex mixtures.

Favorable Research Updates from our university collaborators reveal the promise in our discovery programs with Michigan State University (HIV-Associated Neurodegenerative Disorder and COVID-19 therapies), Chaminade University (Chronic Neuropathic Pain, Metabolic Syndrome, Cannabis Metabolomics with the University of Athens), the University of Athens, Greece (Cannabis Metabolomics), the University of Seville, Spain (Time-Released Nanoparticles), and the National Research Council (NRC) of Canada (Parkinson’s Disease, Chronic Neuropathic Pain).

Intellectual Property Portfolio

GBSGB retained Fenwick & West, a Silicon Valley based law firm focusing on life sciences and high technology companies with a nationally top-ranked intellectual property practice, to develop strategies for the protection of the Company's intellectual property. The status of the intellectual property portfolio is as follows.

Two USPTO Patents Issued/Allowed for Cannabinoid- and Myrcene-Containing Complex Mixtures

Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

U.S. Patent Number 10,653,640; Expiration date: October 23, 2038

Issued: May 19, 2020; Inventors: Andrea Small-Howard et al.

Patent protection was granted for GBSGB’s Cannabinoid-Containing Complex Mixtures for the treatment of Parkinson’s disease.

Title: MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1

U.S. Patent Number 10,709,670; Expiration date: May 22, 2038

Issued: July 14, 2020; Inventors: Andrea Small-Howard, et al.

GBSGB’s MCCMs are protected for use in the treatment of pain related to arthritis, shingles, irritable bowel syndrome, sickle cell disease, and endometriosis.

Table of Contents

Five USPTO & Twenty-Three International Patent Applications Pending

Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

U.S. Patent Application No. 15/729,565; WIPO Application number: PCT/US2017/055989

Filed: October 10, 2017; Inventors: Andrea Small-Howard et al.

National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on October 10, 2017.

On April 3, 2020, GBSGB Received a Notice of Allowance on our Cannabinoid-Containing Complex Mixtures for Neurodegenerative Disease. On the same day as we paid the fee for the allowed patent claims, we filed a Continuation for Review of the non-Parkinson’s formulas within this application, which includes Alzheimer’s disease, Huntington’s disease, Lewy body dementia, and dementia. U.S. Continuation Application No. 16/844,713, filed on Apr 9, 2020, is pending. This application claims benefit of U.S. Patent Application No. 62/406,764 filed October 11, 2016.

Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF MAST CELL-ASSOCIATED OR BASOPHIL-MEDIATED INFLAMMATORY DISORDERS

U.S. Patent Application No.15/885,620; WIPO Application number: PCT/US2018/016296

Filed: January 31, 2018; Inventors: Andrea Small-Howard, et al.

National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on January 31, 2018.

Claims benefit of U.S. Patent Application No. 62/453,161 filed February 1, 2017.

Title: MYRCENE-CONTAINING COMPLEX MIXTURES TARGETING TRPV1

U.S. Patent Application No. 15/986,316; WIPO Patent Application No. PCT/US2018/033956

Filed: May 22, 2018; Inventors: Andrea Small-Howard, et al.

National stage applications entered in AU, CA, CN, EP, HK, IL, and JP on May 22, 2018.

On May 12, 2020, GBSGB received a Notice of Allowance for its Myrcene-Containing Complex Mixtures. On the same day as we paid the fee for the allowed claims, we filed a Continuation for the review of the other formulations including those for heart disease and other TRPV1-related pathologies. U.S. Continuation Application No. 16/878,295, filed on May 19, 2020, is pending. Claims benefit of U.S. Patent Application No. 62/509,546 filed May 22, 2017.

Title: TRPV1 ACTIVATION-MODULATING COMPLEX MIXTURES OF CANNABINOIDS AND/OR TERPENES

U.S. Patent Application No.: 16/420,004; WIPO Patent Application No.: PCT/US2019/033618

Filed: May 22, 2019; Inventors: Andrea Small-Howard, et al.

Claims benefit of U.S. Patent Application Nos. 62/674,843 filed May 22, 2018; 62/769,743 filed November 20, 2018; and 62/849,719 filed May 17, 2019.

Title: THERAPEUTIC NANOPARTICLES ENCAPSULATING TERPENOIDS AND/OR CANNABINOIDS

U.S. Patent Application No.:16/686,069 WIPO Patent Application No.: PCT/ES2019/070765

Filed: November 8, 2019; Inventors: Andrea Small-Howard, et al.

Claims benefit of U.S. Patent Application Nos. 62/757,660 filed November 8, 2018

Two Provisional USPTO Patent Applications Pending

Title: TREATMENT OF PAIN USING ALLOSTERIC MODULATOR OF TRPV1

U.S. Patent Application No.: 62/868,794; Inventors: Andrea Small-Howard, et al.

Filed: June 28, 2019

Title: THERAPEUTIC NANOPARTICLES ENCAPSULATING TERPENOIDS AND/OR

CANNABINOIDS

U.S. Patent Application No.: 62/897,235 Inventors: Andrea Small-Howard, et al.

Filed: September 6, 2019

Table of Contents

Two Additional Provisional Patent Applications Filed on August 18, 2020

Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISORDERS

Filing Date: August 18, 2020; Inventor: Andrea Small-Howard

Title: CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS

Filing Date: August 18, 2020; Inventor: Andrea Small-Howard

Licensed Patents for GBSGB’s Intellectual Property Portfolio

Title: METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF CARDIAC HYPERTROPHY.

Inventor: Alexander Stokes; Assignee: University of Hawai’i

Commercialization rights licensed to Makai Biotech, LLC

Sublicensed by Makai Biotech, LLC to GBS Global Biopharma, Inc.

Status: Granted in the following territories on the corresponding dates

U.S. Patent Number: 9,084,786; Issued: July 21, 2015

U.S. Patent Number: 10,137,123; Issued: November 27, 2018

U.S. Continuation Application: 16/181,204

European Union Patent Number: 2,635,281; Granted: March 14, 2018

Europe Patent Application: 3,348,267

Hong Kong Patent Number: 14102182.8; Granted: March 14, 2018

India Patent Application: 1404/KOLNP/2013

China Patent Application: 201180063998.4

Title: METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION OF POLYMERIC NANOPARTICLES FOR TREATING NEUROPATHIC PAIN CAUSED BY PERIPHERAL NERVE COMPRESSION

Inventors: Martin Banderas, Lucia; Fernandez Arevala, Mercedes; Berrocoso, Dominguez, Esther; and Mico Segura, Juan Antonio

Assignees: Universidad de Sevilla, Universidad de Cadiz, and Centro de Investigacion Biomedica En Red (CIBER)

Exclusive worldwide license held by GBS Global Biopharma, Inc.

WIPO/PCT Application: PCT/ES2016/000016 (Pub. No. WO 2016/128591)

Filed: August 18, 2016

Claims benefit of Spanish Patent Application no. P201500129 (Pub. No. ES 2582287)

Filed: February 9, 2015

U.S. Patent Application: 15/549,653

Spain Patent ES2582287; Granted: September 29, 2017

Europe Patent Application: EP3257503

Canada Patent Application CA2976040

Table of Contents

Partnering Strategy

GBSGB runs a lean drug development program and minimizes expenses, including personnel, overhead, and fixed capital expenses (such as lab and diagnostic equipment), through strategic partnerships with Universities and Contract Research Organizations (“CROs”). Through these research and development agreements, GBSGB has created a virtual pipeline for the further development of novel medicines extracted from the cannabis plant. The partners bring both expertise and infrastructure at a reasonable cost to the life sciences program. In most instances, GBSGB has also negotiated with these partners to keep 100% of the ownership of the IP within GBSGB for original patent filings.

GBSGB currently has on-going research agreements with the following institutions covering the indicated areas of research:

Chaminade University: Broad-based research program to support the drug discovery platform that has yielded most of GBSGB’s original patents to date in the areas of neurodegenerative diseases, heart disease, inflammatory diseases, neuropathic pain and chronic pain. They have also performed the bioassay portion of the Cannabis Metabolomics study performed with the University of Athens, Greece and GBSGB.

University of Athens: Broad-based metabolomics analysis of over 100 cannabis genotypes including both hemp and THC-producing cannabis varieties, in combination with GBSGB’s bioassay data linking genotypes and potential disease-remediations. This project has the potential to define active ingredients from plant-derived mixtures beyond the standard cannabinoids and terpenoids. The discovery potential is huge, and novel agents have recently been discovered.

Michigan State University: Discovery work using a cutting-edge, multi-cellular model of the human immune system and a multi-cell model of the brain to explore CCCM™s for use in the prevention of HIV-Associated Neurocognitive Disorders (HAND). Although combination antiretroviral therapy keeps symptoms for most HIV-patients well controlled, between 40% and 70% of these well-controlled HIV patients end up with HAND symptoms that range from movement disorders to dementia-like symptoms. The results from this work were included in a new patent application that will be filed in Q3 of 2020. In addition, MSU has performed experiments using their novel model of the human-immune system that have allowed GBSGB to prepare cannabis-based formulas for the potential treatment of virally-induced hyperinflammation/cytokine storm syndrome that has led to the majority of COVID-19 deaths. The new patent application for our novel, cannabinoid-containing complex mixtures (CCCM™) for the treatment of hyperinflammation and cytokine storm syndrome in COVID-19 patients will also be filed in Q3 of 2020.

The University of Seville: Bringing their novel expertise to the development and functional testing of time-released and disease-targeted nanoparticles of cannabis-based complex mixtures for oral administration. These specialized nanoparticles are being used for the precise and time-released delivery of several of our therapies, including GBSGB’s MCCM™ and CCCM™’s used in the preclinical animal testing performed at the NRC Canada. The University of Seville has completed functional testing on nanoparticles containing myrcene, nerolidol, and beta-caryophyllene for our Myrcene-Containing Complex Mixtures. In these cell-based assays, the effectiveness and kinetics of the nanoparticle-forms of these terpenes were compared with the “naked” terpenes both individually and in mixtures. In all cases, the effectiveness of the nanoparticles were superior to the naked terpenes, however, the mixtures were dramatically more effective than the individuals. These results from Seville are very promising as these nanoparticles have entered the animal testing phase at the NRC in Halifax.

The National Research Center (NRC) of Canada, Halifax, Nova Scotia: Two animal-phase studies are being performed by Dr. Lee Ellis’ group at the NRC. An animal safety and efficacy study was initiated in Q4 of 2018 for GBSGB’s Parkinson’s disease therapies, and the NRC has demonstrated that the company’s PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the pathology of Parkinson’s disease in the animal model. Based on achieving the statistically significant reduction in Parkinson’s disease symptomology, GBSGB has signed an amendment to include a final phase of testing, which will study the mechanism of action for these promising formulations. In Q1 of 2019, GBSGB started a safety and efficacy study in animals for GBSGB’s Chronic Neuropathic Pain (CNP) formulas. The midterm results for these preclinical pain studies are promising.

The University of Cadiz: Testing the safety and efficacy of the above-mentioned time-released nanoparticles in rodent models of chronic pain. Proof of concept complete for one formulation.

University of Hawaii: Validating the efficacy of a complex cannabis-based mixture for the treatment of cardiac hypertrophy and cardiac disease in a rodent model. Proof of concept work is complete.

Table of Contents

Path to Market: Drug Development Stages and Proposed Clinical Trials

GBSGB has cannabis-based therapeutic products in the following stages of drug development: Discovery, Pre-Clinical, and entering the Clinical Phase. It has also licensed therapeutic products that the Company intends to develop through partners, labeled Partner Programs.

The completion of pre-clinical studies, clinical trials, and obtaining FDA-approvals for pharmaceutical products is traditionally a long and expensive process. However, GBSGB asserts that its cannabis-based drug discovery engine, lean development program, novel regulatory strategy, experienced development partners, and aggressive licensing of these products at early clinical stages can mitigate some of the risks. The Company uses a combination of in silico discovery methods and automated screening of cellular models of disease to decrease the time in Discovery prior to filing novel patent applications for disease-specific therapeutics. GBSGB’s original patent applications cover new chemical entities (“NCE”) based on complex combinations of plant-derived compounds. Its Exploratory IND/Phase 0 Program gets the Company to First-in-Man sooner than traditional programs, which reduces translational risks, and includes preliminary efficacy measures for responsible development decisions. In contrast, a traditional phased-development path would not provide any efficacy measures until Phase II. After the completion of our Phase 0 study, which compares the efficacies of multiple related cannabis-based formulations, the Company plans to advance the lead drug candidate using an adaptive trial design that is more efficient than the traditional phased-development pathway. GBSGB has entered into research contracts, partnerships, and/or joint ventures with several respected, independent contract research organizations, medical schools, universities, and other scientific researchers to increase developmental efficiencies. If and when one or more of GBSGB’s drugs, therapies or treatments are approved by the FDA, GBSGB will seek to market them under licensing arrangements with major biotechnology or pharmaceutical companies.

GBSGB plans to use a combination of FDA-registered human clinical trials, as described in detail above, and pilot human studies in the development of its therapeutic product portfolio. Early in product development, human pilot studies that are fully compliant with state medical cannabis programs will be used to gather early data on safety and efficacy that can later be referenced in the next phase of product development. GBSGB may be able to produce and sell the early products that prove efficacious, through licensing agreements with cannabis companies in other US states and countries that have legalized cannabis programs. GBSGB believes that these pilot studies will provide significant value by reducing the cost of commercialization, more rapidly putting effective drugs in the hands of patients, and accelerating by years the monetization of the research. GBSGB’s goal is to be the perfect partner to those companies with greater resources and experience in the marketing and distribution of medications worldwide.

There can be no assurance that we will ever be able to enter into any joint ventures or other arrangements with third parties to finance our drug development program or that if we are able to do so, that any of our projected therapies will ever be approved by the FDA. Even if we obtain FDA approval for a therapy, there can be no assurance that it could be successfully marketed or would not be superseded by another cannabis-based therapy produced by one or more of our competitors. It also may be anticipated that even if we enter into a joint venture development with a financially stable pharmaceutical or institutional partner, we will still be required to raise significant additional capital in the future to achieve the strategic goals of GBSGB. There can be no assurance that we will be able to obtain such additional capital on reasonable terms, if at all. If GBSGB fails to achieve its goal of producing one or more cannabis-based pharmaceuticals or therapies, it would have a material adverse effect on our future financial condition and business prospects.

In addition to our biopharmaceutical research and development activities described in detail above, the Company has operated in the medical and adult-use cannabis markets under State-issued cultivation and production licenses. Our wholly owned subsidiary GB Sciences Nevada, LLC (“GBSN”) leases a warehouse facility at 3550 W. Teco Avenue, Las Vegas Nevada (the "Teco Facility") and operates a cannabis cultivation facility under Nevada licenses for the medical and adult-use markets. Our wholly owned subsidiary GB Sciences Las Vegas, LLC ("GBLV") holds Nevada certificates for medical and adult-use cannabis production and produces extracts and concentrates for the wholesale market.

On September 18, 2017, our subsidiary GB Sciences Louisiana, LLC finalized its agreement with Louisiana State University (“LSU”) AgCenter to be the sole operator of LSU’s medical marijuana program. The LSU Board of Supervisors entered into a five-year agreement—that has an option to renew for two additional five-year terms—with GB Sciences.The contract included the Company’s commitment to make a minimum financial contribution to the LSU AgCenter in the amount of $3.4 million, or a 10% commission of gross receipts, in addition to annual research investments of $500,000 to the LSU AgCenter. The monetary contributions would be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, which AgCenter would retain 50% of those rights.

On November 15, 2019, the Company entered into the Membership Interest Purchase Agreement ("MIPA") with the noncontrolling interest in GB Sciences Louisiana, LLC. In consideration for the sale of its 50.01% membership interest in GBSLA, the Company received the $8,000,000 Promissory Note ("Wellcana Note") and may receive up to an additional $8,000,000 in earn-out payments.

Table of Contents

On November 15, 2019, we entered into a Binding Letter of Intent (the "LOI") to sell 75% of the Company's membership interest interests in GBSN and GBLV (together, the "Teco Subsidiaries") for $3.0 million cash upon close and up to an additional $3.0 million in earn-out payments after close. In connection with the LOI, we entered into a Management Agreement with the purchaser whereby the facilities will be managed by an affiliate of the purchaser until the close of the sale. On March 24, 2020, we entered into the Membership Interest Purchase Agreement ("Teco MIPA") which formalized the sale of the Teco Subsidiaries and modified the terms of the sale. Pursuant to the Teco MIPA, the Company will sell 100% of its membership interests in GBSN and GBLV for $4.0 million cash upon close and will receive a $4.0 million 8% promissory note to be paid in monthly installments over 36 months.

The sales of the Teco Facility and Nopah are expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevadahas been subject to an indefinite moratorium since October 2019. In a meeting held on July 21, 2020, the Nevada Cannabis Compliance Board lifted the moratorium, however, the board has indicated that there are over 90 requests pending and it will take up to several months to process the entire backlog of pending license transfers. Based on this information, we cannot provide any assurances as to the timing of the close of the sale. The lifting of the moratorium and processing of cannabis license transfers have been delayed by the COVID-19 pandemic and could be further delayed if the pandemic continues.

Table of Contents

RESULTS OF OPERATIONS

The following table sets forth certain of our Statements of Operations data:

	For the Three Months Ended
	June 30,
	2020			2019

SALES REVENUE	$	551,197		$	910,676
COST OF GOODS SOLD		(491,795	)		(624,369	)
GROSS PROFIT		59,402			286,307
GENERAL AND ADMINISTRATIVE EXPENSES		804,708			2,065,549
LOSS FROM OPERATIONS		(745,306	)		(1,779,242	)
OTHER INCOME/(EXPENSE)		(1,092,554	)		(437,815	)
NET LOSS BEFORE INCOME TAX EXPENSE		(1,837,860	)		(2,217,057	)
INCOME TAX EXPENSE		(8,840	)		(57,392	)
LOSS FROM CONTINUING OPERATIONS		(1,846,700	)		(2,274,449	)
LOSS FROM DISCONTINUED OPERATIONS		-			(264,434	)
NET LOSS		(1,846,700	)		(2,538,883	)
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST		-			(132,216	)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	$	(1,846,700	)	$	(2,406,667	)

Comparison of the Three Months Ended June 30, 2020 and 2019

Sales revenue

The Company recorded sales revenue of $551,197 for the three months ended June 30, 2020, as compared to $910,676 for the same period in the prior year. The decrease in sales is largely attributable to the COVID-19 pandemic and the temporary closing of retail cannabis stores in the State of Nevada.

Cost of goods sold

Cost of goods sold decreased to $491,795 for the three months ended June 30, 2020, compared to $624,369 for the three months ended June 30, 2019. The decrease is largely attributable to the decrease in sales volume as the result of the COVID-19 pandemic.

General and Administrative Expenses

General and Administrative Expenses decreased by $(1,260,841) to $804,708 for the three months ended June 30, 2020, compared to $2,065,549 for the three months ended June 30, 2019. The decrease is attributable to a company-wide initiative to reduce general and administrative costs, including a substantial reduction in the number of employees involved in administrative functions.

Other expense

Other expenses increased $654,739 to $1,092,554 for the three months ended June 30, 2020, compared to $437,815 for the three months ended June 30, 2019. The increase in other expense is primarily the result of the $286,059 default penalty related to the note payable to Iliad Research and Trading, LP, which is recorded in other expense, and an increase of $357,498 in interest expense due to larger debt balances outstanding at higher effective interest rates.

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

Current Liquidity

The Company will need additional capital to implement its strategies. There is no assurance that it will be able to raise the amount of capital needed for future growth plans. Even if financing is available, it may not be on terms that are acceptable. If unable to raise the necessary capital at the times required, the Company may have to materially change the business plan, including delaying implementation of aspects of the business plan or curtailing or abandoning the business plan. The Company represents a speculative investment and investors may lose all of their investment. In order to be able to achieve the strategic goals, the Company needs to further expand its business and financing activities. Based on the Company's cash position, it is necessary to raise additional capital by the end of the next quarter in order to continue to fund current operations. These factors raise substantial doubt about the ability to continue as a going concern. The Company is pursuing several alternatives to address this situation, including the raising of additional funding through equity or debt financings. In order to finance existing operations and pay current liabilities over the next twelve months, the Company will need to raise additional capital. No assurance can be given that the Company will be able to operate profitably on a consistent basis, or at all, in the future.

The principal sources of liquidity to date have been cash generated from sales of debt and equity securities and loans.

At June 30, 2020, cash was $101,230, other current assets excluding cash were $7,019,880, and our working capital deficit was $(5,381,534). At the same time, current liabilities were $12,502,644 and consisted principally of $2,712,122 in accounts payable, $1,843,698 in accrued liabilities, $6,327,113 in notes and convertible notes payable, net of $(247,695) in discounts, $712,176 in indebtedness to related parties, a note payable to related party of $151,923, $601,822 in income tax payable, and $146,211 in current finance lease obligations. At March 31, 2020, the Company had a cash balance of $151,766, other current assets excluding cash were $6,849,114, and our working capital deficit was $(3,884,877). Current liabilities were $10,885,757, which consisted principally of $2,559,914 in accounts payable, $1,285,664 in accrued liabilities, $5,534,728 in notes and convertible notes payable, $586,512 of indebtedness to related parties, a note payable to related party of $151,923, $592,982 in income taxes payable, and $166,769 in current finance lease obligations.

Table of Contents

Sources and Uses of Cash

Operating Activities

Net cash used in operating activities was $(323,845) for the three months ended June 30, 2020, compared to $(2,631,121) for the three months ended June 30, 2019, including $(883,295) used in discontinued operations. We anticipate that cash flows from operations may be insufficient to fund business operations for the next twelve-month period. Accordingly, we will have to generate additional liquidity or cash flow to fund our current and anticipated operations. This will likely require the sale of additional common stock or other securities. There is no assurance that we will be able to realize any significant proceeds from such sales, if at all.

Investing Activities

During the three months ended June 30, 2020, the Company used no cash in investing activities, compared to $(257,674) during the three months ended June 30, 2019, including $(48,000) used in discontinued operations. The cash used in investing activities during the three months ended June 30, 2019 was primarily for the purchase of property and equipment and the acquisition of intangible assets.

Financing Activities

During the three months ended June 30, 2020 and 2019, cash flows provided by financing activities totaled $273,309 and $2,802,349, respectively. Cash flows from financing activities for the three months ended June 30, 2020 related primarily to $151,202 in proceeds from warrant exercises and $150,000 in proceeds from the issuance of a note payable, offset by $(17,772) of principal payments on debt and finance lease obligations and $(15,121) in brokerage fees. Cash flows from financing activities for the three months ended June 30, 2019 related primarily to $745,975 in proceeds from the sale of common stock and $2,500,000 in proceeds from issuing convertible notes, offset by $(175,000) in fees for the issuance of a convertible note, $(91,104) of brokerage fees, and $(62,641) of principal payments on debt and finance lease obligations.

Going Concern

Table of Contents

VARIABLES AND TRENDS

In the event the Company is able to obtain the necessary financing to progress with its business plan, the Company expects expenses to increase significantly to grow the business. Accordingly, the comparison of the financial data for the periods presented may not be a meaningful indicator of future performance and must be considered in light of these circumstances.

CRITICAL ACCOUNTING POLICIES

A description of the Company's significant accounting policies is included in Note 3 of its Annual Report on Form 10–K for the fiscal year ended March 31, 2020.

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are designed to ensure that material information required to be disclosed in the periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to management, including the chief executive officer and chief financial officer as appropriate, to allow timely decisions regarding required disclosure. At the end of the quarter ended June 30, 2020, the Company carried out an evaluation, under the supervision and with the participation of management, including the principal executive officer and the principal financial officer, of the effectiveness of the design and operation of disclosure controls and procedures, as defined in Rule 13(a)-15(e) and Rule 15d-15(e) under the 1934 Act. Based on this evaluation, management concluded that as of June 30, 2020, the disclosure controls and procedures were not effective due to material weaknesses as no member of our board of directors qualifies as an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K promulgated under the Securities Act.

Limitations on Effectiveness of Controls and Procedures

Management, including the Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), does not expect that disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Controls

During the fiscal quarter ended June 30, 2020, there have been no changes in the internal controls over financial reporting that have materially affected or are reasonably likely to materially affect the internal controls over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. Legal Proceedings

On April 22, 2020, the Company failed to repay any of the outstanding balance of the Convertible Promissory Note Payable to Iliad Research and Trading, L.P., resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10% and the Company recorded expense of $286,059 related to the default. As of June 30, 2020, the total balance due under the note was $3,146,453.

ITEM 1A. Risk Factors

There are no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, as filed with the SEC.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

On April 1, 2020, the Company entered into the Advisory Agreement with its brokers and effected a temporary decrease in the exercise price of the Company's outstanding warrants to $0.03-$.05 per share. As a result of the price reduction, the Company received notice of the exercise of 4,991,084 warrants during the June 30, 2020 and received proceeds of $136,081, net of brokerage fees of $(15,121).

On May 7, 2020, the Company received $135,000 cash from an investor, net of $(15,000) in brokerage fees, and issued a $150,000 convertible promissory note. The note bears interest at a rate of 8.0% per annum. The note is to be repaid upon the first proceeds received from the $8 million promissory note related to the sale of the Company's membership interest in GB Sciences Louisiana, LLC, or from the proceeds of the sale of the Teco Facility. As inducement to enter into the note transaction, the Company repriced 8,002,500 preexisting warrants held by the investor to an exercise price of $0.04. The repriced warrants were valued at $272,085 on the date of the transaction using the Black-Scholes Model, which exceeded the value of the warrants prior to the price reduction of $49,525 by $222,560. As the result of the increase in the estimated fair value of the warrants, the Company recorded a full discount on notes payable of $(150,000).

Table of Contents

ITEM 3. Defaults Upon Senior Securities

ITEM 4. Mine Safety Disclosures

Not Applicable.

ITEM 5. Other Information

None.

ITEM 6. Exhibits

In reviewing the agreements included as exhibits to this Form 10-Q, please remember that they are included to provide you with information regarding their terms and are not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties have been made solely for the benefit of the parties to the applicable agreement and:

●should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;

●have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;

●may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and

●were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments.

Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Additional information about the Company may be found elsewhere in this Form 10-Q and the Company’s other public filings, which are available without charge through the SEC’s website at http://www.sec.gov.

Table of Contents

The following exhibits are included as part of this report:

Exhibit Number		Description of Exhibit
3.1		Articles of Incorporation (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)
3.2		Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.2 to Form S-1/A No. 333-82580 filed with the Commission on October 6, 2014 and Exhibit 3.2 to the Annual Report on Form 10-K filed with the Commission on June 27, 2014)
3.3		Articles of Incorporation (Incorporated by reference to Exhibit 3.3 to the Annual Report on Form 10-K filed with the Commission on August 28, 2020)
3.4		Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.3 to the Annual Report on Form 10-K filed with the Commission on August 28, 2020)
3.5		Bylaws (Incorporated by reference to an exhibit to Form SB-2 No. 333-82580 filed with the Commission on February 12, 2002)
31.1		Certification of Principal Executive Officer and Pursuant to Rule 13a-14
31.2		Certification of Principal Financial Officer Pursuant to Rule 13a-14
32.1*		CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
32.2*		CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Extension Labels Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

* This certification is being furnished and shall not be deemed “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

Table of Contents

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GB SCIENCES, INC.

September 2, 2020	By:	/s/ John Poss
	John Poss, Chief Executive Officer (Principal Executive Officer)

	GB SCIENCES, INC.

September 2, 2020	By:	/s/ Zach Swarts
	Zach Swarts, Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 ex_200414.htm EXHIBIT 31.1 ex_168439.htm

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John Poss, certify that:

1.I have reviewed this quarterly report on Form 10-Q of GB Sciences, Inc.;

2.Based on my knowledge, the quarterly report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures; and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: September 2, 2020

/s/ John Poss

John Poss, Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_200415.htm EXHIBIT 31.2 ex_168440.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Zach Swarts, certify that:

1.I have reviewed this quarterly report on Form 10-Q of GB Sciences, Inc.;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: September 2, 2020

/s/ Zach Swarts

Zach Swarts, Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 ex_200416.htm EXHIBIT 32.1 ex_168441.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GB Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Poss, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: September 2, 2020	/s/ John Poss
	John Poss, Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 ex_200417.htm EXHIBIT 32.2 ex_168442.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GB Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Zach Swarts, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 2, 2020	/s/ Zach Swarts
	Zach Swarts, Chief Financial Officer (Principal Financial Officer)

EX-101.INS 6 gblx-20200630.xml XBRL INSTANCE DOCUMENT false --03-31 Q1 2021 2020-06-30 10-Q 0001165320 280532686 Yes false Non-accelerated Filer Yes GB SCIENCES INC false true 250000 250000 250000 15121 4991084 8000000 28804000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font: inherit;">6</div> – Convertible Notes </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"> March 2017 </div><div style="display: inline; font-style: italic; font: inherit;">$2M</div> Convertible Note Offering</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font: inherit;"> March 2017, </div>the Company entered into a Placement Agent's Agreement with a <div style="display: inline; font-style: italic; font: inherit;">third</div>-party brokerage firm to offer units consisting of a <div style="display: inline; font-style: italic; font: inherit;">$1,000</div> <div style="display: inline; font-style: italic; font: inherit;">6%</div> promissory note convertible into <div style="display: inline; font-style: italic; font: inherit;">4,000</div> shares of the Company's common stock at <div style="display: inline; font-style: italic; font: inherit;">$0.25</div> per share and <div style="display: inline; font-style: italic; font: inherit;">4,000</div> warrants to purchase shares of the Company's' common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.60</div> per share for the period of <div style="display: inline; font-style: italic; font: inherit;">three</div> years. Between <div style="display: inline; font-style: italic; font: inherit;"> March 2017 </div>and <div style="display: inline; font-style: italic; font: inherit;"> May 2017, </div>the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of <div style="display: inline; font-style: italic; font: inherit;">$2,000,000.</div> The Notes are payable within <div style="display: inline; font-style: italic; font: inherit;">three</div> years of issuance and are convertible into <div style="display: inline; font-style: italic; font: inherit;">8,000,000</div> shares of the Company's common stock. The Company also issued <div style="display: inline; font-style: italic; font: inherit;">8,000,000</div> common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> share of common stock of the Company at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.60</div> per share for a period of <div style="display: inline; font-style: italic; font: inherit;">three</div> years.  The Company recorded an aggregate discount on convertible notes of <div style="display: inline; font-style: italic; font: inherit;">$1,933,693,</div> which included <div style="display: inline; font-style: italic; font: inherit;">$904,690</div> related to the relative fair value of beneficial conversion features and <div style="display: inline; font-style: italic; font: inherit;">$1,029,003</div> for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"> July 2017 </div><div style="display: inline; font-style: italic; font: inherit;">$7.2M</div> Convertible Note Offering</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font: inherit;"> July, 2017, </div>the Company entered into a Placement Agent's Agreement with a <div style="display: inline; font-style: italic; font: inherit;">third</div>-party brokerage firm to offer units consisting of a <div style="display: inline; font-style: italic; font: inherit;">$1,000</div> <div style="display: inline; font-style: italic; font: inherit;">6%</div> promissory note convertible into <div style="display: inline; font-style: italic; font: inherit;">4,000</div> shares of the Company's common stock at <div style="display: inline; font-style: italic; font: inherit;">$0.25</div> per share and <div style="display: inline; font-style: italic; font: inherit;">4,000</div> warrants to purchase shares of the Company's' common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.65</div> per share for the period of <div style="display: inline; font-style: italic; font: inherit;">three</div> years. Between <div style="display: inline; font-style: italic; font: inherit;"> July 2017 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 2017, </div>the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of <div style="display: inline; font-style: italic; font: inherit;">$7,201,000.</div> The Notes are payable within <div style="display: inline; font-style: italic; font: inherit;">three</div> years of issuance and are convertible into <div style="display: inline; font-style: italic; font: inherit;">28,804,000</div> shares of the Company's common stock. The Company also issued <div style="display: inline; font-style: italic; font: inherit;">28,804,000</div> common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> share of common stock of the Company at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$0.60</div> per share for a period of <div style="display: inline; font-style: italic; font: inherit;">three</div> years.The Company recorded an aggregate discount on convertible notes of <div style="display: inline; font-style: italic; font: inherit;">$7,092,796,</div> which included <div style="display: inline; font-style: italic; font: inherit;">$3,142,605</div> related to the relative fair value of beneficial conversion features and <div style="display: inline; font-style: italic; font: inherit;">3,950,191</div> for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">As of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, convertible notes having a carrying value of <div style="display: inline;">$ <div style="display: inline; font-style: italic; font: inherit;">1,198,188</div></div>, net of unamortized discount of <div style="display: inline;">$ (<div style="display: inline; font-style: italic; font: inherit;">58,812</div>)</div> remained outstanding from the <div style="display: inline; font-style: italic; font: inherit;"> March 2017 </div>and <div style="display: inline; font-style: italic; font: inherit;"> July 2017 </div>note offerings, and accrued interest on the notes is <div style="display: inline; font-style: italic; font: inherit;">$228,052.</div> Discount amortization was <div style="display: inline; font-style: italic; font: inherit;">$96,527</div> for the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8%</div> Senior Secured</div> <div style="display: inline; font-weight: bold;">Convertible Promissory Note dated <div style="display: inline; font-style: italic; font: inherit;"> February 28, 2019</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> February 28, 2019, </div>the Company issued a <div style="display: inline; font-style: italic; font: inherit;">$1,500,000</div> <div style="display: inline; font-style: italic; font: inherit;">8%</div> Senior Secured Convertible Promissory Note and entered into the Note Purchase Agreement and Security Agreement with CSW Ventures, L.P. (together, “CSW Note”). The note matures on <div style="display: inline; font-style: italic; font: inherit;"> August 28, 2020 </div>and is convertible at any time until maturity into <div style="display: inline; font-style: italic; font: inherit;">8,823,529</div> shares of the Company's common stock at <div style="display: inline; font-style: italic; font: inherit;">$0.17</div> per share. Collateral pledged as security for the note includes all of the Company's <div style="display: inline; font-style: italic; font: inherit;">100%</div> membership interests in GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC, which together represent substantially all of the Company's cannabis cultivation and production operations and assets located at the Teco facility in Las Vegas, Nevada. The intrinsic value of the beneficial conversion feature resulting from the market price of the Company's common stock in excess of the conversion price was <div style="display: inline; font-style: italic; font: inherit;">$176,471</div> on the date of issuance, and the Company recorded a discount on the CSW Note in that amount.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> May 28, 2019, </div>the Company received notice from CSW Ventures, L.P. of the conversion of a total of <div style="display: inline; font-style: italic; font: inherit;">$170,000</div> of the principal balance of the <div style="display: inline; font-style: italic; font: inherit;">8%</div> Senior Secured Promissory Note dated <div style="display: inline; font-style: italic; font: inherit;"> February 28, 2019. </div>Accordingly, the Company issued <div style="display: inline; font-style: italic; font: inherit;">1,000,000</div> shares of its common stock based on a <div style="display: inline; font-style: italic; font: inherit;">$0.17</div> per share conversion price. In connection with the conversions, $ <div style="display: inline; font-style: italic; font: inherit;">17,225</div> in unamortized discount was recorded as interest expense and the Company reduced the carrying amount of convertible notes payable by <div style="display: inline; font-style: italic; font: inherit;">$152,775.</div> After conversion, the remaining balance outstanding was <div style="display: inline; font-style: italic; font: inherit;">$1,330,000.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> July 12, 2019, </div>the Company entered into the Amendment to Note Documents and the Amended and Restated <div style="display: inline; font-style: italic; font: inherit;">8%</div> Senior Secured Promissory Note (together, “Amended CSW Note”). The Amended CSW Note increased the note balance by <div style="display: inline; font-style: italic; font: inherit;">$100,000</div> to reflect an additional <div style="display: inline; font-style: italic; font: inherit;">$100,000</div> advanced to the Company on <div style="display: inline; font-style: italic; font: inherit;"> July 12, 2019, </div>by <div style="display: inline; font-style: italic; font: inherit;">$41,863</div> to add accrued interest to date to the principal balance, and decreased the conversion price to <div style="display: inline; font-style: italic; font: inherit;">$0.11</div> per share, with the remaining terms substantially unchanged from the original CSW Note.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We evaluated the modification under the guidance in ASC <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">50</div> and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the carrying value of the CSW Note on the amendment date. The carrying value of the amended note on the date of extinguishment was <div style="display: inline; font-style: italic; font: inherit;">$1,338,057,</div> net of a beneficial conversion feature discount of <div style="display: inline; font-style: italic; font: inherit;">$133,806,</div> and we recorded a loss on extinguishment of <div style="display: inline; font-style: italic; font: inherit;">$124,158.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> August 1, 2019, </div>the Company received notice from CSW Ventures, L.P. of the conversion of a total of $ <div style="display: inline; font-style: italic; font: inherit;">110,000</div> of the principal balance of the Amended CSW Note at <div style="display: inline; font-style: italic; font: inherit;">$0.11</div> per share. Accordingly, the Company issued <div style="display: inline; font-style: italic; font: inherit;">1,000,000</div> shares of its common stock. In connection with the conversions, <div style="display: inline; font-style: italic; font: inherit;">$9,579</div> in unamortized discount was recorded as interest expense and the Company has reduced the carrying amount of convertible notes payable by <div style="display: inline; font-style: italic; font: inherit;">$100,421.</div> After conversion, the remaining balance outstanding was $ <div style="display: inline; font-style: italic; font: inherit;">1,361,863.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> October 23, 2019, </div>the Company entered into the Amendment to Promissory Note. The <div style="display: inline; font-style: italic; font: inherit;"> October 23, 2019 </div>amendment decreased the conversion price to <div style="display: inline; font-style: italic; font: inherit;">$0.08</div> per share, with the remaining terms substantially unchanged from the Amended CSW Note.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We evaluated the modification under the guidance in ASC <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">50</div> and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the carrying value of the Amended CSW Note immediately prior to the <div style="display: inline; font-style: italic; font: inherit;">2nd</div> Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was <div style="display: inline; font-style: italic; font: inherit;">$1,269,067,</div> net of a beneficial conversion feature discount of <div style="display: inline; font-style: italic; font: inherit;">$92,796,</div> and we recorded a loss on extinguishment of <div style="display: inline; font-style: italic; font: inherit;">$92,796.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> November 27, 2019, </div>the Company entered into the Second Amendment to Note Documents and the Second Amended and Restated <div style="display: inline; font-style: italic; font: inherit;">8%</div> Senior Secured Promissory Note (together, <div style="display: inline; font-style: italic; font: inherit;">“2nd</div> Amended CSW Note”). The <div style="display: inline; font-style: italic; font: inherit;">2nd</div> Amended CSW Note decreased the conversion price to <div style="display: inline; font-style: italic; font: inherit;">$0.04</div> per share and increased the note balance by <div style="display: inline; font-style: italic; font: inherit;">$30,000</div> to reflect an advance received on that date, with the remaining terms substantially unchanged from the Amended CSW Note.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"> We evaluated the modification under the guidance in ASC <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">50</div> and determined that the <div style="display: inline; font-style: italic; font: inherit;">2nd</div> Amended CSW Note represents an extinguishment because the change in the fair value of the conversion feature exceeded <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the carrying value of the Amended CSW Note immediately prior to the <div style="display: inline; font-style: italic; font: inherit;">2nd</div> Amended CSW Note; however, <div style="display: inline; font-style: italic; font: inherit;">no</div> loss on extinguishment was recorded because the net consideration paid for the <div style="display: inline; font-style: italic; font: inherit;">2nd</div> Amended CSW Note was equal to the extinguished carrying value of the Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was <div style="display: inline; font-style: italic; font: inherit;">$1,361,863.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> December 16, 2019, </div>the Company received notice from CSW Ventures, L.P. of the conversion of a total of <div style="display: inline; font-style: italic; font: inherit;">$120,000</div> of the principal balance of the Amended CSW Note at <div style="display: inline; font-style: italic; font: inherit;">$0.04</div> per share and we issued <div style="display: inline; font-style: italic; font: inherit;">3,000,000</div> shares of common stock. In connection with the conversions, <div style="display: inline; font-style: italic; font: inherit;">$57,551</div> in unamortized discount was recorded as interest expense, and the Company has reduced the carrying amount of convertible notes payable by <div style="display: inline; font-style: italic; font: inherit;">$62,449.</div> After conversion, the remaining balance outstanding was <div style="display: inline; font-style: italic; font: inherit;">$1,271,863</div> and the carrying amount of the note was <div style="display: inline; font-style: italic; font: inherit;">$687,021,</div> net of <div style="display: inline; font-style: italic; font: inherit;">$584,842</div> in unamortized discount from the beneficial conversion feature.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">During the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, we recorded interest expense of <div style="display: inline; font-style: italic; font: inherit;">$252,573</div> related to the CSW Note and its amendments consisting of <div style="display: inline; font-style: italic; font: inherit;">$25,367</div> in accrued interest and <div style="display: inline; font-style: italic; font: inherit;">$227,206</div> related to amortization of the note discount. As of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, the carrying amount of the CSW Note was $<div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">1,089,587</div></div>, net of unamortized discount of $<div style="display: inline;">(<div style="display: inline; font-style: italic; font: inherit;">182,276</div>)</div>.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on <div style="display: inline; font-style: italic; font: inherit;"> October 1, 2019, </div><div style="display: inline; font-style: italic; font: inherit;"> January 1, 2020,  </div><div style="display: inline; font-style: italic; font: inherit;"> March 1, 2020, </div>and <div style="display: inline; font-style: italic; font: inherit;"> June 1, 2020, </div>and for nonpayment of an income tax liability related to the <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2018 </div>tax year. The terms of the note provide that the Company has <div style="display: inline; font-style: italic; font: inherit;">5</div> days to cure a default caused by nonpayment of interest and <div style="display: inline; font-style: italic; font: inherit;">ten</div> days to cure a default caused by noncompliance with affirmative or negative debt covenants. The lender has agreed to provide forbearance of the defaults in connection with the sale of the Teco facilities, and the Company anticipates that the CSW Note will be settled in full upon close of the sale of the Company's interests in its Nevada operations to an entity affiliated with CSW Ventures, L.P. (Note <div style="display: inline; font-style: italic; font: inherit;">11</div>).</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8%</div> Convertible Promissory Note dated <div style="display: inline; font-style: italic; font: inherit;"> April 23, 2019</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> April 23, 2019, </div>the Company entered into the Note Purchase Agreement with Iliad Research and Trading, L.P. ("Iliad") and issued an <div style="display: inline; font-style: italic; font: inherit;">8%</div> Convertible Promissory Note with a face value of <div style="display: inline; font-style: italic; font: inherit;">$2,765,000.</div> The Note was issued with original issue discount of <div style="display: inline; font-style: italic; font: inherit;">$265,000</div> and is convertible into shares of the Company's common stock at a price of <div style="display: inline; font-style: italic; font: inherit;">$0.17</div> per share at the option of the note holder at any time until the Note is repaid. The Note matures on <div style="display: inline; font-style: italic; font: inherit;"> April 22, 2020. </div>A total discount of <div style="display: inline; font-style: italic; font: inherit;">$440,000</div> was recorded on the note, which includes <div style="display: inline; font-style: italic; font: inherit;">$265,000</div> of original issue discount and <div style="display: inline; font-style: italic; font: inherit;">$175,000</div> in fees paid to brokers.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>the Company honored the conversion of a total of a total of <div style="display: inline; font-style: italic; font: inherit;">$125,000</div> of accrued interest on the Iliad Note at reduced conversion rates. On <div style="display: inline; font-style: italic; font: inherit;"> October 30, 2019, </div>the Company received notice of the conversion of <div style="display: inline; font-style: italic; font: inherit;">$75,000</div> at <div style="display: inline; font-style: italic; font: inherit;">$0.06</div> per share and issued <div style="display: inline; font-style: italic; font: inherit;">1,250,000</div> shares of its common stock. The fair value of the shares issued exceeded the fair value of the shares issuable under the original terms of the Note by <div style="display: inline; font-style: italic; font: inherit;">$64,706,</div> and the Company recorded an induced conversion expense. On <div style="display: inline; font-style: italic; font: inherit;"> November 18, 2019, </div>the Company received notice of the conversion of <div style="display: inline; font-style: italic; font: inherit;">$50,000</div> of the note balance at <div style="display: inline; font-style: italic; font: inherit;">$0.0375</div> per share and issued <div style="display: inline; font-style: italic; font: inherit;">1,333,333</div> shares of its common stock.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> April 22, 2020, </div>the Company failed to make payment of the principal and accrued interest due under the Iliad Note, resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by <div style="display: inline; font-style: italic; font: inherit;">10%.</div> As the result of the default, Company recorded an expense of <div style="display: inline; font-style: italic; font: inherit;">$9,559</div> related to a <div style="display: inline; font-style: italic; font: inherit;">10%</div> increase in the accrued interest balance, which is recorded in interest expense, and <div style="display: inline; font-style: italic; font: inherit;">$276,500</div> related to the <div style="display: inline; font-style: italic; font: inherit;">10%</div> increase in the principal balance, which is recorded in debt default penalty and other expense. As of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, the principal balance due under the note was $<div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">3,041,500</div></div>, including the <div style="display: inline; font-style: italic; font: inherit;">10%</div> penalty increase to the principal balance, and accrued interest was <div style="display: inline; font-style: italic; font: inherit;">$192,649,</div> including an increase of <div style="display: inline; font-style: italic; font: inherit;">$9,559</div> attributable to the <div style="display: inline; font-style: italic; font: inherit;">10%</div> default penalty.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">During the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, interest expense related to the note was <div style="display: inline; font-style: italic; font: inherit;">$130,659,</div> of which <div style="display: inline; font-style: italic; font: inherit;">$29,831</div> was amortization of the note discount and <div style="display: inline; font-style: italic; font: inherit;">$100,828</div> was interest accrued at the pre-default rate of <div style="display: inline; font-style: italic; font: inherit;">8.0%</div> through <div style="display: inline; font-style: italic; font: inherit;"> April 22, 2020, </div>and at the default rate of <div style="display: inline; font-style: italic; font: inherit;">15.0%</div> for the period from <div style="display: inline; font-style: italic; font: inherit;"> April 23, 2020 </div>through <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> May 20, 2020, </div>Iliad filed a lawsuit against the Company in the Third Judicial District Court of Salt Lake County in the State of Utah demanding repayment of the note. The lawsuit further seeks to compel the Company to participate in arbitration pursuant to the arbitration provisions contained within the Note Purchase Agreement and to prohibit the Company to raise funds through the issuance of its common stock unless the note is paid in full simultaneously with such issuance. The Company filed a confession of judgment in response to the complaint and does <div style="display: inline; font-style: italic; font: inherit;">not</div> intend to defend the lawsuit. On <div style="display: inline; font-style: italic; font: inherit;"> July 14, 2020, </div>the Court entered judgment in favor of Iliad in the amount of <div style="display: inline; font-style: italic; font: inherit;">$3,264,594</div> and the judgment accrues interest at the default rate of <div style="display: inline; font-style: italic; font: inherit;">15%</div> per annum. The Company will also be responsible for reasonable attorney's fees and costs incurred by Iliad for obtaining and collecting on the judgment. The amount of such fees has <div style="display: inline; font-style: italic; font: inherit;">not</div> been established as of the date of this report. The Company believes it will have sufficient resources to repay the Iliad Note from the proceeds of the sale of the Teco Facility and the note receivable therefrom, along with the proceeds of the note receivable from Wellcana Group from the sale of the Company's membership interest in GB Sciences Louisiana, LLC. </div></div> 7551 10 5 10 150000 286059 286059 286059 291660 1029003 3950191 4000 4000 9236 0.1 9559 0.1 0.1 0.15 276500 286059 1000 1000 521067 286059 164654 8000000 1957500 4991084 196 175979 176175 500 135581 136081 143599 3781101 -1895434 264662 100887 17263 74400 74400 -74400 17263 -17263 9559 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font: inherit;">4</div> – Leases </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from <div style="display: inline; font-style: italic; font: inherit;">2024</div> to <div style="display: inline; font-style: italic; font: inherit;">2025.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">As a result of the adoption of ASC <div style="display: inline; font-style: italic; font: inherit;">842,</div> certain real estate and equipment operating leases have been recorded on the balance sheet with a lease liability and right-of-use asset ("ROU"). Application of this standard resulted in the recognition of ROU assets of <div style="display: inline; font-style: italic; font: inherit;">$182,624,</div> net of accumulated amortization, and a corresponding lease liability of <div style="display: inline; font-style: italic; font: inherit;">$190,173</div> at the <div style="display: inline; font-style: italic; font: inherit;"> April 1, 2019, </div>the date of adoption. Accounting for finance leases is substantially unchanged.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from <div style="display: inline; font-style: italic; font: inherit;">10.2%</div> to <div style="display: inline; font-style: italic; font: inherit;">11.5%.</div> Operating leases were discounted at a rate of <div style="display: inline; font-style: italic; font: inherit;">17.0%.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of <div style="display: inline; font-style: italic; font: inherit;">12</div> months or less are <div style="display: inline; font-style: italic; font: inherit;">not</div> recorded on the consolidated balance sheet.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">During the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, finance lease costs recorded in the consolidated financial statements were <div style="display: inline; font-style: italic; font: inherit;">$143,599,</div> of which <div style="display: inline; font-style: italic; font: inherit;">$104,924</div> represents interest expense and <div style="display: inline; font-style: italic; font: inherit;">$38,675</div> represents amortization of the right-of-use assets. Operating lease costs were <div style="display: inline; font-style: italic; font: inherit;">$3,243,</div> of which <div style="display: inline; font-style: italic; font: inherit;">$1,242</div> represents interest expense and <div style="display: inline; font-style: italic; font: inherit;">$2,001</div> represents amortization of the right-of-use assets.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">  </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>, from continuing operations are as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12.4%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Year Ending</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Operating</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">March 31,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Finance Leases</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Leases</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021 (9 months)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">422,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,836</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">544,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">11,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">560,625</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">11,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">577,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,926</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">594,767</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,781,101</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total minimum lease payments</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,481,034</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">36,320</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Amount representing interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,835,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,242</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of minimum lease payments</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,645,823</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">28,078</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Current maturities of capital lease obligations</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(146,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(7,579</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term capital lease obligations</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,499,612</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,499</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> <div style=""> </div> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div></div> 15000 500000 8000000 0.08 750000 500000 P3Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12.4%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Year Ending</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Operating</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">March 31,</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Finance Leases</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Leases</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021 (9 months)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">422,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,836</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">544,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">11,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">560,625</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">11,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2024</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">577,444</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,926</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2025</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">594,767</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,781,101</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total minimum lease payments</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,481,034</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">36,320</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Amount representing interest</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,835,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,242</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Present value of minimum lease payments</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,645,823</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">28,078</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: Current maturities of capital lease obligations</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(146,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(7,579</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term capital lease obligations</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,499,612</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,499</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 1242 2 1 1 78226 500000 5224423 135000 213218 70959 3000000 0.05 0.15 0.5001 0.75 1 1 0.35 400000 40 -40 P5Y P3Y P5Y 84497 447633 109087 -5381534 3884877

2712122

2559914

192509

117967

1188938

888012

97574001

97271157

150000

176402

126650

130378

150000

96527

57551

227206

29831

510885

200382

153412936

158404020

14373642

14352868

7121110

7000880

101230

151766

101230

33574

151766

227758

101230

141312

-50536

-86446

-114881

-48000

-883295

0.04

0.60

0.65

0.60

0.03

0.05

0.25

8002500

79547077

0.0001

600000000

250000000

400000000

600000000

280532686

275541602

280532686

275541602

28054

27554

491795

624369

491795

624369

170000

1000000

3000000

1250000

1333333

170000

110000

120000

125000

75000

50000

1198188

687021

1089587

3041500

904690

3142605

176471

133806

92796

0.25

0.17

0.11

0.08

0.04

0.17

0.06

0.0375

4000

8000000

4000

28804000

8823529

324423

700000

150000

2000000

7201000

1500000

2765000

1257000

1271863

3041500

369445

485000

150000

6574808

41863

-152775

100000

-100421

30000

-62449

0.08

0.06

0.08

0.15

0.08

P3Y

178933

6607

150000

1933693

7092796

58812

17225

9579

584842

182276

265000

58812

182276

6607

247695

440000

91504

13028

99485

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Discontinued Operations</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">There were <div style="display: inline; font-style: italic; font: inherit;">no</div> assets or liabilities of discontinued operations included in the Company's condensed consolidated balance sheets as of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div> and <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020</div></div>.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div></div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="22" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">For the Three Months Ended June 30,</div></div></div></div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2020</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2019</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,065,549</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,267,389</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS FROM OPERATIONS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,779,242</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,981,082</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">OTHER EXPENSE</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Debt default penalty</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS BEFORE INCOME TAXES</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,217,057</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,481,491</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">NET LOSS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,274,449</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,538,883</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"> </div></div></div>

107738

712176

586512

712176

189423

-0.01

222560

104924

3645823

146211

166769

3499612

3533090

6481034

544296

594767

577444

560625

422801

2835211

38675

15344

12287

1776045

1699966

-124158

-92796

804708

2065549

201840

2267389

804708

2065549

59402

286307

59402

286307

-1846700

-2274449

-1837860

-2217057

-264434

-2481491

-1837860

-2217057

-1846700

-2274449

-0.01

-264434

8840

57392

8840

57392

72280

-222008

70814

-126579

8840

-8762

125664

247549

86719

-64602

311887

-3828

-192733

64706

151742

795313

437815

62594

500409

795313

437815

7321

252573

130659

1742

25367

100828

17225

228052

654760

397652

9641

192649

619491

466319

1672361

1724295

1545891

1445839

129133

91465

126470

278456

923737

1166511

0.102

0.115

0.17

36320

11779

3926

11779

8836

8242

16022755

14441362

14373642

14352868

12502644

10885757

485000

470000

500000

3264594

3234149

73050

0.4999

273309

2802349

273309

2917230

-257674

-209674

-323845

-2631121

-323845

-1747826

-2406667

-1846700

-132216

-1846700

-2406667

-1846700

-2274449

-132218

-1092554

-437815

-62594

-500409

-1092554

-437815

5224423

6327113

5534728

151923

5224423

4000000

-745306

-1779242

-201840

-1981082

-745306

-1779242

3243

190173

28078

7579

7265

20499

22515

182624

24684

26685

2001

-11182

175000

15000

175000

15121

91104

39027

170647

57057

60885

4900000

150000

2500000

8000000

4000000

745975

485000

5000

100000

136081

151202

-1846700

-2538883

-1846700

-2274449

-264434

-2538883

5360299

5533833

-3728

51344

0.203

8000000000000

17772

62641

500000

250000

750000

-99251168

-97387205

551197

910676

551197

910676

3000000

7000000

3000000

300000

1000000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="22" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">For the Three Months Ended June 30,</div></div></div></div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2020</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2019</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,065,549</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,267,389</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS FROM OPERATIONS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,779,242</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,981,082</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">OTHER EXPENSE</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Debt default penalty</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS BEFORE INCOME TAXES</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,217,057</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,481,491</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">NET LOSS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,274,449</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,538,883</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">June 30, 2020</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">March 31, 2020</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">129,133</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">91,465</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Work in progress</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">923,737</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,166,511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">619,491</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">466,319</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subtotal</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,672,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,724,295</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Allowance to reduce inventory to net realizable value</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(126,470</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(278,456</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total inventory, net</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1,545,891</div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1,445,839</div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

176402

13366334

0.28

240627102

246852769

275541602

280532686

1330000

1338057

1361863

1269067

1361863

1271863

1198188

1089587

3041500

362838

485000

150000

6327113

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font: inherit;">1</div> – Background and Significant Accounting Policies</div> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses  through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes <div style="display: inline; font-style: italic; font: inherit;">two</div> issued USPTO Patents, <div style="display: inline; font-style: italic; font: inherit;">five</div> USPTO patent applications, <div style="display: inline; font-style: italic; font: inherit;">four</div> provisional USPTO patent applications, and <div style="display: inline; font-style: italic; font: inherit;">one</div> USPTO application that we anticipate filing by the end of calendar year <div style="display: inline; font-style: italic; font: inherit;">2020,</div> as well as licenses for <div style="display: inline; font-style: italic; font: inherit;">three</div> additional patents covering novel cannabinoid delivery systems. In addition to the USPTO patents and patent applications, the company has filed <div style="display: inline; font-style: italic; font: inherit;">28</div> patent applications internationally.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We were incorporated in the State of Delaware on <div style="display: inline; font-style: italic; font: inherit;"> April 4, 2001, </div>under the name “Flagstick Venture, Inc.” On <div style="display: inline; font-style: italic; font: inherit;"> March 28, 2008, </div>stockholders owning a majority of our outstanding common stock approved changing our then name “Signature Exploration and Production Corp.” as our business model had changed.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> March 13, 2014, </div>we entered into a definitive assets purchase agreement for the acquisition of assets, including the Growblox™ cultivation technology which resulted in a change in our corporate name on <div style="display: inline; font-style: italic; font: inherit;"> April 4, 2014, </div>from Signature Exploration and Production Corporation to Growblox Sciences, Inc.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Effective <div style="display: inline; font-style: italic; font: inherit;"> December 12, 2016, </div>the Company amended its Certificate of Corporation pursuant to shareholder approval as reported in the Form <div style="display: inline; font-style: italic; font: inherit;">8</div>-K filed on <div style="display: inline; font-style: italic; font: inherit;"> October 14, 2016.  </div>Pursuant to the amendment the Company's name was changed from Growblox Sciences, Inc. to GB Sciences, Inc.  </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Effective <div style="display: inline; font-style: italic; font: inherit;"> April 8, 2018, </div>Shareholders of the Company approved the change in corporate domicile from the State of Delaware to the State of Nevada and increase in the number of authorized capital shares from <div style="display: inline; font-style: italic; font: inherit;">250,000,000</div> to <div style="display: inline; font-style: italic; font: inherit;">400,000,000.</div> Effective <div style="display: inline; font-style: italic; font: inherit;"> August 15, 2019, </div>Shareholders of the Company approved an increase in authorized capital shares from <div style="display: inline; font-style: italic; font: inherit;">400,000,000</div> to <div style="display: inline; font-style: italic; font: inherit;">600,000,000.</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-Q and Article <div style="display: inline; font-style: italic; font: inherit;">8</div> of Regulations S-<div style="display: inline; font-style: italic; font: inherit;">X.</div> Accordingly, they do <div style="display: inline; font-style: italic; font: inherit;">not</div> include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are <div style="display: inline; font-style: italic; font: inherit;">not</div> necessarily indicative of the results that <div style="display: inline; font-style: italic; font: inherit;"> may </div>be expected for the year ending <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021. </div>The balance sheet at <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020</div></div> has been derived from the audited financial statements at that date but does <div style="display: inline; font-style: italic; font: inherit;">not</div> include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's annual report on Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K for the year ended <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020</div></div>.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are <div style="display: inline; font-style: italic; font: inherit;">not</div> wholly owned is included as a separate component of equity. The non-controlling participants' share of the net loss is included as “Net loss attributable to non-controlling interest” on the unaudited consolidated statements of operations.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.  The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies.  These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. The actual results the Company experiences <div style="display: inline; font-style: italic; font: inherit;"> may </div>differ materially and adversely from these estimates.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC have been separated from the comparative period amounts to confirm to the current period presentation as discontinued operations as the result of the sale of the Company's interest in GB Sciences Louisiana, LLC (Note <div style="display: inline; font-style: italic; font: inherit;">10</div>). The reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on the reported financial position, results of operations or cash flows of the Company.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Discontinued Operations</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">There were <div style="display: inline; font-style: italic; font: inherit;">no</div> assets or liabilities of discontinued operations included in the Company's condensed consolidated balance sheets as of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div> and <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020</div></div>.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div></div> were as follows:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div> <div> <table style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="22" rowspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">For the Three Months Ended June 30,</div></div></div></div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2020</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">2019</div></div></div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Continuing</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Discontinued</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Sales revenue</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">551,197</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">910,676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(491,795</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(624,369</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">59,402</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">286,307</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">804,708</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,065,549</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,267,389</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS FROM OPERATIONS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(745,306</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,779,242</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(201,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,981,082</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">OTHER EXPENSE</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(795,313</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">Debt default penalty</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">(286,059</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(11,182</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total other expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(1,092,554</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(437,815</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(62,594</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(500,409</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">LOSS BEFORE INCOME TAXES</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,837,860</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,217,057</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,481,491</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(8,840</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(57,392</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">NET LOSS</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">-</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(1,846,700</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,274,449</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(264,434</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">(2,538,883</div></div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;" nowrap="nowrap"><div style="display: inline; font-weight: bold;">)</div></td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"> </div> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Long-Lived Assets</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment <div style="display: inline; font-style: italic; font: inherit;"> may </div>exist under authoritative guidance. The annual testing date is <div style="display: inline; font-style: italic; font: inherit;"> March 31. </div>When management believes impairment indicators <div style="display: inline; font-style: italic; font: inherit;"> may </div>exist, projections of the undiscounted future cash flows associated with the use of and eventual disposition of property and equipment are prepared. If the projections indicate that the carrying value of the property and equipment are <div style="display: inline; font-style: italic; font: inherit;">not</div> recoverable, we reduce the carrying values to fair value. These impairment tests are heavily influenced by assumptions and estimates that are subject to change as additional information becomes available. <div style="display: inline; font-style: italic; font: inherit;">No</div> indicators of impairment were identified by the Company as of <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div>.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Inventory</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">We value our inventory at the lower of the actual cost of our inventory, as determined using the <div style="display: inline; font-style: italic; font: inherit;">first</div>-in, <div style="display: inline; font-style: italic; font: inherit;">first</div>-out method, or its current estimated net realizable value. We periodically review our physical inventory for excess, obsolete, and potentially impaired items and reserve accordingly. Our reserve estimate for excess and obsolete inventory is based on expected future use.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Beneficial Conversion Feature of Convertible Notes Payable</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic <div style="display: inline; font-style: italic; font: inherit;">470</div>-<div style="display: inline; font-style: italic; font: inherit;">20,</div> Debt with Conversion and Other Options and Emerging Issues Task Force (“EITF”) <div style="display: inline; font-style: italic; font: inherit;">00</div>-<div style="display: inline; font-style: italic; font: inherit;">27,</div> “Application of Issue <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">98</div>-<div style="display: inline; font-style: italic; font: inherit;">5</div> to Certain Convertible Instruments”.  A beneficial conversion feature (“BCF”) exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after <div style="display: inline; font-style: italic; font: inherit;">first</div> considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. In accordance with this guidance, the BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The Company calculates the fair value of warrants issued with the convertible notes using the Black-Scholes valuation model and uses the same assumptions for valuing any employee options in accordance with ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718</div> Compensation – Stock Compensation. The only difference is that the contractual life of the warrants is used.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Revenue Recognition</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The FASB issued Accounting Standards Codification (“ASC”) <div style="display: inline; font-style: italic; font: inherit;">606</div> as guidance on the recognition of revenue from contracts with customers. Revenue recognition depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits <div style="display: inline; font-style: italic; font: inherit;">two</div> methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company adopted the guidance on <div style="display: inline; font-style: italic; font: inherit;"> April 1, 2018 </div>and applied the cumulative catch-up transition method.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC <div style="display: inline; font-style: italic; font: inherit;">606,</div> the Company is required to separately identify each performance obligation resulting from its contracts from customers, which <div style="display: inline; font-style: italic; font: inherit;"> may </div>be a good or a service. A contract <div style="display: inline; font-style: italic; font: inherit;"> may </div>contain <div style="display: inline; font-style: italic; font: inherit;">one</div> or more performance obligations. All of the Company's contracts with customers, past and present, contain only a single performance obligation, the delivery of distinct physical goods. Because fulfillment of the company's performance obligation to the customer under ASC <div style="display: inline; font-style: italic; font: inherit;">606</div> results in the same timing of revenue recognition as under the previous guidance (i.e. revenue is recognized upon delivery of physical goods), the Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> record any material adjustment to report the cumulative effect of initial application of the guidance.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Earnings/(loss) per Share</div></div> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had <div style="display: inline; font-style: italic; font: inherit;">153,412,936</div> and <div style="display: inline; font-style: italic; font: inherit;">158,404,020</div> potentially dilutive common shares at <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> June 30, 2020</div></div> and <div style="display: inline;"><div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020</div></div>, respectively. However, such common stock equivalents were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-style: italic;">Recently Adopted Standards</div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> "Financial Instruments—Credit Losses (Topic <div style="display: inline; font-style: italic; font: inherit;">326</div>): Measurement of Credit Losses on Financial Instruments" ("ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13"</div>).  Financial Instruments—Credit Losses (Topic <div style="display: inline; font-style: italic; font: inherit;">326</div>) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities.  For assets held at amortized cost basis, Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses.  The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected.  For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> will require that credit losses be presented as an allowance rather than as a write-down.  ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13</div> affects entities holding financial assets and net investment in leases that are <div style="display: inline; font-style: italic; font: inherit;">not</div> accounted for at fair value through net income.  The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets <div style="display: inline; font-style: italic; font: inherit;">not</div> excluded from the scope that have the contractual right to receive cash.  The amendments in this ASU are effective for smaller reporting companies for fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2022, </div>including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">In <div style="display: inline; font-style: italic; font: inherit;"> August 2018, </div>the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> “<div style="display: inline; font-style: italic;">Fair Value Measurement (Topic <div style="display: inline; font-style: italic; font: inherit;">820</div>): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</div>.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2019, </div>and interim periods within those fiscal years. The Company adopted the standard on <div style="display: inline; font-style: italic; font: inherit;"> April 1, 2020. </div>The adoption of this guidance did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a material impact on the Company's financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">All other newly issued accounting pronouncements but <div style="display: inline; font-style: italic; font: inherit;">not</div> yet effective have been deemed either immaterial or <div style="display: inline; font-style: italic; font: inherit;">not</div> applicable.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"></div></div>

1000000

3668167

100

169900

170000

367

478329

478696

-1649113

-88494

24063

93020015

-84743836

8855757

17155999

-7551

24686

94095065

-87232454

8723541

15610838

27554

97271157

-97387205

28054

97574001

-99251168

601822

592982

272085

49525

P3Y

277968516

244036524

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001165320 gblx:WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember 2017-03-01 2017-03-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-03-01 2017-03-31 0001165320 gblx:WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember 2017-03-01 2017-05-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-03-01 2017-05-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-03-01 2017-05-31 0001165320 gblx:WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember 2017-07-01 2017-07-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-07-01 2017-07-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-07-01 2017-07-31 0001165320 gblx:WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember 2017-07-01 2017-12-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-07-01 2017-12-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-07-01 2017-12-31 0001165320 gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2017-09-18 2017-09-18 0001165320 gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2017-09-18 2020-06-30 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member gblx:PromissoryNoteMember 2017-10-23 2017-10-23 0001165320 gblx:NevadaMedicalMarijuanaProductionLicenseAgreementMember 2017-10-23 2017-10-23 0001165320 gblx:WellcanaGroupLLCMember gblx:GBSciencesLouisianaLLCSaleOfEquityMember 2018-02-12 2018-02-12 0001165320 gblx:WellcanaGroupLLCMember gblx:GBSciencesLouisianaLLCSaleOfEquityMember 2018-02-12 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-02-28 2019-02-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-02-28 2019-02-28 0001165320 2019-04-01 2019-06-30 0001165320 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001165320 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001165320 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0001165320 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001165320 gblx:SegmentContinuingAndDiscontinuedOperationsMember 2019-04-01 2019-06-30 0001165320 us-gaap:SegmentContinuingOperationsMember 2019-04-01 2019-06-30 0001165320 us-gaap:SegmentDiscontinuedOperationsMember 2019-04-01 2019-06-30 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-04-01 2020-03-31 0001165320 gblx:GBSciencesLouisianaLLCMember 2019-04-01 2020-03-31 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-04-23 2019-04-23 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-05-28 2019-05-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-05-28 2019-05-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-07-12 2019-07-12 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-08-01 2019-08-01 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-08-01 2019-08-01 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-10-23 2019-10-23 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-10-30 2019-10-30 0001165320 gblx:WellcanaGroupLLCMember gblx:GBSciencesLouisianaLLCSaleOfEquityMember 2019-11-15 2019-11-15 0001165320 gblx:GBSciencesLouisianaLLCMember 2019-11-15 2019-11-15 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-11-18 2019-11-18 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-11-27 2019-11-27 0001165320 gblx:GbSciencesNopahLLCMember 2019-11-27 2019-11-27 0001165320 gblx:TecoMember 2019-11-27 2019-11-27 0001165320 us-gaap:LineOfCreditMember 2019-11-28 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-12-16 2019-12-16 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-12-16 2019-12-16 0001165320 gblx:TecoMember 2020-03-24 2020-03-24 0001165320 2020-04-01 2020-06-30 0001165320 gblx:WarrantsIssuedToInvestorsInPrivatePlacementsMember 2020-04-01 2020-06-30 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2020-04-01 2020-06-30 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member gblx:PromissoryNoteMember 2020-04-01 2020-06-30 0001165320 gblx:The8NotePayableDatedMay72020Member us-gaap:ConvertibleDebtMember 2020-04-01 2020-06-30 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2020-04-01 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2020-04-01 2020-06-30 0001165320 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001165320 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001165320 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001165320 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001165320 gblx:SegmentContinuingAndDiscontinuedOperationsMember 2020-04-01 2020-06-30 0001165320 us-gaap:SegmentContinuingOperationsMember 2020-04-01 2020-06-30 0001165320 us-gaap:SegmentDiscontinuedOperationsMember 2020-04-01 2020-06-30 0001165320 gblx:GBSciencesLouisianaLLCSaleOfEquityMember 2020-04-01 2020-06-30 0001165320 gblx:NevadaSubsidiariesMember 2020-04-01 2020-06-30 0001165320 gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2020-04-01 2020-06-30 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2020-04-22 2020-04-22 0001165320 gblx:PaymentOfServicesProvidedByContractorMember us-gaap:PendingLitigationMember 2020-04-22 2020-04-22 0001165320 gblx:RepricedPreexistingWarrantsWithConvertibleDebtIssuanceMember 2020-05-07 2020-05-07 0001165320 gblx:The8NotePayableDatedMay72020Member us-gaap:ConvertibleDebtMember 2020-05-07 2020-05-07 0001165320 gblx:The8NotePayableDatedMay72020Member us-gaap:ConvertibleDebtMember srt:ScenarioForecastMember 2020-07-01 2020-09-30 0001165320 gblx:RepaymentOfIliadNoteMember us-gaap:JudicialRulingMember us-gaap:SubsequentEventMember 2020-07-14 2020-07-14 0001165320 us-gaap:SubsequentEventMember gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2020-08-04 2020-08-04 0001165320 us-gaap:SubsequentEventMember gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2020-08-24 2020-08-24 0001165320 gblx:GBSciencesLouisianaLLCMember srt:ScenarioForecastMember 2020-08-24 2020-10-15 0001165320 gblx:WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember 2017-03-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-03-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-03-31 0001165320 gblx:WarrantsIssuedInMarch2017ConvertibleNoteOfferingMember 2017-05-31 0001165320 gblx:March2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-05-31 0001165320 gblx:WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember 2017-07-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-07-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2017-07-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember gblx:PromissoryNoteMember 2017-07-31 0001165320 gblx:AgreementWithLouisianaStateUniversityAgCenterMember 2017-09-18 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member gblx:PromissoryNoteMember 2017-10-23 0001165320 gblx:CultivationLicenseMember gblx:NevadaMedicalMarijuanaProductionLicenseAgreementMember 2017-10-23 0001165320 gblx:ProductionLicenseMember gblx:NevadaMedicalMarijuanaProductionLicenseAgreementMember 2017-10-23 0001165320 gblx:WarrantsRelatedToJuly2017ConvertibleNoteOfferingMember 2017-12-31 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2017-12-31 0001165320 gblx:WellcanaGroupLLCMember gblx:GBSciencesLouisianaLLCSaleOfEquityMember 2018-02-12 0001165320 gblx:WellcanaGroupLLCMember 2018-02-12 0001165320 2018-03-31 0001165320 2018-04-08 0001165320 us-gaap:CollateralPledgedMember gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:GBSciencesNevadaLLCMember gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-02-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-02-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-02-28 0001165320 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:CommonStockMember 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:NoncontrollingInterestMember 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-03-31 0001165320 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001165320 us-gaap:CommonStockMember 2019-03-31 0001165320 us-gaap:NoncontrollingInterestMember 2019-03-31 0001165320 us-gaap:RetainedEarningsMember 2019-03-31 0001165320 us-gaap:AccountingStandardsUpdate201602Member 2019-04-01 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-04-23 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-05-28 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-05-28 0001165320 2019-06-30 0001165320 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001165320 us-gaap:CommonStockMember 2019-06-30 0001165320 us-gaap:NoncontrollingInterestMember 2019-06-30 0001165320 us-gaap:RetainedEarningsMember 2019-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-07-12 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-07-12 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-08-01 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-08-01 0001165320 2019-08-15 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member gblx:PromissoryNoteMember 2019-10-23 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-10-23 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-10-23 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-10-30 0001165320 gblx:GBSciencesLouisianaLLCMember 2019-11-15 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2019-11-18 0001165320 us-gaap:LineOfCreditMember 2019-11-27 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-11-27 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-11-27 0001165320 us-gaap:LineOfCreditMember gblx:TecoNoteMember 2019-12-06 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2019-12-16 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember us-gaap:CommonStockMember 2019-12-16 0001165320 gblx:WarrantsIssuedToInvestorsInPrivatePlacementsMember srt:MaximumMember 2019-12-31 0001165320 gblx:WarrantsIssuedToInvestorsInPrivatePlacementsMember srt:MinimumMember 2019-12-31 0001165320 gblx:TecoMember 2020-03-24 0001165320 2020-03-31 0001165320 gblx:GBSciencesLouisianaLLCMember 2020-03-31 0001165320 gblx:PaymentOfServicesProvidedByContractorMember us-gaap:PendingLitigationMember 2020-03-31 0001165320 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001165320 us-gaap:CommonStockMember 2020-03-31 0001165320 us-gaap:NoncontrollingInterestMember 2020-03-31 0001165320 us-gaap:RetainedEarningsMember 2020-03-31 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2020-04-22 0001165320 gblx:RepricedPreexistingWarrantsWithConvertibleDebtIssuanceMember 2020-05-06 0001165320 gblx:RepricedPreexistingWarrantsWithConvertibleDebtIssuanceMember 2020-05-07 0001165320 gblx:The8NotePayableDatedMay72020Member us-gaap:ConvertibleDebtMember 2020-05-07 0001165320 2020-06-30 0001165320 us-gaap:LineOfCreditMember 2020-06-30 0001165320 gblx:July2017ConvertibleNoteOfferingMember us-gaap:ConvertibleNotesPayableMember 2020-06-30 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member gblx:PromissoryNoteMember 2020-06-30 0001165320 gblx:The0PercentNotePayableDatedOctober232017Member us-gaap:ConvertibleNotesPayableMember 2020-06-30 0001165320 gblx:The6PercentNotePayableDueNovember302018Member us-gaap:ConvertibleNotesPayableMember 2020-06-30 0001165320 gblx:The8ConvertiblePromissoryNoteIssuedToInvestorOnMay72020Member us-gaap:ConvertibleNotesPayableMember 2020-06-30 0001165320 gblx:The8NotePayableDatedMay72020Member us-gaap:ConvertibleDebtMember 2020-06-30 0001165320 gblx:The8PercentConvertiblePromissoryNoteDatedApril232019Member us-gaap:ConvertibleNotesPayableMember 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member srt:MaximumMember gblx:SeniorSecuredConvertiblePromissoryNoteMember 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member srt:MinimumMember gblx:SeniorSecuredConvertiblePromissoryNoteMember 2020-06-30 0001165320 gblx:The8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2020-06-30 0001165320 gblx:TheAmended8PercentSeniorSecuredConvertiblePromissoryNoteDatedFebruary282019Member gblx:SeniorSecuredConvertiblePromissoryNoteMember 2020-06-30 0001165320 gblx:GBSciencesLouisianaLLCMember 2020-06-30 0001165320 srt:MaximumMember 2020-06-30 0001165320 srt:MinimumMember 2020-06-30 0001165320 gblx:JohnDavisMember 2020-06-30 0001165320 us-gaap:LineOfCreditMember 2020-06-30 0001165320 gblx:PromissoryNoteMember 2020-06-30 0001165320 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001165320 us-gaap:CommonStockMember 2020-06-30 0001165320 us-gaap:NoncontrollingInterestMember 2020-06-30 0001165320 us-gaap:RetainedEarningsMember 2020-06-30 0001165320 srt:DirectorMember 2020-06-30 0001165320 srt:OfficerMember 2020-06-30 0001165320 gblx:OfficersAndDirectorsMember 2020-06-30 0001165320 gblx:RepaymentOfIliadNoteMember us-gaap:JudicialRulingMember us-gaap:SubsequentEventMember 2020-07-14 0001165320 us-gaap:RevolvingCreditFacilityMember gblx:July24NoteMember us-gaap:SubsequentEventMember 2020-07-24 0001165320 us-gaap:SecuredDebtMember gblx:TheJuly24NoteMember gblx:AjeManagementLLCMember us-gaap:SubsequentEventMember 2020-07-24 0001165320 gblx:TheJuly24NoteMember us-gaap:SubsequentEventMember 2020-07-24 0001165320 gblx:JohnDavisMember us-gaap:SubsequentEventMember 2020-08-04 0001165320 gblx:GBSciencesLouisianaLLCMember us-gaap:SubsequentEventMember 2020-08-23 0001165320 gblx:GBSciencesLouisianaLLCMember us-gaap:SubsequentEventMember 2020-08-24 0001165320 gblx:GBSciencesLouisianaLLCMember us-gaap:SubsequentEventMember 2020-08-31 0001165320 2020-09-01

EX-101.SCH 7 gblx-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Background and Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Going Concern link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Inventory link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Leases link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Notes Payable and Line of Credit link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Convertible Notes link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Capital Transactions link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Sale of Membership Interests in Nevada Subsidiaries link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 1 - Background and Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Inventory (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 4 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 5 - Notes Payable and Line of Credit (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 1 - Background and Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Going Concern (Details Textual) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Inventory - Schedule of Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 4 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 4 - Leases - Future Minimum Lease Payments (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Notes Payable and Line of Credit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Convertible Notes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Capital Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 12 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 gblx-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 gblx-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 gblx-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Background and Significant Accounting Policies Note 3 - Inventory Note 4 - Leases Note 5 - Notes Payable and Line of Credit Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) Note 3 - Inventory - Schedule of Inventory (Details) Note 4 - Leases - Future Minimum Lease Payments (Details) Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_LiabilitiesCurrent TOTAL CURRENT LIABILITIES Schedule of Debt [Table Text Block] us-gaap_ProceedsFromCollectionOfNotesReceivable Proceeds from Collection of Notes Receivable us-gaap_LitigationSettlementAmountAwardedToOtherParty Litigation Settlement, Amount Awarded to Other Party Notes and convertible notes payable and line of credit, net of unamortized discount of $247,695 and $608,580 at June 30, 2020 and March 31, 2020, respectively gblx_DebtInstrumentFaceAmountPerNote Debt Instrument, Face Amount Per Note The face (par) amount of each note unit offered at time of issuance. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) Induced dividend from warrant exercises The non-cash value of an induced dividend prompted by the exercise of warrants for securities which have a dividend. Income tax payable Accrued liabilities Accrued interest Interest Payable, Current Accounts payable Secured Debt [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Revolving Credit Facility [Member] Credit Facility [Axis] Credit Facility [Domain] us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_PaymentsToAcquireIntangibleAssets Acquisition of intangible assets us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_LossContingencyAccrualAtCarryingValue Loss Contingency Accrual, Ending Balance CURRENT LIABILITIES: us-gaap_Assets TOTAL ASSETS Continuing operations Discontinued operations us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Net loss us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Less: cash and cash equivalents classified as discontinued operations us-gaap_LossContingencyDamagesSoughtValue Loss Contingency, Damages Sought, Value us-gaap_IncomeLossFromContinuingOperations Net loss from continuing operations Net loss us-gaap_NetIncomeLoss NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC. Intangible assets, accumulated amortization Intangible assets, net of accumulated amortization of $15,344 and $12,287 at June 30, 2020 and March 31, 2020, respectively gblx_AnnualResearchContributions Annual Research Contributions The amount of annual research contributions made. Loss attributable to non-controlling interest Interest expense on conversion of notes payable Interest Expense, Debt, Excluding Amortization Judicial Ruling [Member] Litigation Status [Axis] Litigation Status [Domain] Pending Litigation [Member] Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Net loss NET LOSS Loss from discontinued operations Loss from discontinued operations INVESTING ACTIVITIES: Convertible Debt [Member] Convertible Notes Payable [Member] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income tax payable us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest LOSS FROM CONTINUING OPERATIONS us-gaap_IncreaseDecreaseInInterestPayableNet Accrued interest Related Party Transactions Disclosure [Text Block] Line of Credit [Member] us-gaap_IncomeTaxExpenseBenefit Income tax expense Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) gblx_IncreaseDecreaseInAccruedLiabilitiesExcludingInterestPayable Accrued expenses The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid, excluding interest payable. General and administrative expenses us-gaap_IncreaseDecreaseInDueToRelatedParties Indebtedness to related parties us-gaap_DebtInstrumentIncreaseAccruedInterest Debt Instrument, Increase, Accrued Interest gblx_NotesReceivableInterestRate Notes Receivable, Interest Rate The interest rate of the notes receivable. us-gaap_DebtInstrumentDecreaseForgiveness Debt Instrument, Decrease, Forgiveness gblx_NotesReceivableTermOfMonthlyInstallments Notes Receivable, Term of Monthly Installments (Month) The term of monthly installments of notes receivable. us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet Debt Instrument, Increase (Decrease), Net, Total us-gaap_CashAndCashEquivalentsAtCarryingValue Cash and cash equivalents us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) us-gaap_InducedConversionOfConvertibleDebtExpense Induced Conversion of Convertible Debt Expense us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Debt Instrument, Convertible, Number of Equity Instruments us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature Amendment Flag Use of Estimates, Policy [Policy Text Block] gblx_DebtInstrumentDebtDefaultAccruedInterest Debt Instrument, Debt Default, Accrued Interest The amount of accrued interest on debt instrument that has defaulted. New Accounting Pronouncements, Policy [Policy Text Block] Reclassification, Comparability Adjustment [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) gblx_DebtInstrumentDefaultExpense Debt Instrument, Default, Expense The amount of expense during the period for debt instrument that has been defaulted. Repayment of Iliad Note [Member] Represents the repayment of the Iliad note. Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage us-gaap_NotesReceivableNet Financing Receivable, after Allowance for Credit Loss, Total us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus us-gaap_OperatingLeaseCost Operating Lease, Cost us-gaap_IncreaseDecreaseInDepositOtherAssets Decrease in deposits and other noncurrent assets Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Document Period End Date Entity Emerging Growth Company Face Value, short-term notes payable Debt Instrument, Face Amount Document Type us-gaap_GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt, Total Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Payment of Services Provided by Contractor [Member] Represents payments of services provided by contractor. Officers and Directors [Member] Represents officers and directors. us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use Share based compensation expense us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Central Index Key Depreciation and amortization Entity Registrant Name Entity [Domain] Legal Entity [Axis] The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member] Represents the 8% convertible promissory note issued to an investor on May 7, 2020. Accounts receivable, allowance for doubtful accounts Entity Common Stock, Shares Outstanding (in shares) us-gaap_IncreaseDecreaseInInventories Inventory Discount on convertible notes payable attributable to warrant modification us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt Issuance of stock for debt conversion Issuance of stock for debt conversion (in shares) us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Related Party [Axis] Related Party [Domain] Bad debt expense/(recovery) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Issuance of stock for cash, net of issuance costs (in shares) Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT) Issuance of stock for cash, net of issuance costs Changes in operating assets and liabilities: Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance us-gaap_ResearchAndDevelopmentExpense Research and Development Expense, Total Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense us-gaap_InterestExpenseDebt Interest Expense, Debt, Total us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Substantial Doubt about Going Concern [Text Block] Inventory Disclosure [Text Block] Subsequent Event [Member] Operating lease obligations, long term Schedule of Inventory, Current [Table Text Block] Present value of minimum lease payments, operating leases us-gaap_OperatingLeaseLiability Operating Lease, Liability, Total Subsequent Event Type [Axis] Operating lease obligations, current Less: Current maturities of capital lease obligations, operating leases Subsequent Event Type [Domain] Finance lease obligations, current Less: Current maturities of capital lease obligations, finance leases Finance lease obligations, long term Subsequent Events [Text Block] Deposits and other noncurrent assets Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total minimum lease payments, operating leases us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Amount representing interest, operating leases Present value of minimum lease payments, finance leases us-gaap_FinanceLeaseLiability 2024, operating leases 2025, operating leases 2022, operating leases 2023, operating leases us-gaap_FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants Stock-based compensation Stock issued upon conversion of long-term note payable us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) 2021 (9 months), operating leases Earnings Per Share, Policy [Policy Text Block] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Sales revenue Amortization of debt discount and beneficial conversion feature Amortization of Debt Discount (Premium) Discontinued Operations, Policy [Policy Text Block] us-gaap_AssetsCurrent TOTAL CURRENT ASSETS us-gaap_LesseeFinanceLeaseDiscountRate Lessee, Finance Lease, Discount Rate Stockholders' Equity Note Disclosure [Text Block] gblx_UnpaidBonusesRelatedParties Unpaid Bonuses, Related Parties Amount of unpaid bonuses to related parties. gblx_UnpaidWagesRelatedParties Unpaid Wages, Related Parties Amount of unpaid wages to related parties. Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at June 30, 2020 and March 31, 2020, respectively Adjustments to reconcile net loss to net cash used in operating activities: Default penalty on convertible note payable The amount of default penalty on convertible note payable. gblx_ReimbursementForBusinessExpenseRelatedParties Reimbursement for Business Expense, Related Parties Amount of reimbursement for business expense to related parties. EX-101.PRE 11 gblx-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Jun. 30, 2020	Sep. 01, 2020
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		280,532,686
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 101,230	$ 151,766
Accounts receivable, net of allowance for doubtful accounts of $126,650 and $130,378 at June 30, 2020 and March 31, 2020, respectively	192,509	117,967
Inventory, net	1,545,891	1,445,839
Prepaid expenses and other current assets	57,057	60,885
Note receivable	5,224,423	5,224,423
TOTAL CURRENT ASSETS	7,121,110	7,000,880
Property and equipment, net	5,360,299	5,533,833
Intangible assets, net of accumulated amortization of $15,344 and $12,287 at June 30, 2020 and March 31, 2020, respectively	1,776,045	1,699,966
Deposits and other noncurrent assets	91,504	91,504
Operating lease right-of-use assets, net	24,684	26,685
TOTAL ASSETS	14,373,642	14,352,868
CURRENT LIABILITIES:
Accounts payable	2,712,122	2,559,914
Accrued interest	654,760	397,652
Accrued liabilities	1,188,938	888,012
Notes and convertible notes payable and line of credit, net of unamortized discount of $247,695 and $608,580 at June 30, 2020 and March 31, 2020, respectively	6,327,113	5,534,728
Indebtedness to related parties	712,176	586,512
Note payable to related party	151,923	151,923
Income tax payable	601,822	592,982
Finance lease obligations, current	146,211	166,769
Operating lease obligations, current	7,579	7,265
TOTAL CURRENT LIABILITIES	12,502,644	10,885,757
Operating lease obligations, long term	20,499	22,515
Finance lease obligations, long term	3,499,612	3,533,090
TOTAL LIABILITIES	16,022,755	14,441,362
Commitments and contingencies (Note 8)
STOCKHOLDERS' EQUITY:
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at June 30, 2020 and March 31, 2020, respectively	28,054	27,554
Additional paid-in capital	97,574,001	97,271,157
Accumulated deficit	(99,251,168)	(97,387,205)
TOTAL EQUITY/(DEFICIT)	(1,649,113)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY/(DEFICIT)	$ 14,373,642	$ 14,352,868

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 126,650	$ 130,378
Intangible assets, accumulated amortization	$ 15,344	12,287
Notes and convertible notes payable, unamortized discount, current
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	280,532,686	275,541,602
Common stock, shares outstanding (in shares)	280,532,686	275,541,602

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Sales revenue	$ 551,197	$ 910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
OTHER EXPENSE
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
LOSS FROM CONTINUING OPERATIONS	(1,846,700)	(2,274,449)
Loss from discontinued operations		(264,434)
NET LOSS	(1,846,700)	(2,538,883)
Loss attributable to non-controlling interest		(132,216)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(1,846,700)	(2,406,667)
Continuing operations	(1,846,700)	(2,274,449)
Discontinued operations		(132,218)
Net loss	$ (1,846,700)	$ (2,406,667)
Continuing operations (in dollars per share)	$ (0.01)	$ (0.01)
Discontinued operations (in dollars per share)
Net loss (in dollars per share)	$ (0.01)	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in shares)	277,968,516	244,036,524

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited)	3 Months Ended
	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
OPERATING ACTIVITIES:
Net loss	$ (1,846,700)	$ (2,538,883)
Loss from discontinued operations		(264,434)
Net loss from continuing operations	(1,846,700)	(2,274,449)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	13,028	99,485
Stock-based compensation		176,402
Bad debt expense/(recovery)	(3,728)	51,344
Amortization of debt discount and beneficial conversion feature	510,885	200,382
Interest expense on conversion of notes payable		17,225
Default penalty on convertible note payable	286,059
Changes in operating assets and liabilities:
Accounts receivable	(70,814)	126,579
Prepaid expenses and other current assets	3,828	192,733
Decrease in deposits and other noncurrent assets		8,762
Inventory	64,602	(311,887)
Accounts payable	72,280	(222,008)
Accrued expenses	264,662	100,887
Accrued interest	247,549	86,719
Income tax payable	8,840
Indebtedness to related parties	125,664
Net cash used in operating activities of continuing operations	(323,845)	(1,747,826)
Net cash used in operating activities of discontinued operations		(883,295)
Net cash used in operating activities	(323,845)	(2,631,121)
INVESTING ACTIVITIES:
Purchase of property and equipment		(170,647)
Acquisition of intangible assets		(39,027)
Net cash used in investing activities of continuing operations		(209,674)
Net cash used in investing activities of discontinued operations		(48,000)
Net cash used in investing activities		(257,674)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock		745,975
Proceeds from warrant exercises	151,202
Proceeds from convertible notes payable	150,000	2,500,000
Proceeds from line of credit	5,000
Fees for issuance of convertible note		(175,000)
Brokerage fees for issuance of common stock and warrants	(15,121)	(91,104)
Principal payments on debt and lease obligations	(17,772)	(62,641)
Net cash provided by financing activities of continuing operations	273,309	2,917,230
Net cash used in financing activities of discontinued operations		(114,881)
Net cash provided by financing activities	273,309	2,802,349
Net change in cash and cash equivalents	(50,536)	(86,446)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	151,766	227,758
CASH AND CASH EQUIVALENTS AT END OF PERIOD	101,230	141,312
Less: cash and cash equivalents classified as discontinued operations		(107,738)
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS	101,230	33,574
Cash paid for interest
Cash paid for income tax
Non-cash transactions:
Depreciation capitalized in inventory	164,654
Property capitalized under operating leases		213,218
Patent filing and drafting costs capitalized in intangible assets	78,226
Discount on convertible notes payable attributable to warrant modification	150,000
Stock issued upon conversion of long-term note payable		170,000
Induced dividend from warrant exercises	17,263	74,400
Cumulative effect of the new lease standard		$ 7,551

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2019			240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019	$ (7,551)	$ (7,551)
Balance at Mar. 31, 2019			$ 24,063	$ 93,020,015	$ (84,743,836)	$ 8,855,757	$ 17,155,999
Issuance of stock for debt conversion (in shares)			1,000,000
Issuance of stock for debt conversion			$ 100	169,900			170,000
Exercise of warrants for stock (in shares)			1,957,500
Exercise of warrants for stock			$ 196	175,979			176,175
Share based compensation expense				176,402			176,402
Issuance of stock for cash, net of issuance costs (in shares)			3,668,167
Issuance of stock for cash, net of issuance costs			$ 367	478,329			478,696
Exchanged shares issued to consultant for options (in shares)			(400,000)
Exchanged shares issued to consultant for options			$ (40)	40
Inducement dividend from warrant exercises				74,400	(74,400)
Net loss					(2,406,667)		(2,406,667)
Loss attributable to non-controlling interest						(132,216)	(132,216)
Balance (in shares) at Jun. 30, 2019			246,852,769
Balance at Jun. 30, 2019			$ 24,686	94,095,065	(87,232,454)	8,723,541	15,610,838
Balance (in shares) at Mar. 31, 2020			275,541,602
Balance at Mar. 31, 2020			$ 27,554	97,271,157	(97,387,205)		(88,494)
Exercise of warrants for stock (in shares)			4,991,084
Exercise of warrants for stock			$ 500	135,581			136,081
Inducement dividend from warrant exercises				17,263	(17,263)
Net loss					(1,846,700)		(1,846,700)
Loss attributable to non-controlling interest
Discount on convertible notes payable attributable to warrant modification				150,000			150,000
Balance (in shares) at Jun. 30, 2020			280,532,686
Balance at Jun. 30, 2020			$ 28,054	$ 97,574,001	$ (99,251,168)		$ (1,649,113)

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Background and Significant Accounting Policies

3 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Significant Accounting Policies [Text Block]

Note

– Background and Significant Accounting Policies

two

issued USPTO Patents,

five

USPTO patent applications,

four

provisional USPTO patent applications, and

one

USPTO application that we anticipate filing by the end of calendar year

2020,

as well as licenses for

three

additional patents covering novel cannabinoid delivery systems. In addition to the USPTO patents and patent applications, the company has filed

patent applications internationally.

We were incorporated in the State of Delaware on

April 4, 2001,

under the name “Flagstick Venture, Inc.” On

March 28, 2008,

stockholders owning a majority of our outstanding common stock approved changing our then name “Signature Exploration and Production Corp.” as our business model had changed.

March 13, 2014,

we entered into a definitive assets purchase agreement for the acquisition of assets, including the Growblox™ cultivation technology which resulted in a change in our corporate name on

April 4, 2014,

from Signature Exploration and Production Corporation to Growblox Sciences, Inc.

Effective

December 12, 2016,

the Company amended its Certificate of Corporation pursuant to shareholder approval as reported in the Form

-K filed on

October 14, 2016.

Pursuant to the amendment the Company's name was changed from Growblox Sciences, Inc. to GB Sciences, Inc.

Effective

April 8, 2018,

Shareholders of the Company approved the change in corporate domicile from the State of Delaware to the State of Nevada and increase in the number of authorized capital shares from

250,000,000

400,000,000.

Effective

August 15, 2019,

Shareholders of the Company approved an increase in authorized capital shares from

400,000,000

600,000,000.

Basis of Presentation

-Q and Article

of Regulations S-

Accordingly, they do

not

include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the periods presented are

not

necessarily indicative of the results that

may

be expected for the year ending

March 31, 2021.

The balance sheet at

March 31, 2020

has been derived from the audited financial statements at that date but does

not

include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's annual report on Form

-K for the year ended

March 31, 2020

Principles of Consolidation

not

wholly owned is included as a separate component of equity. The non-controlling participants' share of the net loss is included as “Net loss attributable to non-controlling interest” on the unaudited consolidated statements of operations.

Use of Estimates

not

readily apparent from other sources. The actual results the Company experiences

may

differ materially and adversely from these estimates.

Reclassifications

). The reclassifications had

effect on the reported financial position, results of operations or cash flows of the Company.

Discontinued Operations

There were

assets or liabilities of discontinued operations included in the Company's condensed consolidated balance sheets as of

June 30, 2020

and

March 31, 2020

The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the

three

months ended

June 30, 2020

and

2019

were as follows:

	For the Three Months Ended June 30,
	2020								2019
	Continuing			Discontinued		Total			Continuing			Discontinued			Total
Sales revenue	$	551,197		$	-	$	551,197		$	910,676		$	-		$	910,676
Cost of goods sold		(491,795	)		-		(491,795	)		(624,369	)		-			(624,369	)
Gross profit		59,402			-		59,402			286,307			-			286,307
General and administrative expenses		804,708			-		804,708			2,065,549			201,840			2,267,389
LOSS FROM OPERATIONS		(745,306	)		-		(745,306	)		(1,779,242	)		(201,840	)		(1,981,082	)
OTHER EXPENSE
Interest expense		(795,313	)		-		(795,313	)		(437,815	)		(62,594	)		(500,409	)
Debt default penalty		(286,059	)		-		(286,059	)		-			-			-
Other expense		(11,182	)		-		(11,182	)		-			-			-
Total other expense		(1,092,554	)		-		(1,092,554	)		(437,815	)		(62,594	)		(500,409	)
LOSS BEFORE INCOME TAXES		(1,837,860	)		-		(1,837,860	)		(2,217,057	)		(264,434	)		(2,481,491	)
Income tax expense		(8,840	)		-		(8,840	)		(57,392	)		-			(57,392	)
NET LOSS	$	(1,846,700	)	$	-	$	(1,846,700	)	$	(2,274,449	)	$	(264,434	)	$	(2,538,883	)

Long-Lived Assets

may

exist under authoritative guidance. The annual testing date is

March 31.

When management believes impairment indicators

may

exist, projections of the undiscounted future cash flows associated with the use of and eventual disposition of property and equipment are prepared. If the projections indicate that the carrying value of the property and equipment are

not

recoverable, we reduce the carrying values to fair value. These impairment tests are heavily influenced by assumptions and estimates that are subject to change as additional information becomes available.

indicators of impairment were identified by the Company as of

June 30, 2020

Inventory

We value our inventory at the lower of the actual cost of our inventory, as determined using the

first

-in,

first

-out method, or its current estimated net realizable value. We periodically review our physical inventory for excess, obsolete, and potentially impaired items and reserve accordingly. Our reserve estimate for excess and obsolete inventory is based on expected future use.

Beneficial Conversion Feature of Convertible Notes Payable

The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic

470

20,

Debt with Conversion and Other Options and Emerging Issues Task Force (“EITF”)

27,

“Application of Issue

No.

to Certain Convertible Instruments”. A beneficial conversion feature (“BCF”) exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after

first

considering the allocation of a portion of the note proceeds to the fair value of any attached equity instruments, if any related equity instruments were granted with the debt. In accordance with this guidance, the BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The Company calculates the fair value of warrants issued with the convertible notes using the Black-Scholes valuation model and uses the same assumptions for valuing any employee options in accordance with ASC Topic

718

Compensation – Stock Compensation. The only difference is that the contractual life of the warrants is used.

Revenue Recognition

The FASB issued Accounting Standards Codification (“ASC”)

606

as guidance on the recognition of revenue from contracts with customers. Revenue recognition depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The guidance permits

two

methods of adoption: retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). The Company adopted the guidance on

April 1, 2018

and applied the cumulative catch-up transition method.

The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC

606,

the Company is required to separately identify each performance obligation resulting from its contracts from customers, which

may

be a good or a service. A contract

may

contain

one

or more performance obligations. All of the Company's contracts with customers, past and present, contain only a single performance obligation, the delivery of distinct physical goods. Because fulfillment of the company's performance obligation to the customer under ASC

606

results in the same timing of revenue recognition as under the previous guidance (i.e. revenue is recognized upon delivery of physical goods), the Company did

not

record any material adjustment to report the cumulative effect of initial application of the guidance.

Earnings/(loss) per Share

The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had

153,412,936

and

158,404,020

potentially dilutive common shares at

June 30, 2020

and

March 31, 2020

, respectively. However, such common stock equivalents were

not

included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

Recent Accounting Pronouncements

Recently Adopted Standards

June 2016,

the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")

No.

2016

13,

"Financial Instruments—Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments" ("ASU

2016

13"

). Financial Instruments—Credit Losses (Topic

326

) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic

326

eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available-for-sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic

326

will require that credit losses be presented as an allowance rather than as a write-down. ASU

2016

affects entities holding financial assets and net investment in leases that are

not

accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets

not

excluded from the scope that have the contractual right to receive cash. The amendments in this ASU are effective for smaller reporting companies for fiscal years beginning after

December 15, 2022,

including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its financial statements.

August 2018,

the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2018

13,

“

Fair Value Measurement (Topic

820

): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement

.” This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after

December 15, 2019,

and interim periods within those fiscal years. The Company adopted the standard on

April 1, 2020.

The adoption of this guidance did

not

have a material impact on the Company's financial statements.

All other newly issued accounting pronouncements but

not

yet effective have been deemed either immaterial or

not

applicable.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern	3 Months Ended
Note 2 - Going Concern	Jun. 30, 2020
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 – Going Concern The Company's financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 99,251,168 ) at June 30, 2020 . The Company had a working capital deficit of $ ( 5,381,534 ) at June 30, 2020 , compared to $ ( 3,884,877 ) at March 31, 2020 . In addition, the Company has consumed cash in its operating activities of $ ( 323,845 ) for the three months ended June 30, 2020 , compared to $ ( 2,631,121 ) including $ ( 883,295 ) from discontinued operations for the three months ended June 30, 2019 . These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no assurances that the Company will be successful in achieving its goals. In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event the Company is unable to continue as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory

3 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Inventory Disclosure [Text Block]

Note

– Inventory

	June 30, 2020			March 31, 2020

Raw materials	$	129,133		$	91,465
Work in progress		923,737		$	1,166,511
Finished goods		619,491		$	466,319
Subtotal		1,672,361			1,724,295
Allowance to reduce inventory to net realizable value		(126,470	)		(278,456	)
Total inventory, net	$	1,545,891		$	1,445,839

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Leases

3 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Lessee, Operating and Finance Leases [Text Block]

Note

– Leases

2024

2025.

As a result of the adoption of ASC

842,

certain real estate and equipment operating leases have been recorded on the balance sheet with a lease liability and right-of-use asset ("ROU"). Application of this standard resulted in the recognition of ROU assets of

$182,624,

net of accumulated amortization, and a corresponding lease liability of

$190,173

at the

April 1, 2019,

the date of adoption. Accounting for finance leases is substantially unchanged.

10.2%

11.5%.

Operating leases were discounted at a rate of

17.0%.

Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of

months or less are

not

recorded on the consolidated balance sheet.

During the

three

months ended

June 30, 2020

, finance lease costs recorded in the consolidated financial statements were

$143,599,

of which

$104,924

represents interest expense and

$38,675

represents amortization of the right-of-use assets. Operating lease costs were

$3,243,

of which

$1,242

represents interest expense and

$2,001

represents amortization of the right-of-use assets.

Amortization of lease assets is included in general and administrative expenses. The future minimum lease payments of lease liabilities as of

June 30, 2020

, from continuing operations are as follows:

Year Ending				Operating
March 31,	Finance Leases			Leases

2021 (9 months)	$	422,801		$	8,836
2022		544,296			11,779
2023		560,625			11,779
2024		577,444			3,926
2025		594,767			-
Thereafter		3,781,101			-
Total minimum lease payments		6,481,034			36,320
Less: Amount representing interest		(2,835,211	)		(8,242	)
Present value of minimum lease payments		3,645,823			28,078
Less: Current maturities of capital lease obligations		(146,211	)		(7,579	)
Long-term capital lease obligations	$	3,499,612		$	20,499

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Notes Payable and Line of Credit

3 Months Ended

Jun. 30, 2020

Notes to Financial Statements

Debt Disclosure [Text Block]

Note

– Notes Payable and Line of Credit

Note Payable dated

October 23, 2017

October 23, 2017,

the Company amended the existing Nevada Medical Marijuana Production License Agreement (“Amended Production License Agreement”). Per the terms of the Amended Production License Agreement, GB Sciences purchased the remaining percentage of the production license resulting in the

100%

ownership of the license. GB Sciences also received

100%

ownership of the cultivation license included in the original Nevada Medical Marijuana Production License Agreement. In exchange, GB Sciences made

one

-time payment of

$500,000

and issued a

Promissory Note in the amount of

$700,000

payable in equal monthly payments over a

three

-year period commencing on

January 1, 2018.

The present value of the note was

$521,067

on the date of its issuance based on an imputed interest rate of

20.3%

and the Company recorded a discount on notes payable of

$178,933.

During the

three

months ended

June 30, 2020

, the Company recorded interest expense of

$7,321

related to amortization of the note discount. The remaining unamortized discount as of

June 30, 2020

was $

(

6,607

)

The Company has been in default on this note since

June

2019,

and as of the date of this report,

fifteen

monthly payments on the note totaling

$291,660

are unpaid. As the result of the default, the Company has accrued penalty interest at the rate of

10%

according to the terms of the Promissory Note. Total penalty interest accrued was

$9,236

for the

three

months ended

June 30, 2020

. If the Company is unable to cure the default within

ten

days of receiving a written notice, the lender will have the option to accelerate the remaining balance owed of $

369,445

, but must notify the Company in writing should it choose to do so. The Company is currently in the process of negotiating a settlement and/or forbearance agreement with the lender and anticipates repayment of the note upon receiving proceeds from the sales of the Company's Teco and Nopah facilities (Note

Line of Credit dated

November 27, 2019

In connection with the Binding Letter of Intent dated

November 27, 2019 (

Note

), the Company entered into a promissory note and received a line of credit for up to

$470,000

from the purchaser of the Company's membership interest in its Nevada facilities. The purpose of the line of credit is to supply working capital for the Nevada operations. The note matures upon the close of the sale of membership interests. As of

June 30, 2020

, the Company has received $

485,000

in advances under the line of credit, reflecting an informal agreement with the lender to increase the Line of Credit limit by

$15,000.

The Company accrued interest of

$9,641

on the line of credit for the

three

months ended

June 30, 2020

, and the balance of the line of credit was $

485,000

June 30, 2020

. Upon the close of the sale of the Teco Facility all principal and interest due under the line of credit will be considered satisfied in full.

Note Payable dated

May 7, 2020

May 7, 2020,

the Company received

$135,000

cash from an investor, net of $(

15,000

) in brokerage fees, and issued a

$150,000

promissory note. The note bears interest at a rate of

8.0%

per annum. The note is to be repaid upon the

first

proceeds received from the

$8,000,000

promissory note related to the sale of the Company's membership interest in GB Sciences Louisiana, LLC (Note

), or from the proceeds of the sale of the Teco Facility (Note

). As inducement to enter into the note transaction, the Company repriced

8,002,500

preexisting warrants held by the investor to an exercise price of

$0.04.

The repriced warrants were valued at

$272,085

on the date of the transaction using the Black-Scholes Model, which exceeded the value of the warrants prior to the price reduction of

$49,525

$222,560.

As the result of the increase in the estimated fair value of the warrants, the Company recorded a full discount on notes payable of $(

150,000

). During the

three

months ended

June 30, 2020

, the Company recorded interest expense of

$151,742

related to the note consisting of accrued interest of

$1,742

and

$150,000

related to amortization of the note discount. Unamortized discount remaining at

June 30, 2020

was

$0.

Summary of Notes Payable

As of

June 30, 2020

, the following notes payable were recorded in the Company's consolidated balance sheet:

	As of June 30, 2020
Short-Term Notes Payable	Face Value		Discount			Carrying Value
6% Convertible promissory notes payable (Note 6)	$	1,257,000	$	(58,812	)	$	1,198,188
8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6)		1,271,863		(182,276	)		1,089,587
8% Convertible Promissory Note dated April 23, 2019 (Note 6)		3,041,500		-			3,041,500
0% Note Payable dated October 23, 2017 (Note 5)		369,445		(6,607	)		362,838
8% Line of Credit dated November 27, 2019 (Note 5)		485,000		-			485,000
8% Note Payable dated May 7, 2020 (Note 5)		150,000		-			150,000
Total Short-Term Notes Payable	$	6,574,808	$	(247,695	)	$	6,327,113

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Convertible Notes	3 Months Ended
Note 6 - Convertible Notes	Jun. 30, 2020
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 – Convertible Notes March 2017 $2M Convertible Note Offering In March 2017, the Company entered into a Placement Agent's Agreement with a third -party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company's common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company's' common stock at an exercise price of $0.60 per share for the period of three years. Between March 2017 and May 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $2,000,000. The Notes are payable within three years of issuance and are convertible into 8,000,000 shares of the Company's common stock. The Company also issued 8,000,000 common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years. The Company recorded an aggregate discount on convertible notes of $1,933,693, which included $904,690 related to the relative fair value of beneficial conversion features and $1,029,003 for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model. July 2017 $7.2M Convertible Note Offering In July, 2017, the Company entered into a Placement Agent's Agreement with a third -party brokerage firm to offer units consisting of a $1,000 6% promissory note convertible into 4,000 shares of the Company's common stock at $0.25 per share and 4,000 warrants to purchase shares of the Company's' common stock at an exercise price of $0.65 per share for the period of three years. Between July 2017 and December 2017, the Company issued short-term Promissory Notes (“Notes”) to various holders with combined face value of $7,201,000. The Notes are payable within three years of issuance and are convertible into 28,804,000 shares of the Company's common stock. The Company also issued 28,804,000 common stock warrants to the Noteholders. The warrants are exercisable at any time and from time to time before maturity at the option of the holder. Each warrant gives the Noteholder the right to purchase one share of common stock of the Company at an exercise price of $0.60 per share for a period of three years.The Company recorded an aggregate discount on convertible notes of $7,092,796, which included $3,142,605 related to the relative fair value of beneficial conversion features and 3,950,191 for the relative fair value of the warrants issued with each note. The fair value of warrants was derived using the Black-Scholes valuation model. As of June 30, 2020 , convertible notes having a carrying value of $ 1,198,188 , net of unamortized discount of $ ( 58,812 ) remained outstanding from the March 2017 and July 2017 note offerings, and accrued interest on the notes is $228,052. Discount amortization was $96,527 for the three months ended June 30, 2020 . 8% Senior Secured Convertible Promissory Note dated February 28, 2019 On February 28, 2019, the Company issued a $1,500,000 8% Senior Secured Convertible Promissory Note and entered into the Note Purchase Agreement and Security Agreement with CSW Ventures, L.P. (together, “CSW Note”). The note matures on August 28, 2020 and is convertible at any time until maturity into 8,823,529 shares of the Company's common stock at $0.17 per share. Collateral pledged as security for the note includes all of the Company's 100% membership interests in GB Sciences, Nevada, LLC and GB Sciences Las Vegas, LLC, which together represent substantially all of the Company's cannabis cultivation and production operations and assets located at the Teco facility in Las Vegas, Nevada. The intrinsic value of the beneficial conversion feature resulting from the market price of the Company's common stock in excess of the conversion price was $176,471 on the date of issuance, and the Company recorded a discount on the CSW Note in that amount. On May 28, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $170,000 of the principal balance of the 8% Senior Secured Promissory Note dated February 28, 2019. Accordingly, the Company issued 1,000,000 shares of its common stock based on a $0.17 per share conversion price. In connection with the conversions, $ 17,225 in unamortized discount was recorded as interest expense and the Company reduced the carrying amount of convertible notes payable by $152,775. After conversion, the remaining balance outstanding was $1,330,000. On July 12, 2019, the Company entered into the Amendment to Note Documents and the Amended and Restated 8% Senior Secured Promissory Note (together, “Amended CSW Note”). The Amended CSW Note increased the note balance by $100,000 to reflect an additional $100,000 advanced to the Company on July 12, 2019, by $41,863 to add accrued interest to date to the principal balance, and decreased the conversion price to $0.11 per share, with the remaining terms substantially unchanged from the original CSW Note. We evaluated the modification under the guidance in ASC 470 - 50 and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the CSW Note on the amendment date. The carrying value of the amended note on the date of extinguishment was $1,338,057, net of a beneficial conversion feature discount of $133,806, and we recorded a loss on extinguishment of $124,158. On August 1, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $ 110,000 of the principal balance of the Amended CSW Note at $0.11 per share. Accordingly, the Company issued 1,000,000 shares of its common stock. In connection with the conversions, $9,579 in unamortized discount was recorded as interest expense and the Company has reduced the carrying amount of convertible notes payable by $100,421. After conversion, the remaining balance outstanding was $ 1,361,863. On October 23, 2019, the Company entered into the Amendment to Promissory Note. The October 23, 2019 amendment decreased the conversion price to $0.08 per share, with the remaining terms substantially unchanged from the Amended CSW Note. We evaluated the modification under the guidance in ASC 470 - 50 and determined that the amendment represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the Amended CSW Note immediately prior to the 2nd Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was $1,269,067, net of a beneficial conversion feature discount of $92,796, and we recorded a loss on extinguishment of $92,796. On November 27, 2019, the Company entered into the Second Amendment to Note Documents and the Second Amended and Restated 8% Senior Secured Promissory Note (together, “2nd Amended CSW Note”). The 2nd Amended CSW Note decreased the conversion price to $0.04 per share and increased the note balance by $30,000 to reflect an advance received on that date, with the remaining terms substantially unchanged from the Amended CSW Note. We evaluated the modification under the guidance in ASC 470 - 50 and determined that the 2nd Amended CSW Note represents an extinguishment because the change in the fair value of the conversion feature exceeded 10% of the carrying value of the Amended CSW Note immediately prior to the 2nd Amended CSW Note; however, no loss on extinguishment was recorded because the net consideration paid for the 2nd Amended CSW Note was equal to the extinguished carrying value of the Amended CSW Note. The carrying value of the Amended CSW Note on the date of extinguishment was $1,361,863. On December 16, 2019, the Company received notice from CSW Ventures, L.P. of the conversion of a total of $120,000 of the principal balance of the Amended CSW Note at $0.04 per share and we issued 3,000,000 shares of common stock. In connection with the conversions, $57,551 in unamortized discount was recorded as interest expense, and the Company has reduced the carrying amount of convertible notes payable by $62,449. After conversion, the remaining balance outstanding was $1,271,863 and the carrying amount of the note was $687,021, net of $584,842 in unamortized discount from the beneficial conversion feature. During the three months ended June 30, 2020 , we recorded interest expense of $252,573 related to the CSW Note and its amendments consisting of $25,367 in accrued interest and $227,206 related to amortization of the note discount. As of June 30, 2020 , the carrying amount of the CSW Note was $ 1,089,587 , net of unamortized discount of $ ( 182,276 ) . The Company is in default on the amended CSW Note due to non-payment of the quarterly interest payments due on October 1, 2019, January 1, 2020, March 1, 2020, and June 1, 2020, and for nonpayment of an income tax liability related to the March 31, 2018 tax year. The terms of the note provide that the Company has 5 days to cure a default caused by nonpayment of interest and ten days to cure a default caused by noncompliance with affirmative or negative debt covenants. The lender has agreed to provide forbearance of the defaults in connection with the sale of the Teco facilities, and the Company anticipates that the CSW Note will be settled in full upon close of the sale of the Company's interests in its Nevada operations to an entity affiliated with CSW Ventures, L.P. (Note 11 ). 8% Convertible Promissory Note dated April 23, 2019 On April 23, 2019, the Company entered into the Note Purchase Agreement with Iliad Research and Trading, L.P. ("Iliad") and issued an 8% Convertible Promissory Note with a face value of $2,765,000. The Note was issued with original issue discount of $265,000 and is convertible into shares of the Company's common stock at a price of $0.17 per share at the option of the note holder at any time until the Note is repaid. The Note matures on April 22, 2020. A total discount of $440,000 was recorded on the note, which includes $265,000 of original issue discount and $175,000 in fees paid to brokers. During the year ended March 31, 2020, the Company honored the conversion of a total of a total of $125,000 of accrued interest on the Iliad Note at reduced conversion rates. On October 30, 2019, the Company received notice of the conversion of $75,000 at $0.06 per share and issued 1,250,000 shares of its common stock. The fair value of the shares issued exceeded the fair value of the shares issuable under the original terms of the Note by $64,706, and the Company recorded an induced conversion expense. On November 18, 2019, the Company received notice of the conversion of $50,000 of the note balance at $0.0375 per share and issued 1,333,333 shares of its common stock. On April 22, 2020, the Company failed to make payment of the principal and accrued interest due under the Iliad Note, resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10%. As the result of the default, Company recorded an expense of $9,559 related to a 10% increase in the accrued interest balance, which is recorded in interest expense, and $276,500 related to the 10% increase in the principal balance, which is recorded in debt default penalty and other expense. As of June 30, 2020 , the principal balance due under the note was $ 3,041,500 , including the 10% penalty increase to the principal balance, and accrued interest was $192,649, including an increase of $9,559 attributable to the 10% default penalty. During the three months ended June 30, 2020 , interest expense related to the note was $130,659, of which $29,831 was amortization of the note discount and $100,828 was interest accrued at the pre-default rate of 8.0% through April 22, 2020, and at the default rate of 15.0% for the period from April 23, 2020 through June 30, 2020 . On May 20, 2020, Iliad filed a lawsuit against the Company in the Third Judicial District Court of Salt Lake County in the State of Utah demanding repayment of the note. The lawsuit further seeks to compel the Company to participate in arbitration pursuant to the arbitration provisions contained within the Note Purchase Agreement and to prohibit the Company to raise funds through the issuance of its common stock unless the note is paid in full simultaneously with such issuance. The Company filed a confession of judgment in response to the complaint and does not intend to defend the lawsuit. On July 14, 2020, the Court entered judgment in favor of Iliad in the amount of $3,264,594 and the judgment accrues interest at the default rate of 15% per annum. The Company will also be responsible for reasonable attorney's fees and costs incurred by Iliad for obtaining and collecting on the judgment. The amount of such fees has not been established as of the date of this report. The Company believes it will have sufficient resources to repay the Iliad Note from the proceeds of the sale of the Teco Facility and the note receivable therefrom, along with the proceeds of the note receivable from Wellcana Group from the sale of the Company's membership interest in GB Sciences Louisiana, LLC.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Capital Transactions	3 Months Ended
Note 7 - Capital Transactions	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 7 – Capital Transactions Sale of Common Stock and Exercise of Warrants On April 1, 2020, the Company entered into the Advisory Agreement with its brokers and effected a temporary decrease in the exercise price of the Company's outstanding warrants to $0.03 - $.05 per share. As a result of the price reduction, the Company received notice of the exercise of 4,991,084 warrants during the three months ended June 30, 2020 and received proceeds of $ 136,081 , net of brokerage fees of $ ( 15,121 ) . At June 30, 2020 , 79,547,077 warrants at exercise prices ranging from $0.25 to $1.00 per share and 13,366,334 options with a weighted average exercise price of $0.28 were outstanding.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments and Contingencies	3 Months Ended
Note 8 - Commitments and Contingencies	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 – Commitments and Contingencies On September 18, 2017 GB Sciences finalized its agreement with Louisiana State University (“LSU”) AgCenter to be the sole operator of the LSU's medical marijuana program. The LSU Board of Supervisors entered into a five -year agreement that has an option to renew for two additional five -year terms with GB Sciences. The contract includes the Company's commitment to make an annual research investments of $500,000 to the LSU AgCenter. The Company retained its 50% interest in the research relationship with LSU after the sale of its membership interest in GB Sciences Louisiana, LLC (Note 10 ), and accordingly remains obligated for $250,000 of the $500,000 annual research investment for three years, or a total commitment of $750,000. The research investment is paid annually in September and amortized over a one -year period. On August 4, 2020, the Company received its first payment under the Wellcana Note Receivable, net of the $250,000 research contribution due for the twelve month period ended September 30, 2020, and our commitment for that twelve month period was paid by the purchaser with the funds withheld from the note payment. The monetary contributions will be used to conduct research on plant varieties, compounds, extraction techniques and delivery methods that could generate additional revenue through discoveries that are subject to intellectual property rights, of which AgCenter would retain 50% of those rights with the other 50% retained 25% each by the Company and by GB Sciences Louisiana, LLC. On August 24, 2020, the Company entered into a letter of intent with the purchaser to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the purchaser will assume the annual $250,000 research contribution commitment to LSU and the Company will retain no rights in the intellectual property developed under the research relationship (Note 10 ). Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, alleging that she was subjected to sexual harassment and retaliatory discharge. The Company received the Notice of Charge of Discrimination on or about May 15, 2019. The Company submitted its response to the Notice of Discrimination Charge on July 26, 2019. It is the Company's position that Ms. Russel was not an employee of the Company, but rather was an independent contractor. The Company intends to aggressively respond to the charge. To date, the NERC has not issued a ruling regarding the charge. On April 22, 2020, the Company failed to repay any of the outstanding balance of the Convertible Promissory Note Payable to Iliad Research and Trading, L.P. (Note 6 ), resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10% and the Company recorded expense of $286,059 related to the default. As of June 30, 2020 , the total balance due under the note was $3,234,149 including accrued interest of $192,649. On May 20, 2020, Iliad filed a lawsuit against the Company in the Third Judicial District Court of Salt Lake County in the State of Utah demanding repayment of the note. The lawsuit further seeks to compel the Company to participate in arbitration pursuant to the arbitration provisions contained within the Note Purchase Agreement and to prohibit the Company to raise funds through the issuance of its common stock unless the note is paid in full simultaneously with such issuance. The Company filed a confession of judgment in response to the complaint and does not intend to defend the lawsuit. On July 14, 2020, the Court entered judgment in favor of Iliad in the amount of $3,264,594 and the judgment accrues interest at the default rate of 15% per annum. The Company will also be responsible for reasonable attorney's fees and costs incurred by Iliad for obtaining and collecting on the judgment. The amount of such fees has not been established as of the date of this report. The Company believes it will have sufficient resources to repay the Iliad Note from the proceeds of the sale of the Teco Facility and the note receivable therefrom, along with the proceeds of the note receivable from Wellcana Group from the sale of the Company's membership interest in GB Sciences Louisiana, LLC. On April 22, 2020, the Company was served notice of a lawsuit filed in the Eighth Judicial District Court in Clark County, Nevada, filed by a contractor who had been hired to perform architectural and design services. The lawsuit demands payment of $73,050 for the services provided. The Company intends to negotiate a settlement and the full amount demanded in the lawsuit of $73,050 is accrued in accounts payable as of June 30, 2020 . From time to time, the Company may become involved in certain legal proceedings and claims which arise in the ordinary course of business. In management's opinion, based on consultations with outside counsel, the results of any of these ordinary course matters, individually and in the aggregate, are not expected to have a material effect on our results of operations, financial condition, or cash flows. As more information becomes available, if management should determine that an unfavorable outcome is probable on such a claim and that the amount of such probable loss that it will incur on that claim is reasonably estimable, the Company would record a reserve for the claim in question. If and when the Company records such a reserve, it could be material and could adversely impact its results of operations, financial condition, and cash flows.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 9 - Related Party Transactions	3 Months Ended
Note 9 - Related Party Transactions	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 9 – Related Party Transactions As of June 30, 2020 the Company is indebted to its officers and directors for a total of $ 712,176 , consisting of $447,633 in unpaid wages, $109,087 in directors' compensation, $84,497 in unpaid bonuses, and $70,959 in reimbursements for business expenses. In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $ 151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid fees and bonuses. The note matures upon receipt of the first payment from the Wellcana Note Receivable (Note 10 ). The note and interest accrued was repaid on August 4, 2020, when the related funds were withheld from the first payment to the Company under the Wellcana Note Receivable (Note 12 ).

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	3 Months Ended
	Jun. 30, 2020
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10 – Sale of Membership Interests in GB Sciences Louisiana, LLC On February 12, 2018, the Company's wholly-owned subsidiary, GB Sciences Louisiana, LLC (“GBSLA"), issued members' equity interests equal to 15% in GBSLA to Wellcana Group, LLC (“Wellcana”) for $3 million. Under the GBSLA operating agreement, Wellcana had an option to make additional capital contributions for the purchase of up to an additional 35% membership interest in GBSLA, at the rate of 5% membership interest per $1 million contributed. To date, Wellcana has made additional cash contributions of $7.0 million and its non-controlling interest in GBSLA increased to 49.99%. The capital contributions were used to fund the buildout of the Petroleum Drive facility and to pay for the operating costs of GBSLA. On November 15, 2019, the Company entered into the Membership Interest Purchase Agreement ("MIPA") with Wellcana Plus, LLC ("Purchaser"), an affiliate of Wellcana Group, LLC. In consideration for the sale of its remaining 50.01% membership interest in GBSLA, the Company received the $8,000,000 Promissory Note ("Wellcana Note") and may receive up to an additional $8,000,000 in earn-out payments. On August 24, 2020, the Company entered into a letter of intent with Wellcana to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the Company will receive payments totaling $5,224,423, including the forgiveness by Wellcana of $324,423 in liabilities and the payment of $4,900,000 in cash, on or before October 15, 2020, less any cash payments made by Wellcana up to the date of the final payment. Upon receipt of the payment, all liabilities owed to the Company by Wellcana, including the $8,000,000 note receivable and any potential earn-out payments will be considered satisfied in full. Wellcana will assume the annual $250,000 research contribution commitment to LSU (Note 8 ) and the Company will retain no rights in the intellectual property developed under the research relationship. In addition, the Company agreed to reduce the $750,000 note payment due on September 1, 2020 to $500,000. Should Wellcana fail to make the $4,900,000 payment, less any offsets from payments made to date on the note receivable, the term sheet will be void and the original terms of the Membership Interest Purchase Agreement and $8,000,000 note receivable will prevail. As a result of the August 24, 2020 letter of intent, the Company determined that the amount of the note that was collectible as of March 31, 2020 was $ 5,224,423 and recorded a loss on modification of note receivable of $1,895,434 for the year ended March 31, 2020 . As of June 30, 2020 , the balance of the note receivable was $ 5,224,423 . The Company granted forbearance of the June 1, 2020 payment from Wellcana in light of the circumstances created by the COVID- 19 epidemic. The payment was received by the Company on August 4, 2020, net of the Company's $250,000 research contribution commitment to LSU for the twelve months ended September 2020 ( Note 8 ) and the principal and accrued interest payable to John Davis (Note 5 ) totaling $189,423 as of the date of payment. For all periods presented in the unaudited financial statements, the assets, liabilities, income, and cash flows of GBSLA have been reclassified to discontinued operations.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 11 - Sale of Membership Interests in Nevada Subsidiaries	3 Months Ended
	Jun. 30, 2020
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 11 – Sale of Membership Interests in Nevada Subsidiaries On November 15, 2019, we entered into a Binding Letter of Intent ("Teco LOI") to sell 75% of the Company's membership interest interests in GB Sciences Nevada, LLC, and GB Sciences Las Vegas, LLC, for $3.0 million cash upon close and up to an additional $3.0 million in earn-out payments after close. In connection with the Teco LOI, we entered into a Management Agreement with the purchaser whereby the facilities will be managed by an affiliate of the purchaser until the close of the sale. As part of the transaction, the Company also entered into a Line of Credit of up to $470,000 with the purchaser (Note 5 ) to fund the operations of Teco. The line of credit accrues interest at a rate of 8% and the Company pledged its interest in the Teco facilities as collateral for the note, subject to the preexisting lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 ( Note 6 ). The Line of Credit will be considered satisfied in full upon close of the sale of the Teco Facility. On March 24, 2020, we entered into the Membership Interest Purchase Agreement ("Teco MIPA") which formalized the sale of the Teco Subsidiaries and modified the terms of the sale. Pursuant to the Teco MIPA, the Company will sell 100% of its membership interests in GBSN and GBLV for $4,000,000 cash upon close and will receive a $4,000,000 8% promissory note to be paid in monthly installments over 36 months. On July 24, 2020, the Company entered into the Loan Agreement, 8% Secured Promissory Note, and Security Agreement (together, the "July 24 Note") with AJE Management, LLC, which established a revolving loan of up to $500,000 that the Company may draw on from time to time. The loan is collateralized by the Teco Facility, subject to the preexisting lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 ( Note 6 ). Any advances will be made at the sole discretion of the lender following a written request made by the Company. Contemporaneously with the Loan Agreement, the Company and AJE Management entered into the Amendment to the Membership Interest Purchase Agreement with AJE Management. The amendment provides that any balances outstanding under the July 24 Note at the time of the close of the sale of the Teco Facility will be forgiven in exchange for a reduction to the $4,000,000 note receivable that the Company will receive as consideration for the sale of the Teco Facility. The reduction to the note receivable will be equal to 3 times the balance outstanding under the July 24 Note on the date of the close of the sale of the Teco Facility. As of the date of this report, the Company has not received any advances under the July 24 Note. The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada has been subject to an indefinite moratorium since October 2019. In a meeting held on July 21, 2020, the Nevada Cannabis Compliance Board lifted the moratorium, however, the board has indicated that there are over 90 requests pending and it will take up to several months to process the entire backlog of pending license transfers. Based on this information, we cannot provide any assurances as to the timing of the close of the sale. The lifting of the moratorium and processing of cannabis license transfers have been delayed by the COVID- 19 pandemic and could be further delayed if the pandemic continues. The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not begun under the Nopah License. On November 27, 2019, the Company entered into a Binding Letter of Intent to sell its 100% interest in GB Sciences Nopah, LLC (the “Nopah LOI”), with the transaction closing upon transfer of the Nopah License. As consideration for the transfer of the license, the Company will receive $300,000 and the purchaser will pay all expenses related to the upkeep and maintenence of the Nopah License. The transfer of the Nopah License is subject to the same restrictions on license transfers discussed above.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 12 - Subsequent Events	3 Months Ended
Note 12 - Subsequent Events	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12 – Subsequent Events Capital Transactions On July 24, 2020, the Company entered into the Loan Agreement, 8% Secured Promissory Note, and Security Agreement (together, the "July 24 Note") with AJE Management, LLC, which established a revolving loan of up to $500,000 that the Company may draw on from time to time. The loan is collateralized by the Teco Facility, subject to the pre-existing lien held by CSW Ventures, L.P. in connection with the 8% Senior Secured Convertible Promissory Note dated February 28, 2019 ( Note 6 ). Any advances will be made at the sole discretion of the lender following a written request made by the Company. Contemporaneously with the Loan Agreement, the Company and AJE Management entered into the Amendment to the Membership Interest Purchase Agreement with AJE Management. The amendment provides that any balances outstanding under the July 24 Note at the time of the close of the sale of the Teco Facility will be forgiven in exchange for a reduction to the $4,000,000 note receivable that the Company will receive as consideration for the sale of the Teco Facility (Note 11 ). The reduction to the note receivable will be equal to 3 times the balance outstanding under the July 24 Note on the date of the close of the sale of the Teco Facility. As of the date of this report, the Company has not received any advances under the July 24 Note. Note Receivable The Company granted forbearance of the June 1, 2020 payment to Wellcana in light of the circumstances created by the COVID- 19 epidemic. The payment was received by the Company on August 4, 2020, net of the Company's annual $250,000 research contribution commitment to LSU (Note 10 ) and the principal and accrued interest payable to John Davis (Note 5 ) totaling $189,423 as of the date of payment. On August 24, 2020, the Company entered into a letter of intent with Wellcana to discount the note receivable in exchange for accelerated payment. Pursuant to the letter of intent, the Company will receive payments totaling $5,224,423, including the forgiveness by Wellcana of $324,423 in liabilities and the payment of $4,900,000 in cash, on or before October 15, 2020, less any cash payments made by Wellcana up to the date of the final payment. Upon receipt of the payment, all liabilities owed to the Company by Wellcana, including the $8,000,000 note receivable and any potential earn-out payments will be considered satisfied in full. Wellcana will assume the annual $250,000 research contribution commitment to LSU (Note 10 ) and the Company will retain no rights in the intellectual property developed under the research relationship. In addition, the Company agreed to reduce the $750,000 note payment due on September 1, 2020 to $500,000. Should Wellcana fail to make the $4,900,000 payment, less any offsets from payments made to date on the note receivable, the term sheet will be void and the original terms of the Membership Interest Purchase Agreement and $8,000,000 note receivable will prevail. On August 31, 2020, the Company granted a 30 -day forbearance of the $500,000 payment due on September 1, 2020. Any payments received prior to October 15, 2020 will be applied to the $4,900,000 balance due under the August 24, 2020 letter of intent. Litigation On April 22, 2020, the Company failed to repay any of the outstanding balance of the Convertible Promissory Note Payable to Iliad Research and Trading, L.P. (Note 6 ), resulting in a default. Pursuant to the terms of the Promissory Note, upon the default, the principal and accrued interest balances outstanding increased by 10% and the Company recorded expense of $286,059 related to the default. As of June 30, 2020, the total balance due under the note was $3,234,149 including accrued interest of $192,649. On May 20, 2020, Iliad filed a lawsuit against the Company in the Third Judicial District Court of Salt Lake County in the State of Utah demanding repayment of the note. The lawsuit further seeks to compel the Company to participate in arbitration pursuant to the arbitration provisions contained within the Note Purchase Agreement and to prohibit the Company to raise funds through the issuance of its common stock unless the note is paid in full simultaneously with such issuance. The Company filed a confession of judgment in response to the complaint and does not intend to defend the lawsuit. On July 14, 2020, the Court entered judgment in favor of Iliad in the amount of $3,264,594 and the judgment accrues interest at the default rate of 15% per annum. The Company will also be responsible for reasonable attorney's fees and costs incurred by Iliad for obtaining and collecting on the judgment. The amount of such fees has not been established as of the date of this report. The Company believes it will have sufficient resources to repay the Iliad Note from the proceeds of the sale of the Teco Facility and the note receivable therefrom, along with the proceeds of the note receivable from Wellcana Group from the sale of the Company's membership interest in GB Sciences Louisiana, LLC.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

-Q and Article

of Regulations S-

Accordingly, they do

not

necessarily indicative of the results that

may

be expected for the year ending

March 31, 2021.

The balance sheet at

March 31, 2020

has been derived from the audited financial statements at that date but does

not

-K for the year ended

March 31, 2020

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

not

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

not

readily apparent from other sources. The actual results the Company experiences

may

differ materially and adversely from these estimates.

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

). The reclassifications had

effect on the reported financial position, results of operations or cash flows of the Company.

Discontinued Operations, Policy [Policy Text Block]

Discontinued Operations

There were

assets or liabilities of discontinued operations included in the Company's condensed consolidated balance sheets as of

June 30, 2020

and

March 31, 2020

The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the

three

months ended

June 30, 2020

and

2019

were as follows:

	For the Three Months Ended June 30,
	2020								2019
	Continuing			Discontinued		Total			Continuing			Discontinued			Total
Sales revenue	$	551,197		$	-	$	551,197		$	910,676		$	-		$	910,676
Cost of goods sold		(491,795	)		-		(491,795	)		(624,369	)		-			(624,369	)
Gross profit		59,402			-		59,402			286,307			-			286,307
General and administrative expenses		804,708			-		804,708			2,065,549			201,840			2,267,389
LOSS FROM OPERATIONS		(745,306	)		-		(745,306	)		(1,779,242	)		(201,840	)		(1,981,082	)
OTHER EXPENSE
Interest expense		(795,313	)		-		(795,313	)		(437,815	)		(62,594	)		(500,409	)
Debt default penalty		(286,059	)		-		(286,059	)		-			-			-
Other expense		(11,182	)		-		(11,182	)		-			-			-
Total other expense		(1,092,554	)		-		(1,092,554	)		(437,815	)		(62,594	)		(500,409	)
LOSS BEFORE INCOME TAXES		(1,837,860	)		-		(1,837,860	)		(2,217,057	)		(264,434	)		(2,481,491	)
Income tax expense		(8,840	)		-		(8,840	)		(57,392	)		-			(57,392	)
NET LOSS	$	(1,846,700	)	$	-	$	(1,846,700	)	$	(2,274,449	)	$	(264,434	)	$	(2,538,883	)

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Long-Lived Assets

may

exist under authoritative guidance. The annual testing date is

March 31.

When management believes impairment indicators

may

not

indicators of impairment were identified by the Company as of

June 30, 2020

Inventory, Policy [Policy Text Block]

Inventory

We value our inventory at the lower of the actual cost of our inventory, as determined using the

first

-in,

first

Debt, Policy [Policy Text Block]

Beneficial Conversion Feature of Convertible Notes Payable

470

20,

Debt with Conversion and Other Options and Emerging Issues Task Force (“EITF”)

27,

“Application of Issue

No.

first

718

Compensation – Stock Compensation. The only difference is that the contractual life of the warrants is used.

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

The FASB issued Accounting Standards Codification (“ASC”)

606

two

April 1, 2018

and applied the cumulative catch-up transition method.

The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC

606,

the Company is required to separately identify each performance obligation resulting from its contracts from customers, which

may

be a good or a service. A contract

may

contain

one

606

results in the same timing of revenue recognition as under the previous guidance (i.e. revenue is recognized upon delivery of physical goods), the Company did

not

record any material adjustment to report the cumulative effect of initial application of the guidance.

Earnings Per Share, Policy [Policy Text Block]

Earnings/(loss) per Share

The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had

153,412,936

and

158,404,020

potentially dilutive common shares at

June 30, 2020

and

March 31, 2020

, respectively. However, such common stock equivalents were

not

included in the computation of diluted net loss per share as their inclusion would have been anti-dilutive.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Recently Adopted Standards

June 2016,

the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")

No.

2016

13,

"Financial Instruments—Credit Losses (Topic

326

): Measurement of Credit Losses on Financial Instruments" ("ASU

2016

13"

). Financial Instruments—Credit Losses (Topic

326

) amends guideline on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For assets held at amortized cost basis, Topic

326

will require that credit losses be presented as an allowance rather than as a write-down. ASU

2016

affects entities holding financial assets and net investment in leases that are

not

excluded from the scope that have the contractual right to receive cash. The amendments in this ASU are effective for smaller reporting companies for fiscal years beginning after

December 15, 2022,

including interim periods within those fiscal years. The Company is currently evaluating the impact of this guidance on its financial statements.

August 2018,

the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU)

2018

13,

“

Fair Value Measurement (Topic

820

): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement

December 15, 2019,

and interim periods within those fiscal years. The Company adopted the standard on

April 1, 2020.

The adoption of this guidance did

not

have a material impact on the Company's financial statements.

All other newly issued accounting pronouncements but

not

yet effective have been deemed either immaterial or

not

applicable.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 1 - Background and Significant Accounting Policies (Tables)

3 Months Ended

Jun. 30, 2020

Notes Tables

Disposal Groups, Including Discontinued Operations [Table Text Block]

	For the Three Months Ended June 30,
	2020								2019
	Continuing			Discontinued		Total			Continuing			Discontinued			Total
Sales revenue	$	551,197		$	-	$	551,197		$	910,676		$	-		$	910,676
Cost of goods sold		(491,795	)		-		(491,795	)		(624,369	)		-			(624,369	)
Gross profit		59,402			-		59,402			286,307			-			286,307
General and administrative expenses		804,708			-		804,708			2,065,549			201,840			2,267,389
LOSS FROM OPERATIONS		(745,306	)		-		(745,306	)		(1,779,242	)		(201,840	)		(1,981,082	)
OTHER EXPENSE
Interest expense		(795,313	)		-		(795,313	)		(437,815	)		(62,594	)		(500,409	)
Debt default penalty		(286,059	)		-		(286,059	)		-			-			-
Other expense		(11,182	)		-		(11,182	)		-			-			-
Total other expense		(1,092,554	)		-		(1,092,554	)		(437,815	)		(62,594	)		(500,409	)
LOSS BEFORE INCOME TAXES		(1,837,860	)		-		(1,837,860	)		(2,217,057	)		(264,434	)		(2,481,491	)
Income tax expense		(8,840	)		-		(8,840	)		(57,392	)		-			(57,392	)
NET LOSS	$	(1,846,700	)	$	-	$	(1,846,700	)	$	(2,274,449	)	$	(264,434	)	$	(2,538,883	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory (Tables)

3 Months Ended

Jun. 30, 2020

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30, 2020			March 31, 2020

Raw materials	$	129,133		$	91,465
Work in progress		923,737		$	1,166,511
Finished goods		619,491		$	466,319
Subtotal		1,672,361			1,724,295
Allowance to reduce inventory to net realizable value		(126,470	)		(278,456	)
Total inventory, net	$	1,545,891		$	1,445,839

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Leases (Tables)

3 Months Ended

Jun. 30, 2020

Notes Tables

Operating and Finance Lease Liabilities, Maturity [Table Text Block]

Year Ending				Operating
March 31,	Finance Leases			Leases

2021 (9 months)	$	422,801		$	8,836
2022		544,296			11,779
2023		560,625			11,779
2024		577,444			3,926
2025		594,767			-
Thereafter		3,781,101			-
Total minimum lease payments		6,481,034			36,320
Less: Amount representing interest		(2,835,211	)		(8,242	)
Present value of minimum lease payments		3,645,823			28,078
Less: Current maturities of capital lease obligations		(146,211	)		(7,579	)
Long-term capital lease obligations	$	3,499,612		$	20,499

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 5 - Notes Payable and Line of Credit (Tables)

3 Months Ended

Jun. 30, 2020

Notes Tables

Schedule of Debt [Table Text Block]

	As of June 30, 2020
Short-Term Notes Payable	Face Value		Discount			Carrying Value
6% Convertible promissory notes payable (Note 6)	$	1,257,000	$	(58,812	)	$	1,198,188
8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6)		1,271,863		(182,276	)		1,089,587
8% Convertible Promissory Note dated April 23, 2019 (Note 6)		3,041,500		-			3,041,500
0% Note Payable dated October 23, 2017 (Note 5)		369,445		(6,607	)		362,838
8% Line of Credit dated November 27, 2019 (Note 5)		485,000		-			485,000
8% Note Payable dated May 7, 2020 (Note 5)		150,000		-			150,000
Total Short-Term Notes Payable	$	6,574,808	$	(247,695	)	$	6,327,113

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 1 - Background and Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)	600,000,000		600,000,000	600,000,000	400,000,000	250,000,000
Impairment of Long-Lived Assets Held-for-use	$ 0
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	153,412,936	158,404,020

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Sales revenue	$ 551,197	$ 910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
Net loss	(1,846,700)	(2,538,883)
Continuing Operations [Member]
Sales revenue	551,197	910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,065,549
LOSS FROM OPERATIONS	(745,306)	(1,779,242)
Interest expense	(795,313)	(437,815)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(437,815)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,217,057)
Income tax expense	(8,840)	(57,392)
Net loss	(1,846,700)	(2,274,449)
Discontinued Operations [Member]
Sales revenue
Cost of goods sold
Gross profit
General and administrative expenses		201,840
LOSS FROM OPERATIONS		(201,840)
Interest expense		(62,594)
Debt default penalty
Other expense
Total other expense		(62,594)
LOSS BEFORE INCOME TAXES		(264,434)
Income tax expense
Net loss		(264,434)
Segment, Continuing and Discontinued Operations [Member]
Sales revenue	551,197	910,676
Cost of goods sold	(491,795)	(624,369)
Gross profit	59,402	286,307
General and administrative expenses	804,708	2,267,389
LOSS FROM OPERATIONS	(745,306)	(1,981,082)
Interest expense	(795,313)	(500,409)
Debt default penalty	(286,059)
Other expense	(11,182)
Total other expense	(1,092,554)	(500,409)
LOSS BEFORE INCOME TAXES	(1,837,860)	(2,481,491)
Income tax expense	(8,840)	(57,392)
Net loss	$ (1,846,700)	$ (2,538,883)

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern (Details Textual) - USD ($)	3 Months Ended
Note 2 - Going Concern (Details Textual) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (99,251,168)		$ (97,387,205)
Working Capital Deficit	(5,381,534)		$ 3,884,877
Net Cash Provided by (Used in) Operating Activities, Total	(323,845)	$ (2,631,121)
Cash Provided by (Used in) Operating Activities, Discontinued Operations		$ (883,295)

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 3 - Inventory - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Raw materials	$ 129,133	$ 91,465
Work in progress	923,737	1,166,511
Finished goods	619,491	466,319
Subtotal	1,672,361	1,724,295
Allowance to reduce inventory to net realizable value	(126,470)	(278,456)
Total inventory, net	$ 1,545,891	$ 1,445,839

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 4 - Leases (Details Textual) - USD ($)	3 Months Ended
Note 4 - Leases (Details Textual) - USD ($)	Jun. 30, 2020	Mar. 31, 2020	Apr. 01, 2019
Operating Lease, Right-of-Use Asset	$ 24,684	$ 26,685
Operating Lease, Liability, Total	$ 28,078
Lessee, Operating Lease, Discount Rate	17.00%
Finance Lease Costs	$ 143,599
Finance Lease, Interest Expense	104,924
Finance Lease, Right-of-Use Asset, Amortization	38,675
Operating Lease, Cost	3,243
Operating Lease, Interest Expense	1,242
Operating Lease, Right-of-Use Asset, Amortization Expense	$ 2,001
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 182,624
Operating Lease, Liability, Total			$ 190,173

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 4 - Leases - Future Minimum Lease Payments (Details) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
2021 (9 months), finance leases	$ 422,801
2021 (9 months), operating leases	8,836
2022, finance leases	544,296
2022, operating leases	11,779
2023, finance leases	560,625
2023, operating leases	11,779
2024, finance leases	577,444
2024, operating leases	3,926
2025, finance leases	594,767
2025, operating leases
Thereafter, finance leases	3,781,101
Thereafter, operating leases
Total minimum lease payments, finance leases	6,481,034
Total minimum lease payments, operating leases	36,320
Less: Amount representing interest, finance leases	(2,835,211)
Less: Amount representing interest, operating leases	(8,242)
Present value of minimum lease payments, finance leases	3,645,823
Present value of minimum lease payments, operating leases	28,078
Less: Current maturities of capital lease obligations, finance leases	(146,211)	$ (166,769)
Less: Current maturities of capital lease obligations, operating leases	(7,579)	(7,265)
Finance lease obligations, long term	3,499,612	3,533,090
Operating lease obligations, long term	$ 20,499	$ 22,515

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 5 - Notes Payable and Line of Credit (Details Textual)			3 Months Ended			7 Months Ended
	May 07, 2020 USD ($) $ / shares shares	Oct. 23, 2017 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	May 06, 2020 USD ($)	Nov. 27, 2019 USD ($)	Oct. 23, 2019 USD ($)
Proceeds from Lines of Credit, Total				$ 5,000
Payments of Debt Issuance Costs					175,000
Interest Expense, Debt, Excluding Amortization					17,225
Amortization of Debt Discount (Premium)				510,885	$ 200,382
Repriced Preexisting Warrants with Convertible Debt Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) \| shares	8,002,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.04
Warrants and Rights Outstanding	$ 272,085						$ 49,525
Fair Value Adjustment of Warrants	$ 222,560
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 470,000
Proceeds from Lines of Credit, Total						$ 485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased						15,000
Interest Payable				9,641		9,641
Long-term Line of Credit, Total				485,000		485,000
Promissory Note [Member] \| The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage		0.00%
Debt Instrument, Face Amount		$ 700,000
Debt Instrument, Term (Year)		3 years
Debt Instrument, Present Value				$ 521,067		521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)				20.30%
Debt Instrument, Unamortized Discount, Total				$ 6,607		6,607			$ 178,933
Interest Expense, Debt, Total				7,321
Debt Instrument, Accrued Monthly Payments, Amount				$ 291,660		$ 291,660
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%		10.00%
Debt Instrument, Debt Default, Accrued Interest				$ 9,236		$ 9,236
Days to Cure Breach of Default After Notification From Lender				10		10
Convertible Debt [Member] \| The 8% Note Payable dated May 7, 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Face Amount	$ 150,000
Debt Instrument, Unamortized Discount, Total	150,000			$ 0		$ 0
Proceeds from Issuance of Long-term Debt, Net	135,000
Payments of Debt Issuance Costs	$ 15,000
Interest and Debt Expense, Total				151,742
Interest Expense, Debt, Excluding Amortization				1,742
Amortization of Debt Discount (Premium)				$ 150,000
Convertible Debt [Member] \| The 8% Note Payable dated May 7, 2020 [Member] \| Forecast [Member]
Repayments of Long-term Debt, Total			$ 8,000,000,000,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License		$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] \| Production License [Member]
Ownership of Licence		100.00%
Nevada Medical Marijuana Production License Agreement [Member] \| Cultivation License [Member]
Ownership of Licence		100.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Jun. 30, 2020	Apr. 23, 2019
Discount, short-term notes payable
Convertible Notes Payable [Member] \| The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	$ 1,257,000
Discount, short-term notes payable	(58,812)
Carrying Value, short-term notes payable	1,198,188
Convertible Notes Payable [Member] \| The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable	3,041,500	$ 2,765,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	3,041,500
Convertible Notes Payable [Member] \| The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445
Discount, short-term notes payable	(6,607)
Carrying Value, short-term notes payable	362,838
Convertible Notes Payable [Member] \| The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member]
Face Value, short-term notes payable	150,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	150,000
Senior Secured Convertible Promissory Note [Member] \| The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,271,863
Discount, short-term notes payable	(182,276)
Carrying Value, short-term notes payable	1,089,587
Line of Credit [Member]
Face Value, short-term notes payable	485,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	485,000
Promissory Note [Member]
Face Value, short-term notes payable	6,574,808
Discount, short-term notes payable	(247,695)
Carrying Value, short-term notes payable	$ 6,327,113

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Convertible Notes (Details Textual)													1 Months Ended		3 Months Ended			6 Months Ended	12 Months Ended
Note 6 - Convertible Notes (Details Textual)	Jul. 14, 2020 USD ($)	Apr. 22, 2020 USD ($)	Dec. 16, 2019 USD ($) $ / shares shares	Nov. 27, 2019 USD ($) $ / shares	Nov. 18, 2019 USD ($) $ / shares shares	Oct. 30, 2019 USD ($) $ / shares shares	Oct. 23, 2019 USD ($) $ / shares	Aug. 01, 2019 USD ($) $ / shares shares	Jul. 12, 2019 USD ($) $ / shares	May 28, 2019 USD ($) $ / shares shares	Apr. 23, 2019 USD ($) $ / shares	Feb. 28, 2019 USD ($) $ / shares	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	Jun. 30, 2020 USD ($) $ / shares	Jun. 30, 2019 USD ($)	May 31, 2017 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)
Interest Payable, Current															$ 654,760				$ 397,652
Amortization of Debt Discount (Premium)															510,885	$ 200,382
Interest Expense, Debt, Excluding Amortization																$ 17,225
Subsequent Event [Member] \| Repayment of Iliad Note [Member] \| Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty	15.00%
Litigation Settlement, Amount Awarded to Other Party	$ 3,264,594
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares															$ 1
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares														$ 0.60			$ 0.60
Warrants and Rights Outstanding, Term (Year)														3 years			3 years
Class of Warrant or Right, Issued (in shares) \| shares																	8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) \| shares																	1
Warrants Related to July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants													4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)																		3 years
Class of Warrant or Right, Issued (in shares) \| shares																		28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) \| shares																		1
Convertible Notes Payable [Member] \| March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Debt Instrument, Face Amount																	$ 2,000,000
Debt Instrument, Term (Year)																	3 years
Debt Instrument, Unamortized Discount, Total																	$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature																	904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants																	$ 1,029,003
Convertible Notes Payable [Member] \| March 2017 Convertible Note Offering [Member] \| Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000			8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares														$ 0.25
Convertible Notes Payable [Member] \| July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note													$ 1,000
Debt Instrument, Face Amount																		$ 7,201,000
Debt Instrument, Term (Year)													3 years					3 years
Debt Instrument, Unamortized Discount, Total															$ 58,812			$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																		3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																		$ 3,950,191
Long-term Debt, Gross															1,198,188
Interest Payable, Current															228,052
Amortization of Debt Discount (Premium)															$ 96,527
Convertible Notes Payable [Member] \| July 2017 Convertible Note Offering [Member] \| Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares													$ 0.25
Convertible Notes Payable [Member] \| The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%				15.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares					$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount											$ 2,765,000				$ 3,041,500
Debt Instrument, Unamortized Discount, Total											265,000
Long-term Debt, Gross															3,041,500
Amortization of Debt Discount (Premium)															29,831
Debt Conversion, Original Debt, Amount					$ 50,000	$ 75,000													$ 125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares					1,333,333	1,250,000
Short-term Debt, Total															3,041,500
Interest Expense, Debt, Total															130,659
Interest Expense, Debt, Excluding Amortization															100,828
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total											440,000
Payments for Brokerage Fees											$ 175,000
Induced Conversion of Convertible Debt Expense						$ 64,706
Debt Instrument, Debt Default, Interest Rate Penalty		10.00%
Debt Instrument, Debt Default, Interest Expense		$ 9,559
Debt Instrument, Debt Default, Principal Expense		$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent		10.00%
Interest Payable															192,649
Interest Payable, Default Penalty															9,559
Promissory Note [Member]
Debt Instrument, Face Amount															6,574,808
Short-term Debt, Total															6,327,113
Promissory Note [Member] \| July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage													6.00%
Senior Secured Convertible Promissory Note [Member] \| The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.00%					8.00%	8.00%		8.00%
Debt Instrument, Face Amount												$ 1,500,000
Debt Instrument, Unamortized Discount, Total			$ 584,842					$ 9,579		$ 17,225					182,276
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 92,796		$ 133,806			$ 176,471
Long-term Debt, Gross			687,021												1,089,587
Amortization of Debt Discount (Premium)			57,551												227,206
Debt Conversion, Original Debt, Amount			120,000					110,000		170,000
Debt Instrument, Increase (Decrease), Net, Total			(62,449)	$ 30,000				(100,421)	100,000	(152,775)
Short-term Debt, Total			$ 1,271,863	1,361,863			1,269,067	$ 1,361,863	1,338,057	$ 1,330,000
Proceeds from Related Party Debt									100,000
Debt Instrument, Increase, Accrued Interest									41,863
Gain (Loss) on Extinguishment of Debt, Total				$ 0			$ (92,796)		$ (124,158)
Interest Expense, Debt, Total															252,573
Interest Expense, Debt, Excluding Amortization															$ 25,367
Senior Secured Convertible Promissory Note [Member] \| The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] \| Minimum [Member]
Days to Cure Breach of Default After Notification From Lender															5
Senior Secured Convertible Promissory Note [Member] \| The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] \| Maximum [Member]
Days to Cure Breach of Default After Notification From Lender															10
Senior Secured Convertible Promissory Note [Member] \| The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] \| GB Sciences, Nevada, LLC [Member] \| Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent												100.00%
Senior Secured Convertible Promissory Note [Member] \| The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] \| Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments												8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) \| $ / shares			$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11	$ 0.17		$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) \| shares			3,000,000					1,000,000		1,000,000

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Capital Transactions (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Proceeds from Warrant Exercises	$ 151,202
Class of Warrant or Right, Outstanding (in shares)	79,547,077
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	13,366,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)	$ 0.28
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	0.25
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)	4,991,084
Proceeds from Warrant Exercises	$ 136,081
Brokerage Fees for Issuance of Common Stock and Warrants	$ 15,121
Warrants Issued to Investors in Private Placements [Member] \| Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.03
Warrants Issued to Investors in Private Placements [Member] \| Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.05

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 8 - Commitments and Contingencies (Details Textual)						3 Months Ended	33 Months Ended
	Aug. 24, 2020 USD ($)	Aug. 04, 2020 USD ($)	Jul. 14, 2020 USD ($)	Apr. 22, 2020 USD ($)	Sep. 18, 2017 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)
Payment of Services Provided by Contractor [Member] \| Pending Litigation [Member]
Loss Contingency, Damages Sought, Value				$ 73,050
Loss Contingency Accrual, Ending Balance								$ 73,050
Convertible Notes Payable [Member] \| The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%
Debt Instrument, Default, Expense				$ 286,059
Long-term Debt, Total						$ 3,234,149	$ 3,234,149
Interest Payable						$ 192,649	192,649
Subsequent Event [Member] \| Repayment of Iliad Note [Member] \| Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty			15.00%
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Agreement With Louisiana State University AgCenter [Member]
Term of Agreement (Year)					5 years	3 years
Option to Renew Agreement, Amount					2
Term of Agreement, Renewal (Year)					5 years
Research and Development Expense, Total					$ 500,000	$ 250,000	$ 750,000
Agreement With Louisiana State University AgCenter [Member] \| Subsequent Event [Member]
Annual Research Contributions	$ 250,000	$ 250,000

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Jun. 30, 2020	Mar. 31, 2020
Notes Payable, Related Parties, Current	$ 151,923	$ 151,923
John Davis [Member]
Notes Payable, Related Parties, Current	151,923
Officers and Directors [Member]
Due to Related Parties, Total	712,176
Unpaid Bonuses, Related Parties	84,497
Reimbursement for Business Expense, Related Parties	70,959
Officer [Member]
Unpaid Wages, Related Parties	447,633
Director [Member]
Unpaid Wages, Related Parties	$ 109,087

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)					2 Months Ended	12 Months Ended	29 Months Ended
	Aug. 24, 2020	Aug. 04, 2020	Nov. 15, 2019	Feb. 12, 2018	Oct. 15, 2020	Mar. 31, 2020	Jun. 30, 2020	Aug. 23, 2020
Subsequent Event [Member] \| John Davis [Member]
Due to Related Parties, Total		$ 189,423
Subsequent Event [Member] \| Agreement With Louisiana State University AgCenter [Member]
Annual Research Contributions	$ 250,000	$ 250,000
GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses			$ 8,000,000
Earnout Payments			$ 8,000,000
Financing Receivable, after Allowance for Credit Loss, Total						$ 5,224,423	$ 5,224,423
Gain (Loss) on Modification of Note Receivable						$ (1,895,434)
GB Sciences Louisiana, LLC [Member] \| Subsequent Event [Member]
Notes Receivable, Net, Scheduled Payments	$ 500,000							$ 750,000
GB Sciences Louisiana, LLC [Member] \| Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness					$ 5,224,423
Debt Instrument, Decrease, Forgiveness					324,423
Proceeds from Collection of Notes Receivable					4,900,000
Note Receivable Satisfied					8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party					$ 250,000
Wellcana Group, LLC [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners				49.99%
Wellcana Group, LLC [Member] \| GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership			50.01%	15.00%
Sale of Stock, Consideration Received on Transaction				$ 3,000,000			$ 7,000,000
Sale of Stock, Percentage of Ownership Available For Sale				35.00%
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction				5.00%
Sale of Stock, Consideration Received Per Transaction				$ 1,000,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 27, 2019	Jul. 24, 2020	Dec. 06, 2019
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%
Proceeds from Divestiture of Businesses	$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total	$ 4,000,000
Notes Receivable, Interest Rate	8.00%
Notes Receivable, Term of Monthly Installments (Month)	3 years
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 470,000
Teco Note [Member] \| Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 470,000
The July 24 Note [Member] \| Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
The July 24 Note [Member] \| Secured Debt [Member] \| Subsequent Event [Member] \| AJE Management, LLC [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 500,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Teco [Member]
Sale of Stock, Percentage of Ownership		75.00%
Sale of Stock, Consideration Received on Transaction		$ 3,000,000
Sale of Stock, Additional Earn-out Payments		$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership		100.00%
Sale of Stock, Consideration Received on Transaction		$ 300,000

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 12 - Subsequent Events (Details Textual) - USD ($)					2 Months Ended
Note 12 - Subsequent Events (Details Textual) - USD ($)	Aug. 24, 2020	Aug. 04, 2020	Jul. 14, 2020	Apr. 22, 2020	Oct. 15, 2020	Aug. 31, 2020	Aug. 23, 2020	Jul. 24, 2020	Jun. 30, 2020	Apr. 23, 2019
GB Sciences Louisiana, LLC [Member] \| Forecast [Member]
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness					$ 5,224,423
Debt Instrument, Decrease, Forgiveness					324,423
Proceeds from Collection of Notes Receivable					4,900,000
Note Receivable Satisfied					8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party					$ 250,000
Subsequent Event [Member] \| Repayment of Iliad Note [Member] \| Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty			15.00%
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Subsequent Event [Member] \| GB Sciences Louisiana, LLC [Member]
Notes Receivable, Net, Scheduled Payments	$ 500,000						$ 750,000
Note Receivable, Payments in Forbearance						$ 500,000
Subsequent Event [Member] \| John Davis [Member]
Due to Related Parties, Total		$ 189,423
Subsequent Event [Member] \| Agreement With Louisiana State University AgCenter [Member]
Annual Research Contributions	$ 250,000	$ 250,000
The July 24 Note [Member] \| Subsequent Event [Member]
Debt Instrument, Interest Rate, Stated Percentage								8.00%
July 24 Note [Member] \| Subsequent Event [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 500,000
The 8% Convertible Promissory Note Dated April 23, 2019 [Member] \| Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage									15.00%	8.00%
Debt Instrument, Debt Default, Interest Rate Penalty				10.00%
Debt Instrument, Default, Expense				$ 286,059
Long-term Debt, Total									$ 3,234,149
Interest Payable									$ 192,649

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 180 365 1 false 61 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://gbsciences.com/20200630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://gbsciences.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://gbsciences.com/20200630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://gbsciences.com/20200630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://gbsciences.com/20200630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://gbsciences.com/20200630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Background and Significant Accounting Policies Sheet http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies Note 1 - Background and Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Going Concern Sheet http://gbsciences.com/20200630/role/statement-note-2-going-concern Note 2 - Going Concern Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Inventory Sheet http://gbsciences.com/20200630/role/statement-note-3-inventory Note 3 - Inventory Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Leases Sheet http://gbsciences.com/20200630/role/statement-note-4-leases Note 4 - Leases Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Notes Payable and Line of Credit Notes http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit Note 5 - Notes Payable and Line of Credit Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Convertible Notes Notes http://gbsciences.com/20200630/role/statement-note-6-convertible-notes Note 6 - Convertible Notes Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Capital Transactions Sheet http://gbsciences.com/20200630/role/statement-note-7-capital-transactions Note 7 - Capital Transactions Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Commitments and Contingencies Sheet http://gbsciences.com/20200630/role/statement-note-8-commitments-and-contingencies Note 8 - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Related Party Transactions Sheet http://gbsciences.com/20200630/role/statement-note-9-related-party-transactions Note 9 - Related Party Transactions Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC Sheet http://gbsciences.com/20200630/role/statement-note-10-sale-of-50-membership-interest-in-gb-sciences-louisiana-llc Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Sale of Membership Interests in Nevada Subsidiaries Sheet http://gbsciences.com/20200630/role/statement-note-11-sale-of-membership-interests-in-nevada-subsidiaries Note 11 - Sale of Membership Interests in Nevada Subsidiaries Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Subsequent Events Sheet http://gbsciences.com/20200630/role/statement-note-12-subsequent-events Note 12 - Subsequent Events Notes 18 false false R19.htm 018 - Disclosure - Significant Accounting Policies (Policies) Sheet http://gbsciences.com/20200630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies 19 false false R20.htm 019 - Disclosure - Note 1 - Background and Significant Accounting Policies (Tables) Sheet http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies-tables Note 1 - Background and Significant Accounting Policies (Tables) Tables http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies 20 false false R21.htm 020 - Disclosure - Note 3 - Inventory (Tables) Sheet http://gbsciences.com/20200630/role/statement-note-3-inventory-tables Note 3 - Inventory (Tables) Tables http://gbsciences.com/20200630/role/statement-note-3-inventory 21 false false R22.htm 021 - Disclosure - Note 4 - Leases (Tables) Sheet http://gbsciences.com/20200630/role/statement-note-4-leases-tables Note 4 - Leases (Tables) Tables http://gbsciences.com/20200630/role/statement-note-4-leases 22 false false R23.htm 022 - Disclosure - Note 5 - Notes Payable and Line of Credit (Tables) Notes http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit-tables Note 5 - Notes Payable and Line of Credit (Tables) Tables http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit 23 false false R24.htm 023 - Disclosure - Note 1 - Background and Significant Accounting Policies (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies-details-textual Note 1 - Background and Significant Accounting Policies (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies-tables 24 false false R25.htm 024 - Disclosure - Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) Sheet http://gbsciences.com/20200630/role/statement-note-1-background-and-significant-accounting-policies-discontinued-operations-details Note 1 - Background and Significant Accounting Policies - Discontinued Operations (Details) Details 25 false false R26.htm 025 - Disclosure - Note 2 - Going Concern (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-2-going-concern-details-textual Note 2 - Going Concern (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-2-going-concern 26 false false R27.htm 026 - Disclosure - Note 3 - Inventory - Schedule of Inventory (Details) Sheet http://gbsciences.com/20200630/role/statement-note-3-inventory-schedule-of-inventory-details Note 3 - Inventory - Schedule of Inventory (Details) Details 27 false false R28.htm 027 - Disclosure - Note 4 - Leases (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-4-leases-details-textual Note 4 - Leases (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-4-leases-tables 28 false false R29.htm 028 - Disclosure - Note 4 - Leases - Future Minimum Lease Payments (Details) Sheet http://gbsciences.com/20200630/role/statement-note-4-leases-future-minimum-lease-payments-details Note 4 - Leases - Future Minimum Lease Payments (Details) Details 29 false false R30.htm 029 - Disclosure - Note 5 - Notes Payable and Line of Credit (Details Textual) Notes http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit-details-textual Note 5 - Notes Payable and Line of Credit (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit-tables 30 false false R31.htm 030 - Disclosure - Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) Notes http://gbsciences.com/20200630/role/statement-note-5-notes-payable-and-line-of-credit-schedule-of-debt-payable-details Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) Details 31 false false R32.htm 031 - Disclosure - Note 6 - Convertible Notes (Details Textual) Notes http://gbsciences.com/20200630/role/statement-note-6-convertible-notes-details-textual Note 6 - Convertible Notes (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-6-convertible-notes 32 false false R33.htm 032 - Disclosure - Note 7 - Capital Transactions (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-7-capital-transactions-details-textual Note 7 - Capital Transactions (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-7-capital-transactions 33 false false R34.htm 033 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-8-commitments-and-contingencies-details-textual Note 8 - Commitments and Contingencies (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-8-commitments-and-contingencies 34 false false R35.htm 034 - Disclosure - Note 9 - Related Party Transactions (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-9-related-party-transactions-details-textual Note 9 - Related Party Transactions (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-9-related-party-transactions 35 false false R36.htm 035 - Disclosure - Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-10-sale-of-50-membership-interest-in-gb-sciences-louisiana-llc-details-textual Note 10 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-10-sale-of-50-membership-interest-in-gb-sciences-louisiana-llc 36 false false R37.htm 036 - Disclosure - Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-11-sale-of-membership-interests-in-nevada-subsidiaries-details-textual Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-11-sale-of-membership-interests-in-nevada-subsidiaries 37 false false R38.htm 037 - Disclosure - Note 12 - Subsequent Events (Details Textual) Sheet http://gbsciences.com/20200630/role/statement-note-12-subsequent-events-details-textual Note 12 - Subsequent Events (Details Textual) Details http://gbsciences.com/20200630/role/statement-note-12-subsequent-events 38 false false All Reports Book All Reports gblx-20200630.xml gblx-20200630.xsd gblx-20200630_cal.xml gblx-20200630_def.xml gblx-20200630_lab.xml gblx-20200630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 55 0001437749-20-019228-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-019228-xbrl.zip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end